fluoxetine and Depression, Endogenous studies

Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.

Research Excerpts

Excerpt	Relevance	Reference
"The drugs relieve depressive disorders: fluvoxamine by the 7th day of treatment, sertraline, paroxetine, citalopram by the 14th day, fluoxetine by the 30th day of therapy."	9.41	[Fluvoxamine in the treatment of depressive disorders in alcohol dependence: results of randomized open-label comparative study]. ( Komarov, SD; Severtsev, VV; Vdovin, AS; Vinnikova, MA, 2021)
"This very first study evaluated the efficacy and tolerability of ShenZhiLing (SZL) tablets (KXS preparation), compared with fluoxetine (FLX, positive comparator), in patients with mild to moderate depressive disorder."	9.41	A randomized, placebo-controlled, double-blind study on the effects of SZL on patients with mild to moderate depressive disorder with comparison to fluoxetine. ( Chen, C; Hu, Y; Liu, P; Wang, Y; Yang, W; Zhu, W, 2021)
" This is an analysis of the impact of fluoxetine on suicide ideations in outpatients with minor depressive disorder."	9.17	Fluoxetine increases suicide ideation less than placebo during treatment of adults with minor depressive disorder. ( Frank, E; Garlow, SJ; Judd, LL; Kinkead, B; Kupfer, DJ; Rapaport, MH; Rush, AJ; Schettler, PJ; Thase, ME; Yonkers, KA, 2013)
"One hundred fifty (150) moderately to severely depressed patients as determined by a score >20 on the Hamilton Depression Scale (HDS) after a single ischemic or hemorrhagic stroke were randomly divided into the FEWP group (n = 60), the fluoxetine group (n = 60), and the placebo group (n = 30)."	9.13	The beneficial effects of the herbal medicine Free and Easy Wanderer Plus (FEWP) and fluoxetine on post-stroke depression. ( Chen, J; Ge, HY; Li, LT; Wang, SH; Yu, M; Yue, SW, 2008)
"One hundred twenty-three men with HIV/AIDS with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition depressive disorder entered the 8-week trial and were randomized to testosterone (up to 400 mg IM testosterone cypionate biweekly), fluoxetine (up to 60 mg/d), or double placebo."	9.11	Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial. ( Lin, SH; McElhiney, MC; Rabkin, JG; Rabkin, R; Wagner, GJ, 2004)
"The intent of this study was to compare the efficacy and safety of fluoxetine, olanzapine, or the olanzapine-fluoxetine combination (OFC) in the treatment of women meeting criteria for borderline personality disorder (without concurrent major depressive disorder)."	9.11	A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. ( Frankenburg, FR; Parachini, EA; Zanarini, MC, 2004)
"In the present study, we assessed the relationship between serum folate, vitamin B12, and homocysteine levels and clinical response in patients with major depressive disorder (MDD) who had previously failed to respond to open treatment with fluoxetine 20 mg/day and were enrolled in a 4-week, double-blind trial of either (1) fluoxetine dose increase, (2) lithium augmentation of fluoxetine, or (3) desipramine augmentation of fluoxetine."	9.11	Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression. ( Alpert, JE; Bottiglieri, T; Fava, M; Mischoulon, D; Nierenberg, AA; Papakostas, GI; Petersen, T; Rosenbaum, JF; Ryan, JL, 2004)
"In the present study, we assessed the relationship between serum folate, vitamin B12, and homocysteine levels on the rate of relapse in outpatients with remitted major depressive disorder (MDD) during a 28-week continuation phase of treatment with fluoxetine."	9.11	Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy. ( Alpert, JE; Bottiglieri, T; Fava, M; Green, CH; Mischoulon, D; Nierenberg, AA; Papakostas, GI; Petersen, T; Rosenbaum, JF, 2004)
"One hundred sixty-two patients with minor depressive disorder were randomly assigned to receive fluoxetine or placebo in a 12-week, double-blind study; 73% (59 of 81) of the patients in each treatment group completed the study."	9.11	Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder. ( Frank, E; Judd, LL; Kupfer, DJ; Plewes, JM; Rapaport, MH; Rush, AJ; Schettler, PJ; Thase, ME; Tollefson, G; Yonkers, KA, 2004)
"As described elsewhere the oral administration of 5 mg of the 5-HT3-receptor-antagonist Tropisetron in fibromyalgia exhibited less amelioration of pain in patients with a depression in comparison to patients without depression."	9.10	[The influence of depression on the effect of Tropisetron in the therapy of fibromyalgia]. ( Müller, W; Stratz, T; Varga, B, 2003)
" Sexual function during treatment with the selective noradrenaline reuptake inhibitor reboxetine, the selective serotonin reuptake inhibitor (SSRI) fluoxetine and placebo has been assessed in a multicentre, randomized, 8-week, double-blind study of 450 patients diagnosed with major depressive disorder."	9.10	Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. ( Brown, MT; Clayton, AH; Ferguson, JM; Filipiak-Reisner, JK; Schwartz, GE; Zajecka, J, 2003)
"This open clinical trial examined the feasibility, tolerability, and efficacy of treating adolescents who suffer from bulimia nervosa with fluoxetine."	9.10	An open trial of fluoxetine for adolescents with bulimia nervosa. ( Davies, M; Devlin, MJ; Kotler, LA; Walsh, BT, 2003)
"To evaluate fluoxetine efficacy in the treatment of bulimia nervosa patients with or without comorbid depression."	9.09	Effectiveness of fluoxetine therapy in bulimia nervosa regardless of comorbid depression. ( al-Banna, M; Ascroft, RC; Goldstein, DJ; Wilson, MG, 1999)
"This study compared nortriptyline and fluoxetine with placebo in the treatment of depression and in recovery from physical and cognitive impairments after stroke."	9.09	Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. ( Castillo, C; Curdue, K; Kopel, T; Kosier, JT; Newman, RM; Petracca, G; Robinson, RG; Schultz, SK; Starkstein, SE, 2000)
"A multinational study compared tianeptine with fluoxetine in 387 patients with Depressive Episode, or Recurrent Depressive Disorder, or Bipolar Affective Disorder (ICD-10), in a double-blind parallel group design."	9.09	Efficacy and safety of tianeptine in the treatment of depressive disorders in comparison with fluoxetine. ( Ansseau, M; de Risio, S; Dilling, H; Herrington, R; Lôo, H; Saiz-Ruiz, J; Vaz-Serra, A, 1999)
" The safety and effectiveness of a new formulation of enteric-coated fluoxetine (90 mg) given once weekly was tested during the continuation treatment of major depressive disorder."	9.09	The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder. ( Fava, M; Judge, R; Robinson, JM; Schmidt, ME, 2000)
"Patients (N = 284) with major depressive disorder (DSM-IV) were randomly assigned to double-blind treatment with fluoxetine (N = 92), sertraline, (N = 96), or paroxetine (N = 96) for a total of 26 to 32 weeks."	9.09	Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. ( Fava, M; Hoog, SL; Judge, R; Koke, SC; Nilsson, ME, 2000)
"A randomized, single-blind, parallel-group study of 10 weeks' duration comparing the efficacy of sertraline, 50 mg/day; sertraline, 100 mg/day; and fluoxetine, 20 mg/day, was conducted in 44 psychiatric outpatients with DSM-IV unipolar major depressive disorder."	9.09	Efficacy and response time to sertraline versus fluoxetine in the treatment of unipolar major depressive disorder. ( Altshuler, LL; Calcagno, JL; Frye, MA; Gitlin, MJ; Hwang, S; Rasgon, NL; Suri, RA; Zuckerbrow-Miller, J, 2000)
" Because fluoxetine and its primary metabolite norfluoxetine have long half-lives and flat dose-response curves, we examined the tolerability of a weekly dose and its equivalence to daily dosing during the continuation phase of treatment for major depressive disorder (MDD)."	9.09	Exploring treatment alternatives: weekly dosing of fluoxetine for the continuation phase of major depressive disorder. ( Burke, WJ; McArthur-Miller, DA, 2001)
" Forty patients with major depressive disorder (according to DSM-III-R criteria) were enrolled in a 6-week double-blind parallel group study of fluoxetine (N = 20) or doxepin (N = 20)."	9.08	Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. ( Baker, B; Dorian, P; Irvine, MJ; Mitchell, J; Sandor, P; Schell, C; Shapiro, C, 1997)
"Fluoxetine, 20 mg/day for 8 weeks, was given to 213 outpatients with major depressive disorder."	9.08	Folate, vitamin B12, and homocysteine in major depressive disorder. ( Alpert, JE; Borus, JS; Bottiglieri, T; Fava, M; Nierenberg, AA; Rosenbaum, JF, 1997)
"Adult outpatients (N = 106) with DSM-III-R major depressive disorder and a history of either intolerance (N = 34) or nonresponse (N = 72) to treatment with sertraline were treated with fluoxetine (mean dose = 37."	9.08	Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. ( Apter, JT; Birkett, MA; Blomgren, SL; Tepner, RG; Thase, ME, 1997)
"The objective of the present study was to compare the safety and efficacy of moclobemide versus fluoxetine in adult patients with major depressive disorder."	9.08	Moclobemide versus fluoxetine in the treatment of major depressive disorder in adults. ( Annable, L; Beauclair, L; Bland, R; Chouinard, G; Ingram, P; Joffe, R; Kennedy, S; Lapierre, YD; McKenna, K; Reesal, R; Rickhi, BG, 1997)
"The authors conducted a randomized, placebo-controlled, double-blind, 7-week study of fluoxetine at a target daily dose of 60 mg in 31 women with anorexia nervosa receiving treatment for their eating disorder on a clinical research unit."	9.08	Does fluoxetine augment the inpatient treatment of anorexia nervosa? ( Attia, E; Flater, SR; Haiman, C; Walsh, BT, 1998)
"This paper reports combined results of three identical, multisite, randomized, double-blind, 8-week, acute-phase trials comparing nefazodone (n = 64) with fluoxetine (n = 61) in outpatients with nonpsychotic major depressive disorder and insomnia."	9.08	Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. ( Albala, BJ; Armitage, R; Erman, MK; Fleming, JB; Gillin, JC; Kaplita, SB; McQuade, RD; Moldofsky, H; Montplaisir, J; Rush, AJ; Vogel, GW; Winokur, A; Yonkers, KA, 1998)
"This study tested the effectiveness of fluoxetine as a treatment for depression in a population of methadone-maintained opioid addicts."	9.08	Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. ( Carroll, KM; Gordon, L; Kosten, T; Nich, C; Petrakis, I; Rounsaville, B, 1998)
"The authors' goal was to examine the hypnotic effects of slow-release melatonin during the initial 4 weeks of treatment with fluoxetine in 19 patients with major depressive disorder."	9.08	Melatonin for the treatment of sleep disturbances in major depressive disorder. ( Dolberg, OT; Grunhaus, L; Hirschmann, S, 1998)
" This prospective, multicentre cohort study compared the hospital and physician costs associated with TCA and fluoxetine drug overdoses."	9.08	Acute medical costs of fluoxetine versus tricyclic antidepressants. A prospective multicentre study of antidepressant drug overdoses. ( Brent, J; Heiligenstein, JH; Kulig, K; Palmer, CS; Phillips, SD; Reblando, JA; Revicki, DA, 1997)
"Twenty-four men with paraphilias (PA; n = 13) and paraphilia-related disorders (PRD; n = 11) were consecutively treated with sertraline (mean dose, 100 mg/day; mean duration, 17."	9.07	Sertraline pharmacotherapy for paraphilias and paraphilia-related disorders: an open trial. ( Kafka, MP, 1994)
"After 1 week of a single-blind placebo period, and prior to being randomly assigned to receive treatment with either fluoxetine or amitriptyline, patients meeting strict criteria for a diagnosis of major depressive disorder were given an auditory verbal learning test of working memory, and a blood sample was drawn."	9.07	Verbal learning by major depressive disorder patients during treatment with fluoxetine or amitriptyline. ( Blackshaw, SL; Bowen, RC; Cebrian-Perez, S; Dayal, N; Keegan, DL; Richardson, JS; Saleh, S; Shrikhande, S, 1994)
"Recent reports suggest that fluoxetine in doses less than the standard 20 mg/day may be effective in the treatment of depression and that some patients, particularly those with panic disorder, may be intolerant of the 20 mg/day dose."	9.07	Use of low-dose fluoxetine in major depression and panic disorder. ( Lannon, RA; Lewis, TB; Louie, AK, 1993)
"This study extends our previous report of the efficacy and tolerability of fluoxetine in severe premenstrual syndrome (PMS), describes which aspects of the disorder are responsive to such treatment, and assesses the relationship between steady-state drug level and clinical outcome."	9.07	Fluoxetine's spectrum of action in premenstrual syndrome. ( Howard, RC; Mason, PA; Menkes, DB; Taghavi, E, 1993)
"The authors used an individual change model to examine the clinically significant effect of pharmacotherapy with fluoxetine on the attitudes and beliefs characteristic of bulimia nervosa."	9.07	Pharmacotherapy of bulimia nervosa with fluoxetine: assessment of clinically significant attitudinal change. ( Goldbloom, DS; Olmsted, MP, 1993)
"In a double-blind, crossover study, 13 fluoxetine-treated patients with obsessive-compulsive disorder were given adjuvant buspirone and placebo for 4 weeks each."	9.07	Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. ( Bernstein, SE; Grady, TA; Hill, JL; L'Heureux, F; Murphy, DL; Pigott, TA, 1993)
"A double-blind clinical trial was undertaken to evaluate the clinical efficacy and safety of fluoxetine compared with imipramine in the treatment of 59 outpatients suffering from major depressive disorder."	9.07	A comparison of fluoxetine and imipramine in the treatment of outpatients with major depressive disorder. ( Arup, P; Behnke, K; Christiansen, PE; Geisler, A; Ipsen, E; Maach-Møller, B; Nielsen, BM; Ohrberg, SC, 1993)
"Six patients with chronic, refractory anorexia nervosa were treated with fluoxetine."	9.06	Fluoxetine treatment of anorexia nervosa: an open clinical trial. ( Gainsley, B; Guze, BH; Gwirtsman, HE; Yager, J, 1990)
"According to severity of depressive symptomatology 14 inpatients with major depressive disorder (RDC) were assigned to 2 groups of 7 patients each with 6 of them receiving fluoxetine 60-80 mg/day and 1 receiving placebo in each group in a double-blind manner."	9.06	Mood elevating effect of fluoxetine in a diagnostically homogeneous inpatient population with major depressive disorder. ( Benkert, O; Gerken, A; Holsboer, F; von Bardeleben, U, 1989)
"Fluoxetine, a selective serotonin reuptake inhibitor, was compared to amineptine, a tricyclic antidepressant agent, in the treatment of 63 outpatients with major depressive disorders of mild or moderate severity."	9.06	Fluoxetine versus amineptine in the treatment of outpatients with major depressive disorders. ( Ferreri, M, 1989)
"Fluoxetine, a specific serotonin reuptake inhibitor, was compared to amitriptyline in the treatment of 51 outpatients with primary major depressive disorder."	9.05	A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. ( Chouinard, G, 1985)
"The efficacy and safety of fluoxetine, a new antidepressant agent, were assessed in a double-blind, parallel, randomized study of 44 outpatients with major depressive disorder."	9.05	A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder. ( Feighner, JP, 1985)
"Depression may affect patients' recovery and even their survival rate after stroke, but it is often overlooked or inadequately managed; data regarding the prophylactic efficacy and safety of fluoxetine are inconsistent in this setting."	8.86	Fluoxetine for the prophylaxis of poststroke depression in patients with stroke: a meta-analysis. ( Liu, F; Yi, ZM; Zhai, SD, 2010)
"In this article, we report two cases of pustular psoriasis flaring up after fluoxetine administration."	8.85	Flare-up of pustular psoriasis with fluoxetine: possibility of a serotoninergic influence? ( Alli, N; Gur, G; Polat, M; Tamer, E, 2009)
"This study was designed to examine whether there is an increased risk for major malformations following the use of fluoxetine during the first trimester of pregnancy."	8.80	Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies. ( Addis, A; Koren, G, 2000)
"A comprehensive meta-analysis was performed to address the possible association of fluoxetine with violence or aggression."	8.78	Fluoxetine not associated with increased aggression in controlled clinical trials. ( Beasley, CM; Heiligenstein, JH; Potvin, JH, 1993)
"Fluoxetine is commonly prescribed during pregnancy but developmental exposure to the drug, like infection, is associated with sex-specific behavioral changes in the offspring."	8.02	Short communication: Ex-vivo effects of fluoxetine on production of biomarkers for inflammation and neurodevelopment by the placenta. ( Ahmed, S; Arita, Y; Clementelli, C; Jeong Park, H; Levenson, AS; Peltier, MR; Pijush, DB, 2021)
" The influences of N-acetylcysteine (NAC) on neuroinflammation associated depression-like behavior have not been investigated yet, and associated biochemical changes are currently unclear."	7.91	N-acetylcysteine attenuates neuroinflammation associated depressive behavior induced by chronic unpredictable mild stress in rat. ( Fernandes, J; Gupta, GL, 2019)
"Fluoxetine, one of the selective serotonin reuptake inhibitor (SSRI) antidepressants, has been thought to be effective for treating post-stroke depression (PSD)."	7.85	Alleviative effects of fluoxetine on depressive-like behaviors by epigenetic regulation of BDNF gene transcription in mouse model of post-stroke depression. ( He, QW; Hu, B; Jin, HJ; Li, M; Li, YN; Mao, L; Pei, L; Wan, Y; Xia, YP; Yang, S; Yue, ZY; Zheng, H, 2017)
"The effects of the SSRI fluoxetine on genetically based, depression-related circadian disruptions at the behavioral and molecular level were examined using mice selectively bred for high anxiety-related and co-segregating depression-like behavior (HAB) and normal anxiety/depression behavior mice (NAB)."	7.83	Fluoxetine normalizes disrupted light-induced entrainment, fragmented ultradian rhythms and altered hippocampal clock gene expression in an animal model of high trait anxiety- and depression-related behavior. ( Cabatic, M; Pollak, DD; Ronovsky, M; Sartori, SB; Savalli, G; Schaufler, J; Singewald, N, 2016)
" Therefore, the present study was aimed at investigating the effect of ondansetron, a selective 5HT3 receptor antagonist in attenuating depression and anxiety-like behavior comorbid with diabetes."	7.80	Ondansetron, a 5HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: possible implication of serotonergic system. ( Gupta, D; Kurhe, Y; Radhakrishnan, M, 2014)
"In the present study we assessed the relationship between somatic symptoms and the time to onset of clinical response to fluoxetine in patients with major depressive disorder (MDD)."	7.72	Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorder. ( Alpert, JE; Fava, M; Iosifescu, DV; Nierenberg, AA; Papakostas, GI; Petersen, TJ; Sklarsky, KG; Summergrad, P, 2004)
" We present a case of an elderly patient who developed hyponatremia with sertraline and SIADH when rechallenged with fluoxetine."	7.71	Hyponatremia associated with sertraline and fluoxetine: a case report. ( Raphael, K; Tokeshi, J, 2002)
"The objective of this open study was to determine the efficacy and safety of fluoxetine for the treatment of children and adolescents with anxiety disorders."	7.69	Fluoxetine for childhood anxiety disorders. ( Balach, L; Birmaher, B; Brodsky, M; Cully, M; Ingram, J; Ryan, N; Waterman, GS, 1994)
"To test the hypothesis that fluoxetine may be a useful adjunct to antiepileptic therapy, we treated with fluoxetine (20-40 mg/day) nine patients suffering from medically intractable epilepsy with daily seizures."	7.69	Lack of potentiation of anticonvulsant effect by fluoxetine in drug-resistant epilepsy. ( Baldinetti, F; Diomedi, M; Gigli, GL; Girolami, E; Marciani, MG; Pasini, A; Troisi, A, 1994)
"This retrospective chart review examined the relative effectiveness of fluoxetine and trazodone in relieving insomnia associated with depressive disorders in adolescents (aged 13-17 years)."	7.69	Trazodone is only slightly faster than fluoxetine in relieving insomnia in adolescents with depressive disorders. ( Bhatara, VS; Fogas, BS; Kallepalli, BR; Misra, LK; Tervo, RC, 1997)
" We report a case of a possible interaction with pimozide which led to a potentially life threatening bradycardia."	7.68	Possible interaction between fluoxetine and pimozide causing sinus bradycardia. ( Ahmed, I; Dagincourt, PG; Miller, LG; Shader, RI, 1993)
"Two patients suffering from severe obsessive-compulsive disorder which had proven refractory to clomipramine and/or phenelzine treatment were successfully treated with fluoxetine, a new drug with a strong serotonin uptake inhibiting action."	7.68	Fluoxetine treatment of obsessive-compulsive disorder. ( Ledwidge, B; Solyom, C; Solyom, L, 1991)
"Platelet 3H-imipramine binding, serotonin (5-HT) uptake and 5-HT concentrations were studied in 14 hospitalized patients with depressive disorder following 6 weeks of treatment with a selective 5-HT uptake blocker, fluoxetine."	7.68	Effects of fluoxetine treatment of platelet 3H-imipramine binding, 5-HT uptake and 5-HT content in major depressive disorder. ( Asberg, M; Mårtensson, B; Montero, D; Siwers, B; Wgner, A, 1990)
"The authors present a case report of neuroleptic malignant syndrome (NMS) in a patient commencing treatment with fluoxetine alone who had previously been treated with several antipsychotic and antidepressant combinations."	7.68	Fluoxetine and neuroleptic malignant syndrome. ( Goldbloom, DS; Halman, M, 1990)
"Adolescent major depressive disorder (MDD) is a life-threatening brain disease with limited interventions."	6.76	Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study. ( Fiedler, KK; Hellem, TL; Jeong, EK; Kondo, DG; Renshaw, PF; Shi, X; Sung, YH, 2011)
" Study phase I was a baseline assessment of 20 mg of fluoxetine daily dosing for 4 weeks (N = 117)."	6.70	Patient compliance with enteric-coated weekly fluoxetine during continuation treatment of major depressive disorder. ( de Klerk, E, 2001)
"A new formulation of fluoxetine has been developed that is intended to allow for weekly dosing during the long-term treatment of depression."	6.70	Efficacy and safety of weekly treatment with enteric-coated fluoxetine in patients with major depressive disorder. ( Dinan, TG, 2001)
"" These behaviors emerged despite gradual dose elevation (2-5 mg/wk), conservative dosing (maximum 40 mg daily), and careful weekly outpatient monitoring of each patient."	6.69	Manic behaviors associated with fluoxetine in three 12- to 18-year-olds with obsessive-compulsive disorder. ( Birmaher, B; Go, FS; Malley, EE; Rosenberg, DR, 1998)
"Fluoxetine was selected as an agent that might mitigate these behaviors, based on the observations that PAs and NPSAs are associated with depression, compulsion, impulsivity, and disinhibited aggression."	6.67	Fluoxetine treatment of nonparaphilic sexual addictions and paraphilias in men. ( Kafka, MP; Prentky, R, 1992)
"In general, effective treatments for trichotillomania have been elusive."	6.67	Clinical characteristics of trichotillomania and its response to fluoxetine. ( Jones, JS; Molcho, A; Stanley, B; Stanley, M; Winchel, RM, 1992)
" Safety was monitored weekly by recording body weight, blood pressure, pulse rate, temperature, physical conditions, laboratory tests, adverse experiences and concomitant medication."	6.66	Double-blind controlled study on the clinical efficacy and safety of fluoxetine vs clomipramine in the treatment of major depressive disorders. ( Agnoli, A; Manna, V; Martucci, N, 1989)
"Fluoxetine was compared to doxepin in geriatric out-patients with major depressive illness."	6.66	Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. ( Cohn, JB; Feighner, JP, 1985)
"The occurrence of a pathological gambling behavior in a 61-year-old patient with idiopathic Parkinson's disease treated with dopaminergic drugs is reported."	6.42	[Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine]. ( Bagheri, H; Montastruc, JL; Schmitt, L, 2003)
"Fluoxetine is a relatively new antidepressant, reported to have minimal side-effects."	6.38	Seizures associated with fluoxetine therapy. ( Prasher, VP, 1993)
" At the end of dosing schedule, neurobehavioral tests were conducted; followed by mechanistic evaluation through biochemical analysis, RTPCR and western blot in serum and hippocampus."	5.48	Antidepressant activity of vorinostat is associated with amelioration of oxidative stress and inflammation in a corticosterone-induced chronic stress model in mice. ( Js, IC; Kv, A; Lahkar, M; Madhana, RM; Naidu, VGM; Sinha, S, 2018)
"He had a generalised tonic/clonic seizure at 6 hours postingestion."	5.48	Fluoxetine overdose in a teenager resulting in serotonin syndrome, seizure and delayed onset rhabdomyolysis. ( Lee-Kelland, R; Mappa, P; Zehra, S, 2018)
"Effects of enriched environment (EE) combined with fluoxetine in a chronic unpredictable stress (CUS) rat model were examined in our study."	5.46	Enriched environment combined with fluoxetine ameliorates depression-like behaviors and hippocampal SYP expression in a rat CUS model. ( Feng, YY; Gu, JY; Han, JH; Li, Y; Liu, C; Lv, TT; Shao, QJ; Wang, CH; Yan, FL; Zhang, XY; Zhao, LQ, 2017)
"The drugs relieve depressive disorders: fluvoxamine by the 7th day of treatment, sertraline, paroxetine, citalopram by the 14th day, fluoxetine by the 30th day of therapy."	5.41	[Fluvoxamine in the treatment of depressive disorders in alcohol dependence: results of randomized open-label comparative study]. ( Komarov, SD; Severtsev, VV; Vdovin, AS; Vinnikova, MA, 2021)
"This very first study evaluated the efficacy and tolerability of ShenZhiLing (SZL) tablets (KXS preparation), compared with fluoxetine (FLX, positive comparator), in patients with mild to moderate depressive disorder."	5.41	A randomized, placebo-controlled, double-blind study on the effects of SZL on patients with mild to moderate depressive disorder with comparison to fluoxetine. ( Chen, C; Hu, Y; Liu, P; Wang, Y; Yang, W; Zhu, W, 2021)
"Fluoxetine was discontinued and fluids were restricted."	5.30	[Severe hyponatremia during treatment with fluoxetine]. ( Armijo, G; Miranda, M; Miranda, P, 1999)
"Fluoxetine is a selective serotonin re-uptake inhibitor and thus being a specific antidepressant has its specific responder."	5.29	Fluoxetine in patients with major depressive disorder--a responder analysis. ( Heinrich, K; Klieser, E; Lehmann, E, 1995)
"Imipramine was unsuccessful in treating trichotillomania and showed limited success in alleviating depression."	5.29	Fluoxetine treatment of trichotillomania and depression in a prepubertal child. ( Sheikha, SH; Wagner, KD; Wagner, RF, 1993)
"Fluoxetine appears to cause a low incidence of adverse cardiac effects."	5.28	Fluoxetine-induced bradycardia and syncope in two patients. ( Ellison, JM; Ely, E; Milofsky, JE, 1990)
" Participants were diagnosed with depressive disorders and randomly assigned to receive directly observed therapy with fluoxetine or a referral to community mental health treatment."	5.24	Does substance use compromise depression treatment in persons with HIV? Findings from a randomized controlled trial. ( Bangsberg, DR; Dilley, JW; Grelotti, DJ; Hammer, GP; Karasic, DH; Sorensen, JL; Tsai, AC, 2017)
"Although fluoxetine and, in the USA, escitalopram are approved for depression in adolescence, substantial concern surrounds antidepressant use in youth."	5.22	Controversies in the Pharmacotherapy of Adolescent Depression. ( Masi, G, 2022)
" This is an analysis of the impact of fluoxetine on suicide ideations in outpatients with minor depressive disorder."	5.17	Fluoxetine increases suicide ideation less than placebo during treatment of adults with minor depressive disorder. ( Frank, E; Garlow, SJ; Judd, LL; Kinkead, B; Kupfer, DJ; Rapaport, MH; Rush, AJ; Schettler, PJ; Thase, ME; Yonkers, KA, 2013)
"We conducted a nonblinded, randomized controlled trial of once-weekly fluoxetine, directly observed for 24 weeks, then self-administered for 12 weeks (n = 137 persons with major or minor depressive disorder or dysthymia)."	5.17	Directly observed antidepressant medication treatment and HIV outcomes among homeless and marginally housed HIV-positive adults: a randomized controlled trial. ( Bangsberg, DR; Charlebois, ED; Dilley, JW; Hammer, GP; Karasic, DH; Moss, AR; Ragland, K; Sorensen, JL; Tsai, AC, 2013)
"During the 1-year follow-up period, and after adjusting for critical confounders including age, intensity of rehabilitation therapy, baseline stroke severity, and baseline Hamilton Depression Rating Scale, patients who received fluoxetine or nortriptyline had significantly greater improvement in modified Rankin Scale scores compared to patients who received placebo (t [156] = -3."	5.15	Effect of antidepressants on the course of disability following stroke. ( Adams, HP; Davis, PH; Jang, M; Jorge, RE; Leira, EC; Mikami, K; Robinson, RG, 2011)
" The aim of this study was to assess the efficacy and safety of acupuncture in combination with fluoxetine as an intervention for major depressive disorder (MDD)."	5.14	Combination of acupuncture and fluoxetine for depression: a randomized, double-blind, sham-controlled trial. ( Yang, XB; Zhang, WJ; Zhong, BL, 2009)
"One hundred fifty (150) moderately to severely depressed patients as determined by a score >20 on the Hamilton Depression Scale (HDS) after a single ischemic or hemorrhagic stroke were randomly divided into the FEWP group (n = 60), the fluoxetine group (n = 60), and the placebo group (n = 30)."	5.13	The beneficial effects of the herbal medicine Free and Easy Wanderer Plus (FEWP) and fluoxetine on post-stroke depression. ( Chen, J; Ge, HY; Li, LT; Wang, SH; Yu, M; Yue, SW, 2008)
"The authors randomly assigned nondepressed patients at least 3 months poststroke to receive nortriptyline, fluoxetine, or placebo for 3 months using double-blind methodology."	5.12	Risk factors for and correlates of poststroke depression following discontinuation of antidepressants. ( Fiedorowicz, JG; Robinson, RG; Takezawa, K, 2007)
"One hundred twenty-three men with HIV/AIDS with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition depressive disorder entered the 8-week trial and were randomized to testosterone (up to 400 mg IM testosterone cypionate biweekly), fluoxetine (up to 60 mg/d), or double placebo."	5.11	Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial. ( Lin, SH; McElhiney, MC; Rabkin, JG; Rabkin, R; Wagner, GJ, 2004)
"The intent of this study was to compare the efficacy and safety of fluoxetine, olanzapine, or the olanzapine-fluoxetine combination (OFC) in the treatment of women meeting criteria for borderline personality disorder (without concurrent major depressive disorder)."	5.11	A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. ( Frankenburg, FR; Parachini, EA; Zanarini, MC, 2004)
"In the present study, we assessed the relationship between serum folate, vitamin B12, and homocysteine levels and clinical response in patients with major depressive disorder (MDD) who had previously failed to respond to open treatment with fluoxetine 20 mg/day and were enrolled in a 4-week, double-blind trial of either (1) fluoxetine dose increase, (2) lithium augmentation of fluoxetine, or (3) desipramine augmentation of fluoxetine."	5.11	Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression. ( Alpert, JE; Bottiglieri, T; Fava, M; Mischoulon, D; Nierenberg, AA; Papakostas, GI; Petersen, T; Rosenbaum, JF; Ryan, JL, 2004)
"In the present study, we assessed the relationship between serum folate, vitamin B12, and homocysteine levels on the rate of relapse in outpatients with remitted major depressive disorder (MDD) during a 28-week continuation phase of treatment with fluoxetine."	5.11	Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy. ( Alpert, JE; Bottiglieri, T; Fava, M; Green, CH; Mischoulon, D; Nierenberg, AA; Papakostas, GI; Petersen, T; Rosenbaum, JF, 2004)
"One hundred sixty-two patients with minor depressive disorder were randomly assigned to receive fluoxetine or placebo in a 12-week, double-blind study; 73% (59 of 81) of the patients in each treatment group completed the study."	5.11	Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder. ( Frank, E; Judd, LL; Kupfer, DJ; Plewes, JM; Rapaport, MH; Rush, AJ; Schettler, PJ; Thase, ME; Tollefson, G; Yonkers, KA, 2004)
"To compare fluoxetine 20 to 60 mg/day with placebo for prevention of relapse of major depressive disorder in children and adolescents who had achieved Children's Depression Rating Scale, Revised scores of < or =28 during treatment with fluoxetine 20 to 60 mg."	5.11	Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study. ( Emslie, GJ; Findling, RL; Heiligenstein, JH; Hoog, SL; Jacobson, JG; McCracken, JT; Nilsson, ME; Wagner, KD, 2004)
"This report presents results from the acute treatment phase of a clinical trial designed to confirm efficacy of a fixed dose of 20 mg of fluoxetine in children and adolescents with major depressive disorder (MDD)."	5.10	Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. ( Brown, E; Emslie, GJ; Ernest, DE; Heiligenstein, JH; Hoog, SL; Jacobson, JG; Nilsson, M; Wagner, KD, 2002)
"As described elsewhere the oral administration of 5 mg of the 5-HT3-receptor-antagonist Tropisetron in fibromyalgia exhibited less amelioration of pain in patients with a depression in comparison to patients without depression."	5.10	[The influence of depression on the effect of Tropisetron in the therapy of fibromyalgia]. ( Müller, W; Stratz, T; Varga, B, 2003)
" Sexual function during treatment with the selective noradrenaline reuptake inhibitor reboxetine, the selective serotonin reuptake inhibitor (SSRI) fluoxetine and placebo has been assessed in a multicentre, randomized, 8-week, double-blind study of 450 patients diagnosed with major depressive disorder."	5.10	Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. ( Brown, MT; Clayton, AH; Ferguson, JM; Filipiak-Reisner, JK; Schwartz, GE; Zajecka, J, 2003)
"Fifty-five outpatients with DSM-IV major depressive disorder and a confirmed history of intolerance to fluoxetine (mean final dose = 24."	5.10	Citalopram treatment of fluoxetine-intolerant depressed patients. ( Calabrese, JR; Londborg, PD; Shelton, MD; Thase, ME, 2003)
"Adding buspirone to fluoxetine in the treatment of major depressive disorder may delay the time to onset of antidepressant efficacy."	5.10	Faster response in depressive patients treated with fluoxetine alone than in combination with buspirone. ( Onder, E; Tural, U, 2003)
"This open clinical trial examined the feasibility, tolerability, and efficacy of treating adolescents who suffer from bulimia nervosa with fluoxetine."	5.10	An open trial of fluoxetine for adolescents with bulimia nervosa. ( Davies, M; Devlin, MJ; Kotler, LA; Walsh, BT, 2003)
"To evaluate fluoxetine efficacy in the treatment of bulimia nervosa patients with or without comorbid depression."	5.09	Effectiveness of fluoxetine therapy in bulimia nervosa regardless of comorbid depression. ( al-Banna, M; Ascroft, RC; Goldstein, DJ; Wilson, MG, 1999)
"The authors studied 19 outpatients with major depressive disorder using prolactin response to d-fenfluramine as a measure of central serotonergic functioning."	5.09	Prolactin response to d-fenfluramine in major depression before and after treatment with serotonin reuptake inhibitors. ( Coccaro, EF; Hauger, RL; Kavoussi, RJ, 1999)
"Patients who met DSM-IV criteria for major depressive disorder and satisfied eligibility criteria were randomly assigned to once-daily venlafaxine XR, fluoxetine, or placebo for 12 weeks."	5.09	Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group. ( Ravindran, A; Silverstone, PH, 1999)
" We present a case of bulimia nervosa and major depressive disorder, who had been treated with up to 60 mg/d fluoxetine for several weeks."	5.09	In vivo visualization of serotonin transporters in the human brain during fluoxetine treatment. ( Asenbaum, S; Brücke, T; de Zwaan, M; Kasper, S; Pirker, W; Tauscher, J, 1999)
"In 8 patients with major depressive disorder without psychotic features (DSM-IV) who had not responded to an SSRI, risperidone was added to the ongoing SSRI treatment."	5.09	Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. ( Nelson, JC; Ostroff, RB, 1999)
"Common adverse events associated with initiating fluoxetine treatment in depressed patients, including nausea, insomnia, nervousness, and somnolence, resolve in the majority of patients and become significantly less frequent with continued treatment over a 6-month period."	5.09	Changes in adverse events reported by patients during 6 months of fluoxetine therapy. ( Amsterdam, JD; Beasley, CM; Michelson, D; Quitkin, FM; Reimherr, FW; Rosenbaum, JF; Sundell, KL; Tamura, RN; Zajecka, J, 1999)
"Fluoxetine has been associated with weight loss during acute treatment, but no controlled studies of weight change during long-term treatment with fluoxetine or other selective serotonin reuptake inhibitors have been reported."	5.09	Changes in weight during a 1-year trial of fluoxetine. ( Amsterdam, JD; Beasley, CM; Kim, Y; Michelson, D; Quitkin, FM; Reimherr, FW; Rosenbaum, JF; Sundell, KL; Zajecka, J, 1999)
"The results of multivariate analyses to identify potential predictors of response to fluoxetine or placebo separately in 96 child and adolescent outpatients with major depressive disorder from a recent controlled trial are presented."	5.09	Prediction of response to fluoxetine and placebo in children and adolescents with major depression: a hypothesis generating study. ( Carmody, TJ; Emslie, GJ; Hughes, CW; Kowatch, RA; Rintelmann, JW; Rush, AJ, 1999)
"Ambulatory HIV-seropositive women with DSM-IV depressive disorders were enrolled in an 8-week, open trial of fluoxetine (N = 21) or sertraline (N = 9) initiated at standard dosages."	5.09	Antidepressant treatment of depression in HIV-seropositive women. ( de Moore, GM; Ferrando, SJ; Rabkin, JG; Rabkin, R, 1999)
"This study compared nortriptyline and fluoxetine with placebo in the treatment of depression and in recovery from physical and cognitive impairments after stroke."	5.09	Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. ( Castillo, C; Curdue, K; Kopel, T; Kosier, JT; Newman, RM; Petracca, G; Robinson, RG; Schultz, SK; Starkstein, SE, 2000)
"A multinational study compared tianeptine with fluoxetine in 387 patients with Depressive Episode, or Recurrent Depressive Disorder, or Bipolar Affective Disorder (ICD-10), in a double-blind parallel group design."	5.09	Efficacy and safety of tianeptine in the treatment of depressive disorders in comparison with fluoxetine. ( Ansseau, M; de Risio, S; Dilling, H; Herrington, R; Lôo, H; Saiz-Ruiz, J; Vaz-Serra, A, 1999)
"The efficacy of venlafaxine and fluoxetine in the treatment of atypical anorexia nervosa (AN) was compared in a controlled trial."	5.09	Venlafaxine versus fluoxetine in the treatment of atypical anorectic outpatients: a preliminary study. ( Cabras, PL; Cellini, M; Di Bernardo, M; Mannucci, E; Paionni, A; Ricca, V; Rotella, CM, 1999)
"Patients (N = 108) with DSM-IV major depression and high levels of anxiety (a HAM-D-Anxiety/Somatization Factor score > or =7) were randomized to fluoxetine, sertraline, or paroxetine treatment in a double-blind fashion."	5.09	Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. ( Fava, M; Hoog, SL; Kopp, JB; Nilsson, ME; Rosenbaum, JF; Tepner, RG, 2000)
"Two hundred thirty-six outpatients 60 years of age and older who met DSM-III-R criteria for major depressive disorder received 1 week of single-blind placebo before being randomly assigned to 12 weeks of double-blind, parallel-group treatment with flexible daily doses of either sertraline (range, 50-100 mg) or fluoxetine (range, 20-40 mg)."	5.09	A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. ( Batzar, ED; Clary, CM; Doraiswamy, PM; Krishnan, KR; Newhouse, PA; Richter, EM, 2000)
" The safety and effectiveness of a new formulation of enteric-coated fluoxetine (90 mg) given once weekly was tested during the continuation treatment of major depressive disorder."	5.09	The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder. ( Fava, M; Judge, R; Robinson, JM; Schmidt, ME, 2000)
"Patients (N = 284) with major depressive disorder (DSM-IV) were randomly assigned to double-blind treatment with fluoxetine (N = 92), sertraline, (N = 96), or paroxetine (N = 96) for a total of 26 to 32 weeks."	5.09	Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. ( Fava, M; Hoog, SL; Judge, R; Koke, SC; Nilsson, ME, 2000)
"A randomized, single-blind, parallel-group study of 10 weeks' duration comparing the efficacy of sertraline, 50 mg/day; sertraline, 100 mg/day; and fluoxetine, 20 mg/day, was conducted in 44 psychiatric outpatients with DSM-IV unipolar major depressive disorder."	5.09	Efficacy and response time to sertraline versus fluoxetine in the treatment of unipolar major depressive disorder. ( Altshuler, LL; Calcagno, JL; Frye, MA; Gitlin, MJ; Hwang, S; Rasgon, NL; Suri, RA; Zuckerbrow-Miller, J, 2000)
"During up to 1 year of olanzapine therapy, either as monotherapy or in combination with lithium and/or fluoxetine, patients with bipolar disorder demonstrated significant improvement in mania and depression symptoms with a favorable safety profile."	5.09	Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. ( Gibson, PJ; Greaney, MG; Grundy, SL; Namjoshi, MA; Sanger, TM; Tohen, MF, 2001)
" Because fluoxetine and its primary metabolite norfluoxetine have long half-lives and flat dose-response curves, we examined the tolerability of a weekly dose and its equivalence to daily dosing during the continuation phase of treatment for major depressive disorder (MDD)."	5.09	Exploring treatment alternatives: weekly dosing of fluoxetine for the continuation phase of major depressive disorder. ( Burke, WJ; McArthur-Miller, DA, 2001)
"In an open trial, 143 outpatients who met DSM-III-R criteria for major depressive disorder were treated with a regimen of fluoxetine, 20 mg/day."	5.08	Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. ( Alpert, JE; Fava, M; McLean, NE; Nierenberg, AA; Rosenbaum, JF; Worthington, JJ, 1995)
"Two smoking cessation studies provided venues to 1) look for differences in affective symptoms between cigarette smokers with and without a history of major depression or other psychiatric diagnoses who were not currently depressed and 2) evaluate the efficacy of fluoxetine in ameliorating affective symptoms in smokers with a history of major depression but not currently depressed."	5.08	Mood, major depression, and fluoxetine response in cigarette smokers. ( Covey, L; Dalack, GW; Glassman, AH; Rivelli, S; Stetner, F, 1995)
"This randomized, double-blind, parallel-group design study of 100 outpatients with major depressive disorder is the first study in the United States to compare the efficacy and tolerability of fluvoxamine (100-150 mg/day) and fluoxetine (20-80 mg/day)."	5.08	A comparison of fluvoxamine and fluoxetine in the treatment of major depression. ( Bradford, D; Coccaro, E; Fabre, L; Holland, P; Perse, T; Rapaport, M; Sheline, Y, 1996)
"Nondepressed participants (N = 114) in a trial investigating the effect of fluoxetine on smoking cessation were administered the Structured Clinical Interview for DSM-III-R at baseline and posttreatment to evaluate the impact of quitting smoking on the development of MDD."	5.08	Development of major depressive disorder during smoking-cessation treatment. ( Abrams, DB; Borrelli, B; DePue, JD; Goldstein, MG; Keuthen, NJ; Murphy, C; Niaura, R, 1996)
" Forty patients with major depressive disorder (according to DSM-III-R criteria) were enrolled in a 6-week double-blind parallel group study of fluoxetine (N = 20) or doxepin (N = 20)."	5.08	Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. ( Baker, B; Dorian, P; Irvine, MJ; Mitchell, J; Sandor, P; Schell, C; Shapiro, C, 1997)
", 1994) we systematically collected data from 219 patients with Major Depressive Disorder during five weeks of treatment with fluoxetine (20 mg daily)."	5.08	Drug monitoring studies as a method of analyzing response criteria. ( Klieser, E; Lehmann, E, 1997)
"Fluoxetine, 20 mg/day for 8 weeks, was given to 213 outpatients with major depressive disorder."	5.08	Folate, vitamin B12, and homocysteine in major depressive disorder. ( Alpert, JE; Borus, JS; Bottiglieri, T; Fava, M; Nierenberg, AA; Rosenbaum, JF, 1997)
"Adult outpatients (N = 106) with DSM-III-R major depressive disorder and a history of either intolerance (N = 34) or nonresponse (N = 72) to treatment with sertraline were treated with fluoxetine (mean dose = 37."	5.08	Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. ( Apter, JT; Birkett, MA; Blomgren, SL; Tepner, RG; Thase, ME, 1997)
"The objective of the present study was to compare the safety and efficacy of moclobemide versus fluoxetine in adult patients with major depressive disorder."	5.08	Moclobemide versus fluoxetine in the treatment of major depressive disorder in adults. ( Annable, L; Beauclair, L; Bland, R; Chouinard, G; Ingram, P; Joffe, R; Kennedy, S; Lapierre, YD; McKenna, K; Reesal, R; Rickhi, BG, 1997)
" In this study, 25 smokers with DSM-III-R diagnoses of both major depressive disorder and alcohol dependence were randomized to fluoxetine or placebo in a 12-week, double-blind, parallel group trial."	5.08	Double-blind fluoxetine in depressed alcoholic smokers. ( Black, A; Cornelius, JR; Cornelius, MD; Ehler, JG; Jarrett, PJ; Perel, JM; Salloum, IM; Thase, ME, 1997)
"This study was an 8-week, randomized, double-blind, parallel-group investigation that compared the effects of nefazodone and fluoxetine on sleep architecture and on clinician- and patient-rated sleep measures in 43 outpatients with moderate to severe, nonpsychotic major depressive disorder and insomnia."	5.08	A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients. ( Armitage, R; Cole, D; Rush, AJ; Yonkers, K, 1997)
"Forty-four outpatients with moderate to severe, nonpsychotic major depressive disorder (DSM-III-R) and insomnia were randomly assigned to receive nefazodone (Days 1-7, 200 mg/day; Days 8-56, 400 mg/day) or fluoxetine (Days 1-56, 20 mg/day)."	5.08	A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial. ( Albala, BJ; Erman, MK; Gillin, JC; Rapaport, M; Winokur, A, 1997)
"The selective serotonergic medication fluoxetine has demonstrated efficacy in the treatment of major depression and has suggested efficacy in the treatment of alcoholism."	5.08	Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial. ( Black, A; Cornelius, JR; Cornelius, MD; Ehler, JG; Jarrett, PJ; Perel, JM; Salloum, IM; Thase, ME, 1997)
"Fluoxetine is associated with substantial objective and subjective sleep disturbance in adults with major depressive disorders."	5.08	The effect of fluoxetine on sleep EEG in childhood depression: a preliminary report. ( Armitage, R; Emslie, G; Rintelmann, J, 1997)
"Although fluoxetine might be more effective than placebo for treating adolescent depression without major comorbidity, little is known about the response of depressive symptoms to antidepressants in adolescents with comorbid conduct disorder (CD) and substance use disorders (SUD)."	5.08	Fluoxetine in drug-dependent delinquents with major depression: an open trial. ( Coffman, LM; Crowley, TJ; Mikulich, SK; Riggs, PD, 1997)
"Ninety-six child and adolescent outpatients (aged 7-17 years) with nonpsychotic major depressive disorder were randomized (stratified for age and sex) to 20 mg of fluoxetine or placebo and seen weekly for 8 consecutive weeks."	5.08	A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. ( Carmody, T; Emslie, GJ; Hughes, CW; Kowatch, RA; Rintelmann, J; Rush, AJ; Weinberg, WA, 1997)
"The authors conducted a randomized, placebo-controlled, double-blind, 7-week study of fluoxetine at a target daily dose of 60 mg in 31 women with anorexia nervosa receiving treatment for their eating disorder on a clinical research unit."	5.08	Does fluoxetine augment the inpatient treatment of anorexia nervosa? ( Attia, E; Flater, SR; Haiman, C; Walsh, BT, 1998)
" In this study, 17 patients with DSM-III-R diagnoses of major depressive disorder, alcohol dependence, and cocaine abuse were included along with 34 non-cocaine-abusing depressed alcoholics in a pharmacotherapy trial involving the SSRI antidepressant fluoxetine."	5.08	Fluoxetine versus placebo in depressed alcoholic cocaine abusers. ( Cornelius, JR; Daley, DC; Haskett, RF; Jones-Barlock, A; Perel, JM; Salloum, IM; Thase, ME; Upsher, C, 1998)
"The objective was to present naturalistic 1-year follow-up information of 96 child and adolescent outpatients with major depressive disorder who had been randomized in an 8-week double-blind, placebo-controlled trial of fluoxetine."	5.08	Fluoxetine in child and adolescent depression: acute and maintenance treatment. ( Carmody, T; Emslie, GJ; Kowatch, RA; Mayes, TL; Rush, AJ; Weinberg, WA, 1998)
"This paper reports combined results of three identical, multisite, randomized, double-blind, 8-week, acute-phase trials comparing nefazodone (n = 64) with fluoxetine (n = 61) in outpatients with nonpsychotic major depressive disorder and insomnia."	5.08	Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. ( Albala, BJ; Armitage, R; Erman, MK; Fleming, JB; Gillin, JC; Kaplita, SB; McQuade, RD; Moldofsky, H; Montplaisir, J; Rush, AJ; Vogel, GW; Winokur, A; Yonkers, KA, 1998)
"This study tested the effectiveness of fluoxetine as a treatment for depression in a population of methadone-maintained opioid addicts."	5.08	Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. ( Carroll, KM; Gordon, L; Kosten, T; Nich, C; Petrakis, I; Rounsaville, B, 1998)
"The authors' goal was to examine the hypnotic effects of slow-release melatonin during the initial 4 weeks of treatment with fluoxetine in 19 patients with major depressive disorder."	5.08	Melatonin for the treatment of sleep disturbances in major depressive disorder. ( Dolberg, OT; Grunhaus, L; Hirschmann, S, 1998)
" Efficacy, compliance and its determinants were investigated in 66 patients suffering from major depressive disorder and treated in a double-blind manner with fluoxetine 20 mg/day or amitriptyline 150 mg/day for 9 weeks."	5.08	Compliance in depressed patients treated with fluoxetine or amitriptyline. Belgian Compliance Study Group. ( Demyttenaere, K; Gaens, E; Gregoire, J; Mesters, P; Van Ganse, E, 1998)
" This prospective, multicentre cohort study compared the hospital and physician costs associated with TCA and fluoxetine drug overdoses."	5.08	Acute medical costs of fluoxetine versus tricyclic antidepressants. A prospective multicentre study of antidepressant drug overdoses. ( Brent, J; Heiligenstein, JH; Kulig, K; Palmer, CS; Phillips, SD; Reblando, JA; Revicki, DA, 1997)
"Twenty-four men with paraphilias (PA; n = 13) and paraphilia-related disorders (PRD; n = 11) were consecutively treated with sertraline (mean dose, 100 mg/day; mean duration, 17."	5.07	Sertraline pharmacotherapy for paraphilias and paraphilia-related disorders: an open trial. ( Kafka, MP, 1994)
"After 1 week of a single-blind placebo period, and prior to being randomly assigned to receive treatment with either fluoxetine or amitriptyline, patients meeting strict criteria for a diagnosis of major depressive disorder were given an auditory verbal learning test of working memory, and a blood sample was drawn."	5.07	Verbal learning by major depressive disorder patients during treatment with fluoxetine or amitriptyline. ( Blackshaw, SL; Bowen, RC; Cebrian-Perez, S; Dayal, N; Keegan, DL; Richardson, JS; Saleh, S; Shrikhande, S, 1994)
"Suicidality data from 11 double-blind controlled trials in the United States Investigational New Drug fluoxetine obesity clinical trial data base (3819 randomized outpatients) were reviewed."	5.07	Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction. ( Beasley, CM; Goldstein, DJ; Masica, DN; Potvin, JH; Rampey, AH, 1993)
"Fluoxetine, a serotonin uptake inhibitor, and amitriptyline, a tricyclic antidepressant, were compared in a 5-week, multicenter, double-blind, randomized trial in 136 out-patient men and women, aged 21-70 years, with major depressive disorder."	5.07	Fluoxetine versus amitriptyline in the treatment of major depression: a multicenter trial. ( Beasley, CM; Potvin, JH; Sayler, ME, 1993)
"Recent reports suggest that fluoxetine in doses less than the standard 20 mg/day may be effective in the treatment of depression and that some patients, particularly those with panic disorder, may be intolerant of the 20 mg/day dose."	5.07	Use of low-dose fluoxetine in major depression and panic disorder. ( Lannon, RA; Lewis, TB; Louie, AK, 1993)
"Fluoxetine and imipramine were compared in a six-week, double-blind, randomized trial in 118 men and women, ages 18 to 70 years, hospitalized for major depressive disorder."	5.07	Fluoxetine compared with imipramine in the treatment of inpatient depression. A multicenter trial. ( Beasley, CM; Holman, SL; Potvin, JH, 1993)
"The selective serotonergic agonist fluoxetine has demonstrated efficacy in the treatment of depression and has suggested efficacy in the treatment of alcoholism."	5.07	Fluoxetine trial in suicidal depressed alcoholics. ( Cornelius, JR; Cornelius, MD; Ehler, JG; Mann, JJ; Perel, JM; Salloum, IM; Thase, ME, 1993)
"This study extends our previous report of the efficacy and tolerability of fluoxetine in severe premenstrual syndrome (PMS), describes which aspects of the disorder are responsive to such treatment, and assesses the relationship between steady-state drug level and clinical outcome."	5.07	Fluoxetine's spectrum of action in premenstrual syndrome. ( Howard, RC; Mason, PA; Menkes, DB; Taghavi, E, 1993)
"The relationship between plasma concentration, clinical outcome and side-effects was examined in 23 patients with major depressive disorder (DSM-III-R) treated with fluoxetine."	5.07	Relationship between antidepressant response and plasma concentrations of fluoxetine and norfluoxetine. ( Burrows, GD; Gupta, RK; Judd, FK; Norman, TR; Parker, G, 1993)
"The authors used an individual change model to examine the clinically significant effect of pharmacotherapy with fluoxetine on the attitudes and beliefs characteristic of bulimia nervosa."	5.07	Pharmacotherapy of bulimia nervosa with fluoxetine: assessment of clinically significant attitudinal change. ( Goldbloom, DS; Olmsted, MP, 1993)
"In a double-blind, crossover study, 13 fluoxetine-treated patients with obsessive-compulsive disorder were given adjuvant buspirone and placebo for 4 weeks each."	5.07	Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. ( Bernstein, SE; Grady, TA; Hill, JL; L'Heureux, F; Murphy, DL; Pigott, TA, 1993)
"A double-blind clinical trial was undertaken to evaluate the clinical efficacy and safety of fluoxetine compared with imipramine in the treatment of 59 outpatients suffering from major depressive disorder."	5.07	A comparison of fluoxetine and imipramine in the treatment of outpatients with major depressive disorder. ( Arup, P; Behnke, K; Christiansen, PE; Geisler, A; Ipsen, E; Maach-Møller, B; Nielsen, BM; Ohrberg, SC, 1993)
" To assess rates and temporal patterns of activation and sedation as well as dose-effect relationships, adverse event data were evaluated from a fixed-dose study comparing placebo and fluoxetine 5, 20, and 40 mg/day in the treatment of major depressive disorder (N = 363) and two fixed-dose studies pooled together comparing placebo and fluoxetine 20, 40, and 60 mg/day in the treatment of major depressive disorder (N = 746)."	5.07	Fluoxetine: activating and sedating effects at multiple fixed doses. ( Beasley, CM; Potvin, JH; Sayler, ME; Weiss, AM, 1992)
" For individual adverse events that developed or worsened during therapy, more fluoxetine-treated patients reported rhinitis and tremor (p less than or equal to ."	5.07	Fluoxetine versus trazodone: efficacy and activating-sedating effects. ( Beasley, CM; Bosomworth, JC; Dornseif, BE; Pultz, JA; Sayler, ME, 1991)
"Six patients with chronic, refractory anorexia nervosa were treated with fluoxetine."	5.06	Fluoxetine treatment of anorexia nervosa: an open clinical trial. ( Gainsley, B; Guze, BH; Gwirtsman, HE; Yager, J, 1990)
"In a multicentered study, 372 patients with mild major depressive disorder with a Hamilton Rating Scale for Depression (HAM-D) score of 15 to 19 were randomly assigned to 6 weeks of treatment with placebo or 20 mg, 40 mg, or 60 mg/day of fluoxetine."	5.06	Pattern analysis shows beneficial effect of fluoxetine treatment in mild depression. ( Dornseif, BE; Dunlop, SR; Potvin, JH; Wernicke, JF, 1990)
"According to severity of depressive symptomatology 14 inpatients with major depressive disorder (RDC) were assigned to 2 groups of 7 patients each with 6 of them receiving fluoxetine 60-80 mg/day and 1 receiving placebo in each group in a double-blind manner."	5.06	Mood elevating effect of fluoxetine in a diagnostically homogeneous inpatient population with major depressive disorder. ( Benkert, O; Gerken, A; Holsboer, F; von Bardeleben, U, 1989)
"Fluoxetine, a selective serotonin reuptake inhibitor, was compared to amineptine, a tricyclic antidepressant agent, in the treatment of 63 outpatients with major depressive disorders of mild or moderate severity."	5.06	Fluoxetine versus amineptine in the treatment of outpatients with major depressive disorders. ( Ferreri, M, 1989)
"Seventy patients with unipolar major depressive disorder were treated with fluoxetine or placebo in a 6-week double-blind trial and were evaluated by changes in scores on the Hamilton Rating Scale for Depression (HAM-D) and the global improvement measure of the Clinical Global Impressions (CGI) scale."	5.06	Pattern analysis of antidepressant response to fluoxetine. ( Barouche, F; Fieve, RR; Goodnick, PJ; Peselow, ED; Schlegel, A, 1986)
"A 6-week double-blind trial of fluoxetine treatment of unipolar major depressive disorder in 49 patients was evaluated in terms of improvement in the Hamilton Depression Rating Scale (HDRS) and Clinical Global Improvement (CGI) scores."	5.06	Fluoxetine response: endpoint vs pattern analysis. ( Fieve, RR; Goodnick, PJ; Peselow, E; Schlegel, A, 1986)
"Fluoxetine, a specific serotonin reuptake inhibitor, was compared to amitriptyline in the treatment of 51 outpatients with primary major depressive disorder."	5.05	A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. ( Chouinard, G, 1985)
"The effect of dose frequency on fluoxetine efficacy and safety was evaluated in a double-blind study in patients with major depressive disorder."	5.05	Comparison of two dosage regimens of fluoxetine in major depression. ( Amsterdam, JB; Glaudin, V; Rickels, K; Settle, GP; Smith, WT; Weise, C, 1985)
"The efficacy and safety of fluoxetine, a new antidepressant agent, were assessed in a double-blind, parallel, randomized study of 44 outpatients with major depressive disorder."	5.05	A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder. ( Feighner, JP, 1985)
"Depression may affect patients' recovery and even their survival rate after stroke, but it is often overlooked or inadequately managed; data regarding the prophylactic efficacy and safety of fluoxetine are inconsistent in this setting."	4.86	Fluoxetine for the prophylaxis of poststroke depression in patients with stroke: a meta-analysis. ( Liu, F; Yi, ZM; Zhai, SD, 2010)
"In this article, we report two cases of pustular psoriasis flaring up after fluoxetine administration."	4.85	Flare-up of pustular psoriasis with fluoxetine: possibility of a serotoninergic influence? ( Alli, N; Gur, G; Polat, M; Tamer, E, 2009)
"In comorbid diabetes mellitus and depression, most evidence supports the use of fluoxetine in control of glucose handling."	4.81	Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. ( Goodnick, PJ, 2001)
"This study was designed to examine whether there is an increased risk for major malformations following the use of fluoxetine during the first trimester of pregnancy."	4.80	Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies. ( Addis, A; Koren, G, 2000)
"A comprehensive meta-analysis was performed to address the possible association of fluoxetine with violence or aggression."	4.78	Fluoxetine not associated with increased aggression in controlled clinical trials. ( Beasley, CM; Heiligenstein, JH; Potvin, JH, 1993)
" To assess the rates and temporal patterns of activation and sedation as well as dose-effect relationships, adverse event data were evaluated from a fixed-dose study comparing placebo and fluoxetine, 5, 20 and 40 mg/day, in the treatment of major depressive disorder (n = 363) and the pooled data from two fixed-dose studies comparing placebo and fluoxetine, 20, 40 and 60 mg/day, in the treatment of major depressive disorder (n = 746)."	4.78	Fluoxetine: activating and sedating effects. ( Beasley, CM; Potvin, JH, 1993)
"Retrospective analysis of pooled data from 17 double blind clinical trials in patients with major depressive disorder comparing fluoxetine (n = 1765) with a tricyclic antidepressant (n = 731) or placebo (n = 569), or both."	4.78	Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. ( Beasley, CM; Bosomworth, JC; Dornseif, BE; Heiligenstein, JH; Masica, DN; Murphy, DJ; Rampey, AH; Sayler, ME; Thompson, VL, 1991)
"Fluoxetine is commonly prescribed during pregnancy but developmental exposure to the drug, like infection, is associated with sex-specific behavioral changes in the offspring."	4.02	Short communication: Ex-vivo effects of fluoxetine on production of biomarkers for inflammation and neurodevelopment by the placenta. ( Ahmed, S; Arita, Y; Clementelli, C; Jeong Park, H; Levenson, AS; Peltier, MR; Pijush, DB, 2021)
" This study investigated antidepressant-like effects and possible underlying mechanisms of Lactobacillus paracasei PS23 (PS23), live or heat-killed, in a mouse model of corticosterone-induced depression using fluoxetine as standard drug."	3.91	Antidepressant-like activities of live and heat-killed Lactobacillus paracasei PS23 in chronic corticosterone-treated mice and possible mechanisms. ( Cheng, YF; Hsu, CC; Liao, CL; Tsai, YC; Wang, S; Wei, CL; Wu, CC; Yen, JT, 2019)
" The influences of N-acetylcysteine (NAC) on neuroinflammation associated depression-like behavior have not been investigated yet, and associated biochemical changes are currently unclear."	3.91	N-acetylcysteine attenuates neuroinflammation associated depressive behavior induced by chronic unpredictable mild stress in rat. ( Fernandes, J; Gupta, GL, 2019)
"Recent studies demonstrated beneficial effects of zileuton, a 5-lipoxygenase (5LO) inhibitor, on some brain diseases in animal models, but the role of zileuton in the depression remains unknown."	3.88	Antidepressant-like effect of zileuton is accompanied by hippocampal neuroinflammation reduction and CREB/BDNF upregulation in lipopolysaccharide-challenged mice. ( Du, YF; Hong, H; Hu, M; Li, DD; Long, Y; Reed, MN; Suppiramaniam, V; Tang, SS; Xie, H, 2018)
"Our goal was to find out the impact of two antidepressant drugs with various mechanisms of action - imipramine and fluoxetine, on the frontal cortex mitochondria-enriched fraction in an animal model of depression based on the prenatal stress procedure."	3.88	Mitochondrial proteomics investigation of frontal cortex in an animal model of depression: Focus on chronic antidepressant drugs treatment. ( Basta-Kaim, A; Chamera, K; Głombik, K; Kotarska, K; Olszanecki, R; Ślusarczyk, J; Stachowicz, A; Suski, M; Trojan, E, 2018)
" Interrupted time series analyses measured changes due to the warning in levels and trends, by race/ethnicity, of three outcomes: antidepressant prescription fills, depression treatment visits, and incident fluoxetine prescription fills."	3.85	A decline in depression treatment following FDA antidepressant warnings largely explains racial/ethnic disparities in prescription fills. ( Carson, NJ; Cook, BL; Progovac, AM; Wang, Y, 2017)
"Fluoxetine, one of the selective serotonin reuptake inhibitor (SSRI) antidepressants, has been thought to be effective for treating post-stroke depression (PSD)."	3.85	Alleviative effects of fluoxetine on depressive-like behaviors by epigenetic regulation of BDNF gene transcription in mouse model of post-stroke depression. ( He, QW; Hu, B; Jin, HJ; Li, M; Li, YN; Mao, L; Pei, L; Wan, Y; Xia, YP; Yang, S; Yue, ZY; Zheng, H, 2017)
" Here, we investigated the role of aging in the behavioral effects of the antidepressants, desipramine (DMI) (5, 10, and 20 mg/kg) and fluoxetine (FLX) (5, 10, and 20 mg/kg) in young adults (3-5 months), middle-aged (MA, 12-15 months), and senescent (SE, 23-25 months) male rats in the forced-swim test."	3.83	Age-related changes in the antidepressant-like effect of desipramine and fluoxetine in the rat forced-swim test. ( Fernández-Guasti, A; Martínez-Mota, L; Olivares-Nazario, M, 2016)
"The effects of the SSRI fluoxetine on genetically based, depression-related circadian disruptions at the behavioral and molecular level were examined using mice selectively bred for high anxiety-related and co-segregating depression-like behavior (HAB) and normal anxiety/depression behavior mice (NAB)."	3.83	Fluoxetine normalizes disrupted light-induced entrainment, fragmented ultradian rhythms and altered hippocampal clock gene expression in an animal model of high trait anxiety- and depression-related behavior. ( Cabatic, M; Pollak, DD; Ronovsky, M; Sartori, SB; Savalli, G; Schaufler, J; Singewald, N, 2016)
" Therefore, the present study was aimed at investigating the effect of ondansetron, a selective 5HT3 receptor antagonist in attenuating depression and anxiety-like behavior comorbid with diabetes."	3.80	Ondansetron, a 5HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: possible implication of serotonergic system. ( Gupta, D; Kurhe, Y; Radhakrishnan, M, 2014)
"The selective serotonin reuptake inhibitor (SSRI) Prozac® (fluoxetine) is the only registered antidepressant to treat depression in children and adolescents."	3.77	Fluoxetine exerts age-dependent effects on behavior and amygdala neuroplasticity in the rat. ( Arentsen, T; Blom, T; Homberg, JR; Korte-Bouws, G; Olivier, JD; Reneman, L; Schipper, P; van Brunschot, C; van Luijtelaar, G, 2011)
"Of the 76 patients with DSM-III melancholia given active medication, 41 (54%) had a complete or partial response, but only 10 (23%) of the 44 patients with melancholia given placebo had a complete or partial response."	3.77	Melancholic/endogenous depression and response to somatic treatment and placebo. ( Difiglia, C; Fieve, RR; Peselow, ED; Sanfilipo, MP, 1992)
"Developmental deficits in GABAergic inhibition in the forebrain cause behavioral and endocrine abnormalities and selective antidepressant drug responsiveness indicative of anxious-depressive disorders such as melancholic depression, which are frequently characterized by HPA axis hyperactivity and greater efficacy of desipramine versus fluoxetine."	3.76	gamma-Aminobutyric acid-type A receptor deficits cause hypothalamic-pituitary-adrenal axis hyperactivity and antidepressant drug sensitivity reminiscent of melancholic forms of depression. ( Andrews, AM; Earnheart, JC; Lal, R; Luellen, BA; Luscher, B; Shen, Q, 2010)
"Fluoxetine is a new antidepressant which enhances serotoninergic neurotransmission through potent and selective inhibition of neuronal reuptake of serotonin."	3.76	Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. ( Benfield, P; Heel, RC; Lewis, SP, 1986)
"(1) When an antidepressant is considered a necessary addition to psychological support in treating patients with depression, the first-line drug is a tricyclic such as clomipramine or a selective serotonin reuptake inhibitor (SSRI) such as paroxetine; (2) Agomelatine, a melatonin receptor agonist, is approved in the European Union for the treatment of depression; (3) Available evaluation does not include any clinical trials designed to compare the efficacy of agomelatine with that of a tricyclic or a selective serotonin reuptake inhibitor."	3.75	Agomelatine: new drug. Adverse effects and no proven efficacy. ( , 2009)
" Her mother was on 20 mg of fluoxetine throughout her pregnancy."	3.73	Fluoxetine withdrawal syndrome in the newborn. ( Anbu, AT; Theodore, A, 2006)
"Fluoxetine seems to be a better cost-utility SSRI option for treating depressive disorders in PC."	3.73	Cost-utility of selective serotonin reuptake inhibitors for depression in primary care in Catalonia. ( Haro, JM; Peñarrubia, MT; Pinto-Meza, A; Serrano-Blanco, A; Suárez, D, 2006)
"Since the prefrontal cortex (PFC) is thought to play an important role in depression and schizophrenia, we studied the effects of fluoxetine and olanzapine on PFC neurons in rats using extracellular, in vivo recordings."	3.72	Electrophysiological effects of acute and chronic olanzapine and fluoxetine in the rat prefrontal cortex. ( Gronier, BS; Rasmussen, K, 2003)
"In the present study we assessed the relationship between somatic symptoms and the time to onset of clinical response to fluoxetine in patients with major depressive disorder (MDD)."	3.72	Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorder. ( Alpert, JE; Fava, M; Iosifescu, DV; Nierenberg, AA; Papakostas, GI; Petersen, TJ; Sklarsky, KG; Summergrad, P, 2004)
"Transdermal fentanyl is an opioid analgesic that is effective on chronic pain, and which appears to be advantageous due to several factors such as ease of administration, the relatively stable serum concentration and long dose intervals."	3.72	Oral transmucosal abuse of transdermal fentanyl. ( Dimopoulos, NP; Gitsa, OE; Liappas, AI; Liappas, IA; Mellos, E; Rabavilas, AD, 2004)
" We present a case of an elderly patient who developed hyponatremia with sertraline and SIADH when rechallenged with fluoxetine."	3.71	Hyponatremia associated with sertraline and fluoxetine: a case report. ( Raphael, K; Tokeshi, J, 2002)
"Twenty-one pediatric subjects with diagnoses of autistic disorder or other pervasive developmental disorders, 6-15 years old and stabilized with a consistent dose of fluvoxamine or fluoxetine, were recruited for the study; 16 successfully completed the imaging protocol."	3.71	Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders. ( Cowan, C; Dager, SR; Dawson, G; Strauss, WL; Unis, AS, 2002)
"A 39-year-old white woman with depression and panic attacks was being treated with fluoxetine, trazodone, clonazepam, and cimetidine."	3.70	Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. ( Bhatara, VS; Magnus, RD; Paul, KL; Preskorn, SH, 1998)
"Five patients with depressive disorder who experienced sexual side effects during treatment with standard doses of fluoxetine (20 to 40 mg per day)."	3.70	Switching to moclobemide to reverse fluoxetine-induced sexual dysfunction in patients with depression. ( Ramasubbu, R, 1999)
"Two hundred and fifteen outpatients with major depressive disorder as assessed with the Structured Clinical Interview for DSM-III-R (SCID-P) were treated openly with fluoxetine 20 mg/day for 8 weeks."	3.70	Residual symptoms in depressed patients who respond acutely to fluoxetine. ( Alpert, JE; Fava, M; Keefe, BR; Leslie, VC; Nierenberg, AA; Pava, JA; Rosenbaum, JF; Worthington, JJ, 1999)
"The objective of this open study was to determine the efficacy and safety of fluoxetine for the treatment of children and adolescents with anxiety disorders."	3.69	Fluoxetine for childhood anxiety disorders. ( Balach, L; Birmaher, B; Brodsky, M; Cully, M; Ingram, J; Ryan, N; Waterman, GS, 1994)
"To test the hypothesis that fluoxetine may be a useful adjunct to antiepileptic therapy, we treated with fluoxetine (20-40 mg/day) nine patients suffering from medically intractable epilepsy with daily seizures."	3.69	Lack of potentiation of anticonvulsant effect by fluoxetine in drug-resistant epilepsy. ( Baldinetti, F; Diomedi, M; Gigli, GL; Girolami, E; Marciani, MG; Pasini, A; Troisi, A, 1994)
"Prospectively identified fluoxetine-exposed pregnancies were evaluated to determine whether fluoxetine, a serotonin reuptake inhibitor commonly used for the treatment of depression and obsessive-compulsive disorder, might be associated with neonatal complications after maternal fluoxetine exposure during the third trimester through delivery."	3.69	Effects of third trimester fluoxetine exposure on the newborn. ( Goldstein, DJ, 1995)
"We studied the children of 80 mothers who had received a tricyclic antidepressant drug during pregnancy, 55 children whose mothers had received fluoxetine during pregnancy, and 84 children whose mothers had not been exposed during pregnancy to any agent known to affect the fetus adversely."	3.69	Neurodevelopment of children exposed in utero to antidepressant drugs. ( Gardner, HA; Koren, G; Kulin, N; Nulman, I; Rovet, J; Stewart, DE; Theis, JG; Wolpin, J, 1997)
" One hundred thirty-nine outpatients (82 women and 57 men) with major depressive disorder (MDD) filled out the eating disorder inventory (EDI) before and after 8 weeks of treatment with fluoxetine 20 mg/day."	3.69	Eating disorder symptomatology in major depression. ( Abraham, M; Clancy-Colecchi, K; Fava, M; Matthews, J; Pava, JA; Rosenbaum, JF, 1997)
"This retrospective chart review examined the relative effectiveness of fluoxetine and trazodone in relieving insomnia associated with depressive disorders in adolescents (aged 13-17 years)."	3.69	Trazodone is only slightly faster than fluoxetine in relieving insomnia in adolescents with depressive disorders. ( Bhatara, VS; Fogas, BS; Kallepalli, BR; Misra, LK; Tervo, RC, 1997)
" We assessed 42 outpatients, diagnosed with major depressive disorder with or without comorbid obsessive-compulsive disorder, over their first 8 weeks of treatment with paroxetine 20 mg/day, sertraline 50-200 mg/day, or fluoxetine 20-60 mg/day."	3.69	Treatment-emergent changes in sexual function with selective serotonin reuptake inhibitors as measured with the Rush Sexual Inventory. ( Fawcett, J; Mitchell, S; Zajecka, J, 1997)
"The aim of this study was to estimate the cost effectiveness of nefazodone compared with imipramine or fluoxetine in treating women with major depressive disorder."	3.69	Modelling the cost effectiveness of antidepressant treatment in primary care. ( Anton, SF; Bakish, D; Brown, RE; Feeny, D; Palmer, W; Revicki, DA; Rosser, WW, 1995)
"Three patients with histories of impotence experienced a return of sexual potency after treatment with fluoxetine."	3.68	Association of fluoxetine and return of sexual potency in three elderly men. ( Levitte, SS; Smith, DM, 1993)
" Eighty of 230 patients who met the DSM-III-R criteria for panic disorder received, during the course of treatment, fluvoxamine (a selective serotonin reuptake inhibitor) at a dose level between 50-200 mg/day."	3.68	Emergence of depressive symptoms during treatment for panic disorder with specific 5-hydroxytryptophan reuptake inhibitors. ( Fux, M; Taub, M; Zohar, J, 1993)
"Four patients developed nocturnal bruxism within 2 to 4 weeks after initiation of treatment with fluoxetine or sertraline."	3.68	SSRI-associated nocturnal bruxism in four patients. ( Ellison, JM; Stanziani, P, 1993)
" Psychiatrists were much more likely than family practitioners to prescribe fluoxetine for obsessive-compulsive disorder (OCD), and more likely to prescribe for a patient with a history of substance abuse or seizure disorder."	3.68	Prescribing attitudes of different physician groups regarding fluoxetine. ( DeVane, CL; Levin, GM, 1993)
" We report a case of a possible interaction with pimozide which led to a potentially life threatening bradycardia."	3.68	Possible interaction between fluoxetine and pimozide causing sinus bradycardia. ( Ahmed, I; Dagincourt, PG; Miller, LG; Shader, RI, 1993)
"In vivo 19fluorine nuclear magnetic resonance spectroscopy was used to measure the brain concentration of fluoxetine and norfluoxetine in five patients with obsessive-compulsive disorder and three with major depression."	3.68	Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration. ( Clancy, K; Fava, M; Flood, JG; Gonzalez, RG; Guimaraes, AR; Pearlman, JD; Puopolo, PR; Renshaw, PF; Rosenbaum, JF, 1992)
"We report on a 32-year old woman with bulimia nervosa treated with fluoxetine for depression."	3.68	Severe disturbance occurring during treatment for depression of a bulimic patient with fluoxetine. ( Hawthorne, ME; Lacey, JH, 1992)
"Four patients treated with fluoxetine alone developed generalized urticaria."	3.68	Adverse cutaneous reactions associated with fluoxetine strategy for reintroduction of this drug in selected patients. ( Binkley, KE; Joffee, RT; Levitt, A; Leznoff, A; Richter, MA, 1992)
"To assess whether fluoxetine use is associated with significant weight loss or other side effects in depressed elderly patients with concomitant medical illness."	3.68	Fluoxetine in elderly patients: is there cause for concern? ( Brymer, C; Winograd, CH, 1992)
"Two patients suffering from severe obsessive-compulsive disorder which had proven refractory to clomipramine and/or phenelzine treatment were successfully treated with fluoxetine, a new drug with a strong serotonin uptake inhibiting action."	3.68	Fluoxetine treatment of obsessive-compulsive disorder. ( Ledwidge, B; Solyom, C; Solyom, L, 1991)
"Depressive illness in a patient with Down's syndrome and autism responded to fluoxetine."	3.68	Depression in autistic disorder. ( Ghaziuddin, M; Tsai, L, 1991)
"Patients were recruited from the UCLA AIDS Research Center who had previously been referred to psychiatry for participation in an open-label pilot treating patients with major depression with fluoxetine."	3.68	Group psychotherapy for HIV-seropositive patients with major depression. ( Baron, D; Bystritsky, A; Jones, LD; Levine, SH, 1991)
"1) Thirty-four (34) out-patients with major depressive disorder as defined by Research Diagnostic Criteria were treated with fluoxetine in an open study."	3.68	The relationship between response to fluoxetine, plasma drug levels, imipramine binding to platelet membranes and whole-blood 5-HT. ( Griffiths, HW; Marshall, EF; Tyrer, SP, 1990)
"Nine of 10 consecutively evaluated men with DSM-III-R nonparaphilic sexual addictions or paraphilias noted improvement in sexual behaviors and depressive symptomatology while treated with fluoxetine, imipramine, or lithium."	3.68	Successful antidepressant treatment of nonparaphilic sexual addictions and paraphilias in men. ( Kafka, MP, 1991)
"Platelet 3H-imipramine binding, serotonin (5-HT) uptake and 5-HT concentrations were studied in 14 hospitalized patients with depressive disorder following 6 weeks of treatment with a selective 5-HT uptake blocker, fluoxetine."	3.68	Effects of fluoxetine treatment of platelet 3H-imipramine binding, 5-HT uptake and 5-HT content in major depressive disorder. ( Asberg, M; Mårtensson, B; Montero, D; Siwers, B; Wgner, A, 1990)
"The authors present a case report of neuroleptic malignant syndrome (NMS) in a patient commencing treatment with fluoxetine alone who had previously been treated with several antipsychotic and antidepressant combinations."	3.68	Fluoxetine and neuroleptic malignant syndrome. ( Goldbloom, DS; Halman, M, 1990)
"Sixty adults with both depression and insomnia symptoms, who were free of significant primary sleep disorders, received open-label fluoxetine for 9weeks."	2.76	Dissection of the factors driving the placebo effect in hypnotic treatment of depressed insomniacs. ( Blocker, J; Boggs, N; D'Agostino, R; Kimball, J; Lasater, B; McCall, WV; Rosenquist, PB, 2011)
"Adolescent major depressive disorder (MDD) is a life-threatening brain disease with limited interventions."	2.76	Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study. ( Fiedler, KK; Hellem, TL; Jeong, EK; Kondo, DG; Renshaw, PF; Shi, X; Sung, YH, 2011)
"The therapeutic effect of acupuncture on depressive neurosis is better than or similar to that of Prozac but with less side effect."	2.74	Depressive neurosis treated by acupuncture for regulating the liver--a report of 176 cases. ( Fan, L; Fu, WB; He, Q; Li, YW; Liu, YS; Meng, CR; Tang, CZ; Wang, L; Yan, J; Zhang, HL; Zhu, XP; Zhuang, LX, 2009)
"Outpatients with recurrent unipolar depression (DSM-IV criteria; N = 1096) were randomly assigned in a 3:1 ratio to 10 weeks of treatment with venlafaxine ER or fluoxetine."	2.73	The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases. ( Ahmed, S; Dunner, DL; Ferguson, JM; Friedman, ES; Gelenberg, AJ; Hirschfeld, RM; Keller, MB; Kocsis, JH; Kornstein, SG; Musgnung, J; Nemeroff, CB; Ninan, PT; Pedersen, RD; Rothschild, AJ; Schatzberg, AF; Shelton, RC; Thase, ME; Trivedi, MH; Yan, B; Zajecka, JM, 2007)
"Fluoxetine was superior to no therapy in the treatment of depression but not anxiety."	2.73	Treatment of depression and anxiety in infertile women: cognitive behavioral therapy versus fluoxetine. ( Alipor, A; Esmaelzadeh, S; Faramarzi, M; Kheirkhah, F; Pash, H; Poladi, K, 2008)
"Lamotrigine was statistically superior to placebo on the Clinical Global Impressions scale at endpoint, both in absolute terms (mean +/- SD Clinical Global Impressions-Severity of Illness scores: lamotrigine, 2."	2.71	A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. ( Barbosa, L; Berk, M; Vorster, M, 2003)
"Pemoline was associated with a significant decrease in the high frequency (HF) power (0."	2.71	Effect of fluoxetine, pemoline and placebo on heart period and QT variability in normal humans. ( Balon, R; Doll, RG; Jayaraman, A; Pohl, R; Yeragani, V, 2003)
" Safety was assessed via adverse events, vital signs, laboratory analytes, electrocardiography, and extrapyramidal symptom measures."	2.71	Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. ( Andersen, SW; Corya, SA; Detke, HC; Dubé, S; Kelly, LS; Sanger, TM; Van Campen, LE; Williamson, DJ, 2003)
"The unified Parkinson's disease rating scale (UPDRS), activities of daily living (ADL), Hamilton rating scale for depression (HRSD), Beck depression inventory (BDI), and mini-mental state examination (MMSE) were assessed by a rater blinded to treatment arm."	2.71	Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease. ( Barbosa, ER; Fregni, F; Gallucci-Neto, J; Marcolin, MA; Myczkowski, ML; Pascual-Leone, A; Rigolino, R; Santos, CM; Valente, KD, 2004)
"Depressive disorders are very common in clinical practice, with approximately 11."	2.71	Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial. ( Akhondzadeh, S; Jamshidi, AH; Noorbala, AA; Tahmacebi-Pour, N, 2005)
"Cotherapy was effective in reducing insomnia but not anxiety or core symptoms (low mood, suicidality, reduced interest)."	2.70	Is extended clonazepam cotherapy of fluoxetine effective for outpatients with major depression? ( Glaudin, V; Londborg, PD; Painter, JR; Smith, WT, 2002)
"fluoxetine in the treatment of patients with depression and anxiety."	2.70	Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. ( De Bleeker, E; De Nayer, A; Evrard, JL; Fossion, P; Geerts, S; Leyman, S; Linkowski, P; Mignon, A; Ruelens, L; Schittecatte, M; Van Eeckhoutte, I, 2002)
"Treatment with fluoxetine was associated with a reversal of high Neuroticism scores and low Extraversion scores in the whole sample and in a subgroup of responders but not in non-responders."	2.70	Does fluoxetine influence major depression by modifying five-factor personality traits? ( Bakish, D; Du, L; Hrdina, PD; Ravindran, AV, 2002)
"The paroxetine treatment group also experienced significant increases in depressive symptoms, clinical global severity scores and difficulty in social functioning; the fluoxetine treatment group did not."	2.70	Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. ( Jacobson, JG; Judge, R; Parry, MG; Quail, D, 2002)
"nortriptyline) was done."	2.70	Clinical and treatment response characteristics of late-life depression associated with vascular disease: a pooled analysis of two multicenter trials with sertraline. ( Clary, CM; Doraiswamy, PM; Krishnan, KR, 2001)
"Fluoxetine was associated with a statistically significantly smaller percentage of patients who had a recurrence compared with placebo (20% vs."	2.70	Fluoxetine in the prevention of depressive recurrences: a double-blind study. ( Arias, M; Bernardo, M; Casais, L; de la Gandara, J; Gilaberte, I; Judge, R; Martin-Santos, R; Massana, J; Montejo, AL; Noguera, R; Perez-Camo, V; Perez-Sola, V; Santiso, A, 2001)
"Fluoxetine was significantly different from placebo only on the HAD depression subscale score."	2.70	Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. ( Salinas, E; Silverstone, PH, 2001)
"Fluoxetine treatment for depression in AD did not differ significantly from treatment with placebo."	2.70	A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease. ( Chemerinski, E; Petracca, GM; Starkstein, SE, 2001)
"Fluoxetine, however, was more frequently associated with sexual dysfunction compared with bupropion SR."	2.70	A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. ( Ascher, J; Batey, S; Bolden-Watson, C; Book, MJ; Coleman, CC; Jamerson, B; King, BR; Metz, A; Richard, N; Segraves, RT, 2001)
" Study phase I was a baseline assessment of 20 mg of fluoxetine daily dosing for 4 weeks (N = 117)."	2.70	Patient compliance with enteric-coated weekly fluoxetine during continuation treatment of major depressive disorder. ( de Klerk, E, 2001)
"A new formulation of fluoxetine has been developed that is intended to allow for weekly dosing during the long-term treatment of depression."	2.70	Efficacy and safety of weekly treatment with enteric-coated fluoxetine in patients with major depressive disorder. ( Dinan, TG, 2001)
"We treated with fluoxetine 235 outpatients meeting DSM-IV criteria for major depression."	2.70	T3 blood levels and treatment outcome in depression. ( Alpert, JE; Fava, M; Howarth, S; Iosifescu, DV; Nierenberg, AA; Worthington, JJ, 2001)
" The purpose of this study was to assess the potential for pharmacokinetic interaction between olanzapine and fluoxetine, a popular antidepressant that is a selective serotonin reuptake inhibitor."	2.70	Influence of fluoxetine on olanzapine pharmacokinetics. ( de Suray, JM; Gangji, D; Gossen, D; Onkelinx, C; Vandenhende, F, 2002)
"We examine whether baseline anxiety or insomnia symptoms (1) show differential response to fluoxetine or imipramine or (2) predict differences between drugs in overall clinical response or likelihood of medication discontinuation."	2.69	Should anxiety and insomnia influence antidepressant selection: a randomized comparison of fluoxetine and imipramine. ( Grothaus, L; Heiligenstein, JH; Katon, W; Revicki, D; Simon, GE, 1998)
"Selective serotonin reuptake inhibitors may be associated with new adverse events after abrupt discontinuation."	2.69	Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study. ( Amsterdam, J; Beasley, C; Fawcett, J; Michelson, D; Quitkin, F; Reimherr, F; Rosenbaum, J; Zajecka, J, 1998)
"" These behaviors emerged despite gradual dose elevation (2-5 mg/wk), conservative dosing (maximum 40 mg daily), and careful weekly outpatient monitoring of each patient."	2.69	Manic behaviors associated with fluoxetine in three 12- to 18-year-olds with obsessive-compulsive disorder. ( Birmaher, B; Go, FS; Malley, EE; Rosenberg, DR, 1998)
"Fluoxetine-treated patients also experienced less reemergence of depressive symptoms than sertraline-treated or paroxetine-treated patients (p < ."	2.69	Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. ( Ascroft, RC; Fava, M; Hoog, SL; Krebs, WB; Rosenbaum, JF, 1998)
" Side-effect profiles were not significantly different between groups except for a significantly greater frequency of dose-related increase in heart rate > or = 100 bpm in milnacipran recipients and a significantly greater weight loss in fluoxetine recipients."	2.69	A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients. ( Ansseau, M; Corruble, E; Guelfi, JD; Plétan, Y; Samuelian, JC; Tonelli, I; Tournoux, A, 1998)
"Clonazepam/placebo was gradually discontinued during days 21-33."	2.69	Short-term augmentation of fluoxetine with clonazepam in the treatment of depression: a double-blind study. ( Glaudin, V; Londborg, PD; Painter, JR; Smith, WT, 1998)
"Fluoxetine is an effective antidepressant in the context of HIV illness."	2.69	Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial. ( Rabkin, JG; Rabkin, R; Wagner, GJ, 1999)
"Pindolol has been reported to hasten the antidepressant action of selective serotonin reuptake inhibitors in open-label and placebo-controlled trials."	2.69	A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius. ( Alvarez, E; Artigas, F; Pérez, V; Puigdemont, D; Soler, J, 1999)
"Pindolol treatment was associated with statistically significant reduction in blood pressure and pulse as compared to the control group."	2.69	The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial. ( Anand, A; Berman, RM; Cappiello, A; Charney, DS; Hu, XS; Miller, HL; Oren, DA, 1999)
"Desipramine or imipramine was added to fluoxetine and Hamilton Rating Scale for Depression (HAM-D) scores, Beck Depression Inventory (BDI) scores, and plasma tricyclic levels were monitored for 3 weeks."	2.69	Do depressed subjects who have failed both fluoxetine and a tricyclic antidepressant respond to the combination? ( Joffe, RT; Kamil, R; Levitt, AJ; McIntyre, R, 1999)
"Fluoxetine was given at a fixed dose of 20 mg/day and amitriptyline was given in a range of 50-250 mg/day (mean of 138."	2.69	Fluoxetine versus amitriptyline in the treatment of major depression with associated anxiety (anxious depression): a double-blind comparison. ( Dávila, J; Mata, S; Mazzotti, G; Ontiveros, A; Ospina, J; Pacheco, A; Palacios, M; Plewes, J; Tamura, R; Versiani, M, 1999)
"Imipramine was included because its known efficacy for treatment of atypical depression helped to calibrate the appropriateness of the study group."	2.69	A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression. ( Janal, MN; Klein, DF; McGrath, PJ; Petkova, E; Quitkin, FM; Stewart, JW, 2000)
"Fluoxetine (FLX) has a unique pharmacokinetic profile."	2.69	Weekly dosing of fluoxetine for the continuation phase of treatment of major depression: results of a placebo-controlled, randomized clinical trial. ( Bessette, D; Burke, WJ; Hendricks, SE; Jacques, D; McArthur-Miller, D; McKillup, T; Stull, T; Wilson, J, 2000)
" Data collection--at the start and the end of the observation period (< or =6 weeks)--included patient characteristics, diagnoses, medication, co-medication, efficacy, and adverse events (AEs)."	2.69	Efficacy and safety findings from naturalistic fluoxetine drug treatment in adolescent and young adult patients. ( Czekalla, J; Dittmann, RW; Hundemer, HP; Linden, M, 2000)
"Fluoxetine is an efficacious, nonsedative antidepressant, but its selective efficacy on symptoms of insomnia has not been thoroughly explored."	2.68	The effects of fluoxetine on symptoms of insomnia in depressed patients. ( Faries, D; Satterlee, WG, 1995)
" Doubling the low dosage in non-responders after 3 weeks resulted in a statistically significant improvement of CGI in the moclobemide group by comparison with the fluoxetine group at study end, suggesting that 600 mg moclobemide/day can still improve the patient's condition, while 40 mg fluoxetine/day does not."	2.68	Moclobemide versus fluoxetine for a major depressive episode. ( Haazen, L; Janne, P; Mirel, J; Parent, M; Reynaert, C, 1995)
" We present our clinical experience with the use of fluoxetine combined with an HCA in a group of 25 treatment-resistant depressed subjects."	2.68	The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: a retrospective analysis. ( Fawcett, J; Jeffries, H; Zajecka, JM, 1995)
"Fluoxetine appears to be an effective and well-tolerated antidepressant in elderly inpatients of varying age, levels of depression, and psychiatric diagnoses."	2.68	The use and tolerability of fluoxetine in geropsychiatric inpatients. ( Kunik, ME; Molinari, V; Orengo, CA; Workman, RH, 1996)
"Fluoxetine 'responders' were defined as patients with a Hamilton Depression Rating Scale score < or = 7 by week 9 of treatment and who remained in remission at least 3 additional weeks."	2.68	TRH stimulation test as a predictor of acute and long-term antidepressant response in major depression. ( Amsterdam, JD; Fava, M; Hornig-Rohan, M; Maislin, G; Rosenbaum, J, 1996)
"Greater numbers of baseline chronic illness indicated worse physical functioning, general health perceptions, and vitality and greater bodily pain and role limitation from physical problems."	2.68	Impact of physical illness on quality of life and antidepressant response in geriatric major depression. Fluoxetine Collaborative Study Group. ( Birkett, M; Bystritsky, A; Koran, LM; Meyers, BS; Nemeroff, CB; Small, GW, 1996)
" If the response was inadequate after two weeks of treatment, the dosage of venlafaxine could be increased to 75 mg twice daily."	2.68	A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. ( Dierick, M; Martin, A; Ravizza, L; Realini, R, 1996)
"Of 115 cancer patients who fulfilled entry criteria for levels of distress, 45 patients were randomized to a fluoxetine treatment group (FA) and 46 patients to a placebo group (PA) after a 1-week placebo period designed to exclude placebo responders."	2.68	The effect of fluoxetine on anxiety and depression symptoms in cancer patients. ( Allilaire, JF; Blin, P; Bouhassira, M; Cordier, B; Desclaux, B; Fresco, R; Gauvain-Piquard, A; Guillibert, E; Mesters, P; Orth, JP; Piollet, I; Razavi, D; Salimpour, A; Saltel, P; Sechter, D; Smith, M; Trichard, C; Verra, M, 1996)
" There were 188 adverse events: insomnia, dizziness, headache, nausea, dry mouth and myoclonic jerks were the most common."	2.68	Safety and tolerability of combined treatment with moclobemide and SSRIs: a systematic study of 50 patients. ( Hawley, CJ; McPhee, S; Pattinson, HA; Quick, SJ; Ratnam, S, 1996)
"This study explored serum concentrations of fluoxetine and norfluoxetine in subjects treated under different dosing regimens."	2.68	Fluoxetine and norfluoxetine serum concentrations and clinical response in weekly versus daily dosing. ( Burke, WJ; Hendricks, SE; Jacques, D; McArthur-Campbell, D; Stull, T, 1996)
" The aim of the present study was to examine whether pindolol may increase the efficacy of a subtherapeutical dosage of trazodone in the treatment of major depression and TRD, defined according to the Thase and Rush criteria (1995)."	2.68	Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. ( Desnyder, R; Maes, M; Vandoolaeghe, E, 1996)
"Fluoxetine-treated patients did show a slight reduction in agitation and in the need for routine."	2.68	A controlled trial of fluoxetine in nondepressed patients with Huntington's disease. ( Como, PG; Henderson, R; Hickey, C; Lawler, K; McDermott, M; McDermott, MP; O'Brien, CF; Rubin, AE; Rubin, AJ; Shoulson, I; Steinberg, K, 1997)
" 1737 patients received fluoxetine at a dosage of 20 mg per day over a period of 6 months."	2.68	[Maintenance therapy with 20 mg fluoxetine. Results of an administration study of 1,737 depressed patients]. ( Hesselmann, B; Kasper, S; Wein, W, 1997)
"Fluoxetine was well tolerated and showed rapid onset of action."	2.68	Fluoxetine in the treatment of anger: an open clinical trial. ( Emmanuel, N; Johnson, MR; Lydiard, RB; Rubey, RN, 1996)
" A daily dosage of 300 mg of moclobemide and 20 mg of fluoxetine would thus appear to be comparable both in antidepressant efficacy and tolerability."	2.67	Moclobemide versus fluoxetine for major depressive episodes. ( Bruynooghe, F; De Cuyper, H; Demeulemeester, F; Geerts, S; Haazen, L, 1994)
"Fluoxetine-treated patients demonstrated a significantly greater reduction in the Hamilton Rating Scale for Depression total score and a significantly greater response rate than placebo-treated patients in both the SREML and the combined strata."	2.67	Latency to rapid eye movement sleep as a predictor of treatment response to fluoxetine and placebo in nonpsychotic depressed outpatients. ( Andersen, JS; Dunner, D; Faries, DE; Gillin, JC; Heiligenstein, JH; James, SP; Lahmeyer, H; Pande, AC; Roffwarg, HP; Rush, AJ, 1994)
"All records were reviewed from a Parkinson's disease clinic to determine how many patients were treated simultaneously with selegiline and fluoxetine."	2.67	Fluoxetine and selegiline--lack of significant interaction. ( Waters, CH, 1994)
"Fluoxetine was statistically superior to placebo both within the melancholic subtype and in the total patient group (all measures)."	2.67	Response patterns of depressed outpatients with and without melancholia: a double-blind, placebo-controlled trial of fluoxetine versus placebo. ( Faries, DE; Heiligenstein, JH; Tollefson, GD, 1994)
"Trazodone is an effective hypnotic for patients with antidepressant-associated insomnia."	2.67	Trazodone for antidepressant-associated insomnia. ( Adler, LA; Nierenberg, AA; Peselow, E; Rosenthal, M; Zornberg, G, 1994)
"Fluoxetine is an effective and well-tolerated treatment for this condition when used over time."	2.67	Long-term fluoxetine treatment of late luteal phase dysphoric disorder. ( Pearlstein, TB; Stone, AB, 1994)
"Paroxetine is a novel phenylpiperidine antidepressant agent that acts as a potent and selective inhibitor of serotonin reuptake."	2.67	A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression. ( Tignol, J, 1993)
"Fluoxetine was significantly better tolerated than trazodone, with respective dropout rates of 7."	2.67	Long-term treatment of double depression: a preliminary study with serotonergic antidepressants. ( Hellerstein, DJ; Hemlock, C; Kasch, K; Rosenthal, J; Samstag, LW; Winston, A; Yanowitch, P, 1994)
"fluoxetine in the treatment of major depression (DSM-III-R)."	2.67	Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. ( Aguglia, E; Bolino, F; Casacchia, M; Cassano, GB; Faravelli, C; Ferrari, G; Giordano, P; Pancheri, P; Ravizza, L; Trabucchi, M, 1993)
"Fluoxetine was statistically significantly superior to placebo in patients with melancholia (endpoint change in the Montgomery-Asberg Depression Rating Scale [MADRS] score, response rates and remission rates)."	2.67	A double-blind trial of fluoxetine, 20 mg, and placebo in out-patients with DSM-III-R major depression and melancholia. ( Faries, DE; Heiligenstein, JH; Tollefson, GD, 1993)
"Fluoxetine, 20 mg/day, is a well-tolerated and effective treatment option in the management of geriatric major depression."	2.67	Analysis of the Hamilton Depression Rating Scale factors from a double-blind, placebo-controlled trial of fluoxetine in geriatric major depression. ( Holman, SL; Tollefson, GD, 1993)
"Fluoxetine was selected as an agent that might mitigate these behaviors, based on the observations that PAs and NPSAs are associated with depression, compulsion, impulsivity, and disinhibited aggression."	2.67	Fluoxetine treatment of nonparaphilic sexual addictions and paraphilias in men. ( Kafka, MP; Prentky, R, 1992)
"In general, effective treatments for trichotillomania have been elusive."	2.67	Clinical characteristics of trichotillomania and its response to fluoxetine. ( Jones, JS; Molcho, A; Stanley, B; Stanley, M; Winchel, RM, 1992)
"or fluoxetine p."	2.67	Efficacy and safety of morning versus evening fluoxetine administration. ( Beasley, CM; Bosomworth, JC; Usher, RW, 1991)
" The frequency of adverse events in response to fluoxetine was lower than under clomipramine treatment."	2.67	[Efficacy and safety of fluoxetine versus clomipramine in ambulatory patients with a depressive syndrome in a clinical trial with private practitioners]. ( Dossenbach, M; Pakesch, G, 1991)
"Fluoxetine was associated more frequently with nausea (p less than ."	2.67	Comparative efficacy and safety of nortriptyline and fluoxetine in the treatment of major depression: a clinical study. ( Fabre, LF; Itil, TM; Scharf, MB, 1991)
" Data pooled from these two studies suggest a dose relationship for adverse events during fluoxetine therapy."	2.67	Fluoxetine: relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression. ( Beasley, CM; Bosomworth, JC; Wernicke, JF, 1990)
"The fluoxetine treatment is not instead of, but in addition to the traditional behavioral treatment with strict limits regarding food and meals."	2.67	Drugs in the treatment of bulimia nervosa. ( Trygstad, O, 1990)
" Safety was monitored weekly by recording body weight, blood pressure, pulse rate, temperature, physical conditions, laboratory tests, adverse experiences and concomitant medication."	2.66	Double-blind controlled study on the clinical efficacy and safety of fluoxetine vs clomipramine in the treatment of major depressive disorders. ( Agnoli, A; Manna, V; Martucci, N, 1989)
"Fluoxetine was generally well tolerated."	2.66	A double-blind comparison of fluoxetine, imipramine and placebo in outpatients with major depression. ( Boyer, WF; Feighner, JP; Hendrickson, GG; Merideth, CH, 1989)
" The authors hypothesize that fluoxetine 20 mg/day may be an ineffective dosage of the drug or that fluoxetine has a slower onset of antidepressant action than does trazodone."	2.66	A comparative trial of fluoxetine versus trazodone in outpatients with major depression. ( Cook, BL; Dunner, FJ; Garvey, MJ; Kelly, MW; Perry, PJ; Winokur, G, 1989)
"Weight gain was detected only in patients receiving amitryptiline."	2.66	Efficacy and tolerability of fluoxetine in the elderly: a double-blind study versus amitryptiline. ( Altamura, AC; Guercetti, G; Invernizzi, G; Percudani, M, 1989)
" Imipramine and fluoxetine have already been compared in other studies, but never at such a low dosage (20 mg) for fluoxetine."	2.66	A double-blind study of fluoxetine and imipramine in major depression. ( Bressa, GM; Brugnoli, R; Pancheri, P, 1989)
"Fluoxetine and trazodone were compared in a double-blind, randomized, parallel, 6-week trial in 43 outpatients with major depression after a 1-week single-blind placebo period."	2.66	Fluoxetine versus trazodone in the treatment of outpatients with major depression. ( Debus, JR; Himmel, C; Polatin, P; Rush, AJ; Tyler, D; Weissenburger, J, 1988)
"The amitriptyline-treated group had complaints of dry mouth and dizziness on standing; the fluoxetine-treated group of sleep disturbances, nausea, and headaches."	2.66	A controlled comparison of fluoxetine and amitriptyline in depressed out-patients. ( Coleman, A; Lader, MH; Young, JP, 1987)
"Fluoxetine was compared to doxepin in geriatric out-patients with major depressive illness."	2.66	Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. ( Cohn, JB; Feighner, JP, 1985)
"Fluoxetine is a pharmacological agent that has been widely used to determine the neurotransmission of serotonin in the central nervous system."	2.61	Hair loss in a female patient after administration of fluoxetine: a case report and review of the literature. ( Ecomomou, M; Kontoangelos, K; Papageorgiou, C; Peppou, L; Yiannopoulou, KG, 2019)
"Depressive disorders are common in young people and are associated with significant negative impacts."	2.48	Newer generation antidepressants for depressive disorders in children and adolescents. ( Cox, GR; Hetrick, SE; McKenzie, JE; Merry, SN; Simmons, MB, 2012)
"At any one time, major depressive disorder (MDD) affects 4 - 6% of adolescents."	2.46	Pharmacotherapy of major depressive disorder in adolescents. ( Brovedani, P; Liboni, F; Masi, G, 2010)
"Depression may affect 2-8% of children and adolescents, with a peak incidence around puberty."	2.45	Depression in children and adolescents. ( Hazell, P, 2009)
"Fluoxetine was the only SSRI where there was consistent evidence from three trials that it was effective in reducing depression symptoms in both children and adolescents (CDRS-R treatment effect -5."	2.44	Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. ( Hetrick, S; McKenzie, J; Merry, S; Proctor, M; Sindahl, P, 2007)
"The occurrence of a pathological gambling behavior in a 61-year-old patient with idiopathic Parkinson's disease treated with dopaminergic drugs is reported."	2.42	[Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine]. ( Bagheri, H; Montastruc, JL; Schmitt, L, 2003)
"Major depressive disorder is a medical condition that includes abnormalities of affect and mood, cognition, and physical functioning."	2.42	The role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression. ( Fava, M, 2003)
"Fluoxetine was superior to placebo but effect size was low."	2.41	Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression. ( Bech, P; Birkett, MA; Boissel, JP; Cialdella, P; Haugh, MC; Hours, A; Tollefson, GD, 2000)
" We hypothesized that in patients taking 20 mg/day, efficacy would be maintained but the incidence of adverse events would be lower."	2.41	Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg/day dose. ( Beasley, CM; Gonzales, JS; Koke, SC; Nilsson, ME, 2000)
" Mild symptoms can often be treated by simply reassuring the patient that they are usually transient, but for more severe symptoms, it may be necessary to reinstitute the dosage of the original antidepressant and slow the rate of taper."	2.40	Clinical management of antidepressant discontinuation. ( Rosenbaum, JF; Zajecka, J, 1997)
"The clinical picture is one of melancholia in 5 to 25% of cases, and of minor or masked depression (with psychomotor retardation and somatic disorders predominating) in 75 to 95% of cases."	2.40	[Post-cerebrovascular stroke depression]. ( Wiart, L, 1997)
"Fluoxetine was superior to placebo in treating suicidal ideation, and the concomitant use of sedatives did not influence this effect."	2.40	Fluoxetine and concomitant centrally acting medication use during clinical trials of depression: the absence of an effect related to agitation and suicidal behavior. ( Koke, SC; Pearson, DK; Sayler, ME; Tollefson, GD; Wernicke, JF, 1997)
"When evaluating the literature on the treatment of late-life depression, it is most critical to consider the methodology of each study, specifically: (1) Is the antidepressant treatment adequate with respect to dosing duration? (2) How is response defined, e."	2.40	Antidepressant response in late-life depression. ( Roose, SP; Suthers, KM, 1998)
"Fluoxetine is an antidepressant drug, a potent and specific inhibitor of serotonin reuptake (SSRI)."	2.40	Review of cardiovascular effects of fluoxetine, a selective serotonin reuptake inhibitor, compared to tricyclic antidepressants. ( Furst, S; Kecskemeti, V; Pacher, P; Ungvari, Z, 1998)
"Patients with unipolar depression and anger attacks frequently experience significant anxiety and somatic symptoms, and are relatively more likely to meet criteria for avoidant, dependent, borderline, narcissistic, and antisocial personality disorders than depressed patients without these attacks."	2.40	Depression with anger attacks. ( Fava, M, 1998)
"Mirtazapine has intrinsic receptor-blocking properties (in particular, serotonin-2 [5-HT2] receptor blockade) that can be linked to an early relief of anxiety symptoms during the treatment."	2.40	Care of depressed patients with anxiety symptoms. ( Nutt, DJ, 1999)
"Therefore, early relief of insomnia in a depressed patient, in addition to alleviating other symptoms, may increase adherence to treatment and increase daytime performance and overall functioning, while complete relief of insomnia may improve prognosis."	2.40	Antidepressant treatment of the depressed patient with insomnia. ( Thase, ME, 1999)
" From a clinical point of view, it is of relevance that potency to inhibit the cytochrome P450 isozyme CYP2D6 gradually decreases from paroxetine, fluoxetine, norfluoxetine, desmethylcitalopram, fluvoxamine, and sertraline down to citalopram, explaining to a great extent differences in pharmacokinetic interactions between the SSRIs and tricyclic antidepressants, which are metabolized by this enzyme."	2.39	Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. ( Baumann, P; Rochat, B, 1995)
"Nefazodone is a new antidepressant that combines blockade of the serotonin-2 receptor with serotonin uptake inhibition."	2.39	Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. ( Preskorn, SH, 1995)
"The general enhancement of central serotonin (5-HT) neurotransmission following long-term administration of serotonin-selective reuptake inhibitors (SSRIs) appears to play an important role in these drugs' anti-depressant efficacy."	2.39	Serotonin and suicidality: the impact of acute fluoxetine administration. I: Serotonin and suicide. ( Anderson, GM; King, RA; Segman, RH, 1994)
"Fluoxetine has a t1/2 of 2-4 days and has an active metabolite with a t1/2 of 7-15 days."	2.39	Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. ( Preskorn, S, 1994)
"This study tested the hypothesis that some patients treated with an antidepressant who develop adverse events (e."	2.39	Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression. ( Beasley, CM; Enas, GG; Potvin, JH; Rampey, AH; Tollefson, GD, 1994)
"Fluoxetine has demonstrated, in controlled studies, significantly lower rates of side-effects and treatment dropout than TCAs while showing similar efficacy."	2.39	The cost of treatment dropout in depression. A cost-benefit analysis of fluoxetine vs. tricyclics. ( Beuzen, JN; Le Pen, C; Levy, E; Meurgey, F; Ravily, V, 1994)
"Fluoxetine was significantly (p < or = ."	2.39	Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. ( Holman, SL; Potvin, JH; Sayler, ME; Tollefson, GD, 1994)
"Sertraline was found to be modestly efficacious and associated with numerous side effects and discontinuation rates in patients who had previously discontinued fluoxetine."	2.39	Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? ( Cole, JO; Kando, JC; Tohen, M; Weiss, MK; Zarate, CA, 1996)
"Nefazodone treatment was associated with fewer side effects than were the control drugs."	2.39	The safety profile of nefazodone. ( Kaplita, SB; Marcus, RN; Roberts, DL; Robinson, DS; Seminara, JA; Smith, JM; Stringfellow, JC, 1996)
"Patients who developed dystonia, parkinsonism, or tardive dyskinesia were older on average than patients with akathisia; 67."	2.39	Movement disorders associated with the serotonin selective reuptake inhibitors. ( Leo, RJ, 1996)
"Fluoxetine is a relatively new antidepressant, reported to have minimal side-effects."	2.38	Seizures associated with fluoxetine therapy. ( Prasher, VP, 1993)
"Fluoxetine-treated patients showed statistically significantly higher rates of response and remission than placebo-treated patients within all three severity subgroups."	2.38	Severity of depression and response to fluoxetine. ( Pande, AC; Sayler, ME, 1993)
"A re-analysis of the profile of adverse events observed in controlled clinical trials in summarized."	2.38	Adverse events and treatment discontinuations in fluoxetine clinical trials. ( Pande, AC; Sayler, ME, 1993)
"Trazodone is an atypical antidepressant drug that is commonly referred to as a serotonin (5-hydroxytryptamine; 5-HT) uptake inhibitor."	2.38	A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action. ( Marek, GJ; McDougle, CJ; Price, LH; Seiden, LS, 1992)
"Adult GM2 gangliosidosis is a rare disorder that often presents with both neurological and psychiatric syndromes."	2.38	Electroconvulsive therapy treatment of depression in a patient with adult GM2 gangliosidosis. ( Kolodny, EH; Renshaw, PF; Schouten, R; Stern, TA; Welch, C, 1992)
"The pharmacokinetic properties of the newer specific serotonin (5-HT) reuptake inhibitors are reviewed."	2.38	Pharmacokinetics of the selective serotonin reuptake inhibitors. ( DeVane, CL, 1992)
"Paroxetine is a highly potent and selective inhibitor of serotonin reuptake, being more potent in vitro than fluoxetine, fluvoxamine, and sertraline."	2.38	The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor. ( Johnson, AM; Tulloch, IF, 1992)
" The primary adverse events associated with serotonin reuptake inhibitors involve the gastrointestinal system, although side effects may be less frequent at lower dosage levels."	2.38	Clinical overview of serotonin reuptake inhibitors. ( Rickels, K; Schweizer, E, 1990)
"Depressive disorder is a common complication of stroke."	2.38	Depression and cerebrovascular disease. ( Fedoroff, JP; Morris, PL; Robinson, RG, 1990)
"Fluoxetine is an antidepressant drug with a unique chemical configuration which enhances serotoninergic transmission by inhibiting serotonin uptake."	2.38	Fluoxetine: prescribing guidelines for the newest antidepressant. ( Lippmann, S; Pary, R; Tobias, C, 1989)
"Investigating adverse events associated with antidepressant treatments in adolescents is important given the concerns about increased risk of suicidal ideation and behavior in this age group."	1.51	Adverse events reported by anxious school refusing adolescents receiving cognitive behavioral therapy with and without fluoxetine. ( Dudley, AL; Finnin, L; Gordon, MS; Klimkeit, EI; Melvin, GA; Taffe, J; Tonge, B, 2019)
"Treatment with atorvastatin (1 or 10 mg/kg/day) or fluoxetine prevented LPS-induced increase in lipid peroxidation and the reduction of glutathione levels in the hippocampus and prefrontal cortex."	1.51	Atorvastatin prevents lipopolysaccharide-induced depressive-like behaviour in mice. ( Buss, ZS; Doneda, DL; Ferreira, YS; Fraga-Junior, EB; Lima, E; Lopes, L; Rios-Santos, F; Stupp, IJV; Taniguti, EH; Vandresen-Filho, S; Viola, GG, 2019)
"Depression is highly prevalent among patients with chronic obstructive pulmonary disease (COPD)."	1.51	Glucocorticoid receptor dysfunction orchestrates inflammasome effects on chronic obstructive pulmonary disease-induced depression: A potential mechanism underlying the cross talk between lung and brain. ( Deng, X; Fu, J; Guo, Q; Ji, Z; Ma, S; Song, Y; Xu, B, 2019)
"Depression is a common mental disorder affecting around 350 million people worldwide."	1.48	A novel 5HT3 receptor-IGF1 mechanism distinct from SSRI-induced antidepressant effects. ( Kondo, M; Koyama, Y; Nakamura, Y; Shimada, S, 2018)
"Agmatine is an endogenous neuromodulator that has been shown to have beneficial effects in the central nervous system, including antidepressant-like effects in animals."	1.48	Antidepressant and pro-neurogenic effects of agmatine in a mouse model of stress induced by chronic exposure to corticosterone. ( Azevedo, DP; Brocardo, PS; Fraga, DB; Gil-Mohapel, J; Melleu, FF; Neis, VB; Olescowicz, G; Rodrigues, ALS; Rosa, PB, 2018)
" At the end of dosing schedule, neurobehavioral tests were conducted; followed by mechanistic evaluation through biochemical analysis, RTPCR and western blot in serum and hippocampus."	1.48	Antidepressant activity of vorinostat is associated with amelioration of oxidative stress and inflammation in a corticosterone-induced chronic stress model in mice. ( Js, IC; Kv, A; Lahkar, M; Madhana, RM; Naidu, VGM; Sinha, S, 2018)
"Fluoxetine was used in our study as a positive control to demonstrate that CUMS-induced depressive-like behaviors in flies can be reversed by antidepressants."	1.48	Chronic unpredictable mild stress-induced depressive-like behavior and dysregulation of brain levels of biogenic amines in Drosophila melanogaster. ( Araujo, SM; Bortolotto, VC; de Almeida, FP; de Freitas Couto, S; de Paula, MT; Meichtry, LB; Pinheiro, FC; Poetini, MR; Prigol, M; Santos Musachio, EA, 2018)
"Depression is associated with uncontrolled diabetes, which indicates a lack of insulin effect, yet the role of the insulin receptor in mediating depression is not clearly established because insulin receptors are not required for glucose entry into the brain."	1.48	Antidepressant-like effects of insulin and IGF-1 are mediated by IGF-1 receptors in the brain. ( Hajnal, A; Mueller, PL; Pritchett, CE; Wiechman, TN; Zharikov, A, 2018)
"He had a generalised tonic/clonic seizure at 6 hours postingestion."	1.48	Fluoxetine overdose in a teenager resulting in serotonin syndrome, seizure and delayed onset rhabdomyolysis. ( Lee-Kelland, R; Mappa, P; Zehra, S, 2018)
"Depression is frequently associated with chronic pain or chronic stress."	1.46	Cingulate Overexpression of Mitogen-Activated Protein Kinase Phosphatase-1 as a Key Factor for Depression. ( Barrot, M; Barthas, F; Belzung, C; Boutillier, AL; Gilsbach, R; Hein, L; Humo, M; Karatas, M; Leman, S; Waltisperger, E; Yalcin, I, 2017)
"Harmine treatment (20mg/kg) prevented the reductions in brain-derived neurotrophic factor (BDNF) protein levels and hippocampal neurogenesis induced by CUS."	1.46	Harmine produces antidepressant-like effects via restoration of astrocytic functions. ( Chen, X; Gong, Y; Huang, C; Ling, Y; Liu, F; Tong, L; Wang, P; Wu, J; Zhu, L, 2017)
"With fluoxetine treatment, these reductions were achieved 12 weeks after OBX and the volumes were comparable to normal control rats."	1.46	The olfactory bulbectomized rat model is not an appropriate model for studying depression based on morphological/stereological studies of the hippocampus. ( Schmitz, C; Steinbusch, HWM; Strekalova, T; Turgut, M; Yurttas, C, 2017)
"Effects of enriched environment (EE) combined with fluoxetine in a chronic unpredictable stress (CUS) rat model were examined in our study."	1.46	Enriched environment combined with fluoxetine ameliorates depression-like behaviors and hippocampal SYP expression in a rat CUS model. ( Feng, YY; Gu, JY; Han, JH; Li, Y; Liu, C; Lv, TT; Shao, QJ; Wang, CH; Yan, FL; Zhang, XY; Zhao, LQ, 2017)
"Sulforaphane (SFN) is a natural compound with antioxidative, anti-inflammatory and neuroprotective activities."	1.43	Sulforaphane produces antidepressant- and anxiolytic-like effects in adult mice. ( Gao, Q; Gao, Y; Liang, Y; Ma, Y; Shi, H; Wang, X; Wu, S; Xi, Y; Zhao, P, 2016)
"Imipramine was rather proinflammatory, whereas other tested drugs expressed immunosuppressive potential."	1.43	Repeatedly administered antidepressant drugs modulate humoral and cellular immune response in mice through action on macrophages. ( Bryk, A; Bryniarski, P; Filipczak-Bryniarska, I; Kozlowski, M; Kuszmiersz, P; Myszka, M; Nazimek, K; Nowakowski, J; Strobel, S; Tyszka, A, 2016)
"Vortioxetine is a multimodal-acting antidepressant that is hypothesized to exert its therapeutic activity through 5-HT reuptake inhibition and modulation of several 5-HT receptors."	1.43	Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression. ( du Jardin, KG; Elfving, B; Liebenberg, N; Müller, HK; Sanchez, C; Wegener, G, 2016)
"Fluoxetine has been used among older adults as an all-purpose drug for the treatment of depressive disorders because of psychosocial adversities, lack of social support, and limited access to adequate healthcare services for the treatment of this disorder."	1.42	Treatment of depression in older adults beyond fluoxetine. ( Wagner, GA, 2015)
"Major depressive disorder is thought to arise in part from dysfunction of the brain's "reward circuitry", consisting of the mesolimbic dopamine system and the glutamatergic and neuromodulatory inputs onto this system."	1.42	Differential induction of FosB isoforms throughout the brain by fluoxetine and chronic stress. ( Cooper, S; Eagle, A; Gajewski, P; Kaska, S; Mazei-Robison, M; Nestler, EJ; Robison, AJ; Thibault, M; Vialou, V, 2015)
"Anhedonia was evaluated using the sucrose preference test (SPT), and behavioural despair was evaluated using the forced swim test (FST) and tail suspension test (TST)."	1.42	Depressive-like behaviours and decreased dendritic branching in the medial prefrontal cortex of mice with tumors: A novel validated model of cancer-induced depression. ( Frey, BN; Nashed, MG; Seidlitz, EP; Singh, G, 2015)
"Fluoxetine treatment in adulthood evokes antidepressant and anxiolytic responses."	1.40	Hippocampal HDAC4 contributes to postnatal fluoxetine-evoked depression-like behavior. ( Chachra, P; Desouza, LA; Kennedy, P; Nestler, EJ; Pena, CJ; Sarkar, A; Vaidya, VA, 2014)
" In terms of in vivo neuronal activities, a CMS-induced decrease in spontaneous firing in burst of medial prefrontal cortex pyramidal neurons rather than ventral tegmental area (VTA) was reversed by the chronic administration of fluoxetine and YY-23."	1.40	Burst-firing patterns in the prefrontal cortex underlying the neuronal mechanisms of depression probed by antidepressants. ( Fu, Z; Guo, F; Huang, C; Li, Y; Wu, B; Zhang, B; Zhang, Q, 2014)
"Treatment with fluoxetine for 3 weeks abolished the neurobehavioral effects of LPS."	1.39	A new animal model of (chronic) depression induced by repeated and intermittent lipopolysaccharide administration for 4 months. ( Basta-Kaim, A; Budziszewska, B; Curzytek, K; Duda, W; Holan, V; Kubera, M; Lason, W; Leskiewicz, M; Maes, M; Roman, A; Szczesny, E; Zajicova, A, 2013)
"Kleptomania is an impulse control disorder characterized by a recurrent failure to resist the impulse to steal worthless objects that are not needed for personal use."	1.38	Naltrexone treatment of kleptomania: a case report. ( Belkız Güngör, B; Çetinay Aydın, P; Gülseren, L, 2012)
"Fluoxetine was the antidepressant most likely to be chosen by psychiatrists for themselves, followed by escitalopram and tricyclic antidepressant."	1.37	Which antidepressant would psychiatrists and nurses from a developing country choose for themselves? ( Ansari, M; Chaudhry, IB; Chaudhry, N; Husain, N; Minhas, HM; Rahman, R; Taylor, D, 2011)
"Fluoxetine was chosen because it has become a first-line drug for the treatment of affective disorders."	1.36	Metabolic mapping of the effects of the antidepressant fluoxetine on the brains of congenitally helpless rats. ( Barrett, DW; Colorado, RA; Gonzalez-Lima, F; Shumake, J, 2010)
"For patients with unipolar depression, discharge rates were higher when they were prescribed one of 'the four' and highest when prescribed escitalopram."	1.36	An audit to compare discharge rates between antidepressant monotherapies prescribed for pure unipolar depression versus depression in the presence of other indications. ( Agius, M; Gardner, J; Liu, K; Zaman, R, 2010)
" Chronic administration of an effective (fluoxetine) or putative antidepressant (corticotropin-releasing factor-1 (CRF1) antagonist, SSR125543) reversed all physical and behavioral effects."	1.35	Corticolimbic transcriptome changes are state-dependent and region-specific in a rodent model of depression and of antidepressant reversal. ( Belzung, C; Edgar, N; Griebel, G; Ibarguen-Vargas, Y; Leman, S; Sibille, E; Surget, A; Wang, Y, 2009)
"Fluoxetine was administrated to either naive rats or stressed rats for 21 days."	1.35	Fluoxetine increases the activity of the ERK-CREB signal system and alleviates the depressive-like behavior in rats exposed to chronic forced swim stress. ( Li, H; Li, J; Lin, W; Qi, X; Sun, M; Wang, D; Wang, W, 2008)
"Treatment with fluoxetine increased CB(1) receptor density in the prefrontal cortex, but had no effect on endocannabinoid contents in any brain region examined."	1.35	Differential effects of the antidepressants tranylcypromine and fluoxetine on limbic cannabinoid receptor binding and endocannabinoid contents. ( Gorzalka, BB; Hill, MN; Hillard, CJ; Ho, WS, 2008)
"Treatment of fluoxetine could reverse CUMS-induced impairment."	1.35	Cytoskeletal alterations in rat hippocampus following chronic unpredictable mild stress and re-exposure to acute and chronic unpredictable mild stress. ( Liu, Z; Wang, G; Wang, H; Wang, X; Yang, C, 2009)
"Treatment with desipramine or imipramine, however, was not effective at reducing immobility in the 21-day-old rats."	1.35	Juvenile rats in the forced-swim test model the human response to antidepressant treatment for pediatric depression. ( Bylund, DB; Happe, HK; Petty, F; Reed, AL, 2008)
" Overall, the dose-response and time-of-recovery relationships for altered NET expression matched those for production of antidepressant-like effects on behavior."	1.35	Norepinephrine transporter regulation mediates the long-term behavioral effects of the antidepressant desipramine. ( Baros, AM; Bondi, CO; Lapiz, MD; Morilak, DA; O'Donnell, JM; Zhang, HT; Zhao, Z, 2008)
"Fluoxetine treatment counteracted the inhibitory effect of stress."	1.34	Chronic social stress inhibits cell proliferation in the adult medial prefrontal cortex: hemispheric asymmetry and reversal by fluoxetine treatment. ( Abumaria, N; Czéh, B; Domenici, E; Fuchs, E; Hiemke, C; Müller-Keuker, JI; Rygula, R, 2007)
"Fluoxetine treatment for 4 and 8 weeks significantly increased basal TPH2 mRNA levels in the midbrain, an effect that was correlated with the appearance of antidepressant-like effects in the forced swim test."	1.34	Up-regulation of tryptophan hydroxylase-2 mRNA in the rat brain by chronic fluoxetine treatment correlates with its antidepressant effect. ( Dygalo, NN; Kalinina, TS; Shishkina, GT, 2007)
"3% at a dosage of 100 mg/kg administrated orally once daily for 5 days, respectively."	1.33	Saponins from Polygala japonica and their effects on a forced swimming test in mice. ( Chen, HS; Li, TZ; Liu, WY; Shen, YH; Yang, GJ; Zhang, WD, 2006)
" These effects were similar to the effects induced for subchronic and chronic administration of the antidepressant fluoxetine (5 mg/kg sc), a selective serotonin re-uptake inhibitor."	1.33	Antidepressant effects of nicotine and fluoxetine in an animal model of depression induced by neonatal treatment with clomipramine. ( Bonilla-Jaime, H; Vázquez-Palacios, G; Velázquez-Moctezuma, J, 2005)
"Fluoxetine is an antidepressant drug, only recently discovered to be a QT interval prolonging agent."	1.33	Prolonged QT interval in an infant of a fluoxetine treated mother. ( Dubnov, G; Fogelman, R; Merlob, P, 2005)
" In contrast chronic administration of all three drugs resulted in increased expression of exon V- and exon I-containing transcripts (fluoxetine and TCP only) but no significant changes were recorded for exon III and IV mRNAs."	1.33	Biphasic change in BDNF gene expression following antidepressant drug treatment explained by differential transcript regulation. ( Khundakar, AA; Zetterström, TSC, 2006)
"Treatment with fluoxetine reversed these changes, as in SC rats."	1.32	Alterations in voiding frequency and cystometry in the clomipramine induced model of endogenous depression and reversal with fluoxetine. ( Dean-McKinney, T; Klausner, AP; Lee, KS; Na, YG; Steers, WD; Tuttle, JB, 2003)
" The patient developed severe restlessness and de novo suicidal ideation approximately 1 week after the dosage of fluoxetine was doubled, 1 year on from when the drug was first introduced."	1.32	Fluoxetine dose-increment related akathisia in depression: implications for clinical care, recognition and management of selective serotonin reuptake inhibitor-induced akathisia. ( Hansen, L, 2003)
" The present study investigated the effects of acute and chronic administration of the selective serotonin reuptake inhibitor, fluoxetine (10mg/kg p."	1.32	Fluoxetine-induced change in rat brain expression of brain-derived neurotrophic factor varies depending on length of treatment. ( Carney, SL; De Foubert, G; Destexhe, EJ; Deville, C; Gaillard, JP; Hicks, CA; Murray, TK; O'Neill, MJ; Robinson, CS; Thomas, CE; Tomlinson, R; Xhenseval, V; Zetterström, TS, 2004)
"After three weeks of treatment an itching rash appeared."	1.32	Itch and skin rash from chocolate during fluoxetine and sertraline treatment: case report. ( Cederberg, J; Knight, S; Melhus, H; Svenson, S, 2004)
"The adaptive neuronal changes that follow chronic administration of antidepressant drugs are thought to underlie clinical improvement in patient populations."	1.31	Adaptation of monoaminergic responses to phencyclidine in nucleus accumbens and prefrontal cortex following repeated treatment with fluoxetine or imipramine. ( De La Garza, R; Jentsch, JD; Roth, RH; Verrico, CD, 2002)
" Prospective studies utilizing flexible dosing of modern antidepressants and, if necessary, sequential trials of dissimilar medications are needed to confirm these findings."	1.31	Treatment of men with major depression: a comparison of sequential cohorts treated with either cognitive-behavioral therapy or newer generation antidepressants. ( Berman, SR; Fasiczka, AL; Frank, E; Friedman, ES; Nofzinger, EA; Reynolds, CF; Thase, ME, 2000)
"Amitriptyline treatment is not less expensive nor more effective than citalopram or fluoxetine therapies."	1.31	Costs and outcomes of use of amitriptyline, citalopram and fluoxetine in major depression: exploratory study. ( Hanus, H; Hosák, L; Straka, L; Tůma, I, 2000)
" Seventeen patients with RBD according to DSM-IV and ICD-10 diagnostic criteria, who had no history of major depression were treated with a dosage of 20-40 mg fluoxetine daily."	1.31	Fluoxetine treatment in patients with recurrent brief depression. ( Aschauer, HN; Blasbichier, T; Brandstätter, N; Kasper, S; Pezawas, L; Riederer, F; Stamenkovic, M, 2001)
" We investigated patient perceptions of antidepressant dosing to determine whether weekly dosing could provide an additional tool to help more patients remain compliant with antidepressant treatment."	1.31	Patient perspectives on once-weekly fluoxetine. ( Judge, R, 2001)
"This is the first study to examine the antidepressant dose-response relationship to 5-HTT kinetics and genetics."	1.31	Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. ( Fei, YJ; Ganapathy, V; Hobby, HM; Johnson, ME; Leibach, FH; Li, JQ; Rausch, JL; Shendarkar, N, 2002)
"To evaluate the CORE measure of melancholia, against the DSM-IV construct of melancholia."	1.31	Melancholia: definitions, risk factors, personality, neuroendocrine markers and differential antidepressant response. ( Abbott, RM; Joyce, PR; Luty, SE; McKenzie, JM; Mulder, RT; Stevens, IF; Sullivan, PF, 2002)
"With conservative dosing and close monitoring, combinations of SRIs with bupropion in this uncontrolled clinical series appeared to be safe and often more effective than monotherapy."	1.30	Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. ( Baldessarini, RJ; Bodkin, JA; Gardner, DM; Lasser, RA; Wines, JD, 1997)
"Fluoxetine was characterised by predominance of a stimulating effect from the first days of treatment as well as by relatively late manifestation of very thymoleptic and tranquilizing impact (during 3-4 weeks)."	1.30	[A comparative clinical evaluation of the antidepressive activity of fluoxetine and fluvoxamine]. ( Lopukhov, IG, 1997)
" Cost, number of prescriptions, and dosage strength data is also presented."	1.30	Trends in the use of selective serotonin reuptake inhibitors in nine Department of Veterans Affairs outpatient facilities. ( Voris, JC, 1999)
"Fluoxetine was discontinued and fluids were restricted."	1.30	[Severe hyponatremia during treatment with fluoxetine]. ( Armijo, G; Miranda, M; Miranda, P, 1999)
" However, assessment of the results of previous studies is confounded by the relative lack of standards in diagnostic criteria, outcome measures, dosage and duration of treatment."	1.29	Studies of reversible and selective inhibitors of monoamine oxidase A in dysthymia. ( Pétursson, H, 1995)
"Fluoxetine is a selective serotonin re-uptake inhibitor and thus being a specific antidepressant has its specific responder."	1.29	Fluoxetine in patients with major depressive disorder--a responder analysis. ( Heinrich, K; Klieser, E; Lehmann, E, 1995)
"Depression is commonly associated with idiopathic Parkinson's disease."	1.29	Anticholinergic effects in a depressed parkinsonian patient. ( Huszonek, JJ, 1995)
"Because of a depressive syndrome, a 39-year-old patient received 20 mg fluoxetine per day."	1.29	[A case of rare side effects of certain antidepressive drugs]. ( Haenel, T; Stöckli, HR; Truog, P, 1995)
"Bupropion is an antidepressant with minimal sexual side effects."	1.29	Treatment of fluoxetine-induced sexual dysfunction with bupropion: a case report. ( Labbate, LA; Pollack, MH, 1994)
"Fluvoxamine was shown to be a safe drug and no unexpected or previously undetected drug-related events were encountered."	1.29	Prescription-event monitoring of 10,401 patients treated with fluvoxamine. ( Edwards, JG; Inman, WH; Pearce, GL; Wilton, L, 1994)
" With a few exceptions, the cumulative dosage of FLU and the AUC of FLU and NFLU were better predictors of the changes in awake and movement time in the PSG than single-sample concentrations of FLU and NFLU taken at the time of PSG assessment."	1.29	The effects of fluoxetine on the polysomnogram of depressed outpatients: a pilot study. ( Armitage, R; Battaglia, J; Cain, JW; Debus, JR; Grannemann, BD; Hendrickse, WA; Orsulak, PJ; Roffwarg, HP; Rush, AJ, 1994)
"Treatment with fluoxetine was followed by an overall increase in the prolactin response to TRH among the depressed patients with anger attacks."	1.29	Anger attacks in unipolar depression, Part 2: Neuroendocrine correlates and changes following fluoxetine treatment. ( Bouffides, E; Fava, M; McCarthy, MK; Pava, JA; Rosenbaum, JF; Steingard, RJ, 1993)
"Imipramine was unsuccessful in treating trichotillomania and showed limited success in alleviating depression."	1.29	Fluoxetine treatment of trichotillomania and depression in a prepubertal child. ( Sheikha, SH; Wagner, KD; Wagner, RF, 1993)
"Data from an intensive observational drug utilization study were analyzed to determine whether patients who received the combination of fluoxetine and lithium had more and different adverse events as compared with those receiving fluoxetine alone."	1.29	Adverse events and tolerability of the combination of fluoxetine/lithium compared with fluoxetine. ( Bauer, M; Linden, M; Schaaf, B; Weber, HJ, 1996)
"Fluoxetine is a specific serotonin reuptake inhibitor."	1.29	Fluoxetine in the treatment of depression in Asian (Chinese and Indian) patients in Singapore. ( Kok, LP; Tan, CT; Tsoi, WF, 1995)
" The mean HAM-D-17 and CGIS scores of these 15 patients decreased significantly at the end of 4 weeks on a higher dosage of fluoxetine (60 or 80 mg/day) with respect to the beginning of the four-week study."	1.28	High-dose fluoxetine in the treatment of depressed patients not responsive to a standard dose of fluoxetine. ( Clancy, K; Cohen, L; Fava, M; McCarthy, M; Reiter, S; Rosenbaum, JF; Steingard, R, 1992)
"Bupropion responders were more likely to have trough blood levels above 30 ng/ml (chi 2 = 3."	1.28	Bupropion treatment of fluoxetine-resistant chronic fatigue syndrome. ( Brickman, A; Goodnick, PJ; Klimas, NG; Sandoval, R, 1992)
"Both fluoxetine and trazodone were well tolerated in dysthymics, and showed similar short-term effectiveness in treating dysthymic symptoms."	1.28	A preliminary study of serotonergic antidepressants in treatment of dysthymia. ( Hellerstein, DJ; Hemlock, C; Kasch, K; Rosenthal, J; Samstag, L; Schupak, C; Winston, A; Yanowitch, P, 1992)
"Fluoxetine is an effective serotonin reuptake inhibitor antidepressant that can fail to alleviate either insomnia or major depression in a substantial minority of depressed patients."	1.28	Possible trazodone potentiation of fluoxetine: a case series. ( Cole, JO; Glass, L; Nierenberg, AA, 1992)
"Triiodothyronine (T3) has been shown to augment the therapeutic effect of tricyclic antidepressants as well as monoamine oxidase inhibitors."	1.28	Triiodothyronine potentiation of fluoxetine in depressed patients. ( Joffe, RT, 1992)
" Further study is needed to determine the optimal dosage and to identify risk factors that increase individual vulnerability to fluoxetine induced mania in adolescents."	1.28	Mania associated with fluoxetine treatment in adolescents. ( King, CA; Naylor, MW; Venkataraman, S, 1992)
"All three patients developed severe akathisia during retreatment with fluoxetine and stated that the development of the akathisia made them feel suicidal and that it had precipitated their prior suicide attempts."	1.28	Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. ( Locke, CA; Rothschild, AJ, 1991)
"Fluoxetine was associated temporally with frequent short episodes of sexual excitement described by the patient as feeling like an orgasm."	1.28	Fluoxetine and orgasmic sexual experiences. ( Morris, PL, 1991)
"Each was an elderly white female with pulmonary disease and atrial arrhythmias, including atrial fibrillation, and each was prescribed diuretics, nitrates, and other cardiac and/or pulmonary agents."	1.28	Unexpected deaths in depressed medical inpatients treated with fluoxetine. ( Frontera, MA; Spier, SA, 1991)
"Fluoxetine is a novel antidepressant known to block the reuptake of serotonin with little effect on other neurotransmitter systems."	1.28	The role of serotonin in sexual dysfunction: fluoxetine-associated orgasm dysfunction. ( Fawcett, J; Guy, C; Jeffriess, H; Schaff, M; Zajecka, J, 1991)
" Desipramine plasma levels drawn 24 hours after an initial standardized dose were used to rapidly adjust desipramine dosage and compensate for the interactive effects of fluoxetine on desipramine levels in the blood."	1.28	A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. ( Bowers, MB; Jatlow, PI; Mazure, CM; Nelson, JC, 1991)
"In this preliminary medication trial, 5 borderline personality disorder patients with severe symptoms resistant to phenelzine and neuroleptics were treated openly with fluoxetine 20 to 40 mg for 8 weeks, with weekly ratings of symptoms."	1.28	A preliminary trial of fluoxetine in refractory borderline patients. ( Cornelius, JR; Perel, JM; Soloff, PH; Ulrich, RF, 1991)
"Fluoxetine, which has a long half-life, was more difficult to titrate."	1.28	Apathy and indifference in patients on fluvoxamine and fluoxetine. ( Hoehn-Saric, R; Lipsey, JR; McLeod, DR, 1990)
"Fluoxetine appears to cause a low incidence of adverse cardiac effects."	1.28	Fluoxetine-induced bradycardia and syncope in two patients. ( Ellison, JM; Ely, E; Milofsky, JE, 1990)
"Fluoxetine treatment may be effective in treating major depression in HIV-seropositive asymptomatic patients."	1.28	A report of eight HIV-seropositive patients with major depression responding to fluoxetine. ( Anderson, D; Baron, D; Bystritsky, A; Levine, S, 1990)
"Fluoxetine is a novel antidepressant, with 5HT uptake inhibitory properties."	1.28	Clinical and experimental studies on fluoxetine: effects on serotonin uptake. ( Butler, J; Leonard, BE, 1990)
"The drug-drug interactions with fluoxetine, a pure serotonergic reuptake blocker with a unique profile of side effects, have not been studied adequately."	1.28	Drug-drug interactions of fluoxetine with tricyclics. ( von Ammon Cavanaugh, S, 1990)
"Fluoxetine may increase the plasma levels of standard tricyclic antidepressants and the likelihood of tricyclic antidepressant toxicity."	1.28	Increased plasma tricyclic antidepressant concentrations in two patients concurrently treated with fluoxetine. ( Akiskal, HS; Deal, N; Downs, AD; Downs, JM; Rosenthal, TL, 1989)

Research

Studies (1,461)

Authors

Clinical Trials (56)

Trial Overview

Trial Outcomes

Change From Baseline in 17-item Hamilton Rating Scale for Depression at 6 Weeks.

Timeframe	Studies, this research(%)	All Research%
pre-1990	100 (6.84)	18.7374
1990's	815 (55.78)	18.2507
2000's	341 (23.34)	29.6817
2010's	194 (13.28)	24.3611
2020's	11 (0.75)	2.80

Authors	Studies
Bymaster, FP	3
Beedle, EE	1
Findlay, J	1
Gallagher, PT	1
Krushinski, JH	1
Mitchell, S	2
Robertson, DW	1
Thompson, DC	1
Wallace, L	1
Wong, DT	2
Li, TZ	1
Zhang, WD	1
Yang, GJ	1
Liu, WY	1
Chen, HS	1
Shen, YH	1
Vinnikova, MA	1
Severtsev, VV	1
Komarov, SD	1
Vdovin, AS	1
Xiang, Y	1
Cuijpers, P	1
Teng, T	1
Li, X	1
Fan, L	2
Liu, X	1
Jiang, Y	1
Du, K	1
Lin, J	2
Zhou, X	2
Xie, P	1
Masi, G	2
Malikowska-Racia, N	2
Golebiowska, J	2
Nikiforuk, A	2
Khoo, SY	2
Popik, P	2
Sun, L	1
Zhang, H	1
Cao, Y	1
Wang, C	1
Zhao, C	2
Wang, H	3
Cui, G	1
Wang, M	2
Pan, Y	2
Shi, Y	1
Nie, Y	1
Kontoangelos, K	1
Ecomomou, M	1
Peppou, L	1
Yiannopoulou, KG	1
Papageorgiou, C	1
Alshammari, TK	1
Alghamdi, H	1
Green, TA	1
Niazy, A	1
Alkahdar, L	1
Alrasheed, N	1
Alhosaini, K	1
Alswayyed, M	1
Elango, R	1
Laezza, F	1
Alshammari, MA	1
Yacoub, H	1
Quintana, GR	1
Mac Cionnaith, CE	1
Pfaus, JG	1
Troy, TF	1
Poweleit, EA	1
Strawn, JR	1
Martin, LJ	1
Ramsey, LB	1
Houwing, DJ	1
Schuttel, K	1
Struik, EL	1
Arling, C	1
Ramsteijn, AS	1
Heinla, I	1
Olivier, JDA	1
Hui, A	1
Zhang, CL	1
Li, YJ	1
Lu, S	1
Zhang, T	1
Xiao, R	1
Luo, HR	1
Li, A	1
Tian, J	1
Yang, J	1
Ren, X	1
Zhou, Z	1
Zhou, W	1
Clementelli, C	1
Arita, Y	1
Ahmed, S	2
Pijush, DB	1
Jeong Park, H	1
Levenson, AS	1
Peltier, MR	1
Hu, Y	1
Wang, Y	7
Chen, C	2
Yang, W	1
Zhu, W	1
Liu, P	2
Macías-Cortés, ED	1
Llanes-González, L	1
Aguilar-Faisal, L	1
Asbun-Bojalil, J	1
Liu, FG	1
Hu, WF	1
Wang, JL	2
Wang, P	2
Gong, Y	3
Tong, LJ	1
Jiang, B	2
Zhang, W	2
Qin, YB	1
Chen, Z	1
Yang, RR	1
Huang, C	3
Lovell, B	1
Barthas, F	1
Humo, M	1
Gilsbach, R	1
Waltisperger, E	1
Karatas, M	1
Leman, S	2
Hein, L	1
Belzung, C	4
Boutillier, AL	1
Barrot, M	1
Yalcin, I	1
Kondo, M	1
Koyama, Y	1
Nakamura, Y	1
Shimada, S	1
Li, Y	5
Yan, J	2
Zhu, X	1
Zhu, Y	1
Yao, S	1
Xu, Y	1
Ju, S	1
Kiryanova, V	1
Meunier, SJ	1
Dyck, RH	1
Jamal, F	1
Durgam, A	1
Aickareth, G	1
Bajaj, R	1
Mathews, M	1
Liu, F	2
Wu, J	1
Zhu, L	2
Tong, L	1
Chen, X	1
Ling, Y	1
Li, L	1
Zheng, Q	1
Thakare, VN	1
Aswar, MK	1
Kulkarni, YP	1
Patil, RR	1
Patel, BM	1
Yurttas, C	1
Schmitz, C	1
Turgut, M	1
Strekalova, T	2
Steinbusch, HWM	1
Sun, Y	2
Liang, Y	2
Jiao, Y	1
Qu, H	1
Xu, J	1
Jiang, H	1
Meng, H	1
Lu, J	2
Li, J	4
Zhang, X	2
Yang, X	1
Zhao, B	1
Bao, T	1
Olescowicz, G	1
Neis, VB	1
Fraga, DB	1
Rosa, PB	1
Azevedo, DP	1
Melleu, FF	1
Brocardo, PS	2
Gil-Mohapel, J	1
Rodrigues, ALS	1
Ren, Y	1
Ye, Y	1
Song, L	1
Wang, YJ	1
Tu, MJ	1
Wang, WW	1
Yang, L	2
Chon, MW	1
Lee, J	2
Chung, S	1
Kim, Y	3
Kim, HW	1
Liu, C	1
Gu, JY	1
Han, JH	1
Yan, FL	1
Lv, TT	1
Zhao, LQ	1
Shao, QJ	1
Feng, YY	1
Zhang, XY	1
Wang, CH	1
Carson, NJ	1
Progovac, AM	1
Cook, BL	2
Faye, A	1
Kirpekar, V	1
Tadke, R	1
Gawande, S	1
Bhave, S	1
Kudryashov, NV	1
Kalinina, TS	2
Shimshirt, AA	1
Korolev, AO	1
Volkova, AV	1
Voronina, TA	1
Jin, HJ	1
Pei, L	1
Li, YN	1
Zheng, H	1
Yang, S	1
Wan, Y	1
Mao, L	1
Xia, YP	1
He, QW	1
Li, M	1
Yue, ZY	1
Hu, B	1
Li, DD	1
Xie, H	1
Du, YF	1
Long, Y	1
Reed, MN	1
Hu, M	1
Suppiramaniam, V	1
Hong, H	1
Tang, SS	1
Casan, P	1
Fernández Tena, A	1
Martínez, C	1
Zhao, Y	1
Lin, Z	1
Chen, L	2
Ouyang, L	1
Gu, L	1
Chen, F	1
Zhang, Q	2
Kv, A	1
Madhana, RM	1
Js, IC	1
Lahkar, M	1
Sinha, S	1
Naidu, VGM	1
Głombik, K	2
Stachowicz, A	1
Trojan, E	2
Ślusarczyk, J	2
Suski, M	1
Chamera, K	2
Kotarska, K	1
Olszanecki, R	1
Basta-Kaim, A	4
Bogi, E	1
Belovicová, K	1
Ujhazy, E	1
Mach, M	1
Koprdova, R	1
Zilava, L	1
Garafová, A	1
Jezova, D	1
Dubovicky, M	1
Ratnapala, US	1
Yucel-Finn, A	1
Walbaum, D	1
Dempsey, O	1
Araujo, SM	1
Poetini, MR	1
Bortolotto, VC	1
de Freitas Couto, S	1
Pinheiro, FC	1
Meichtry, LB	1
de Almeida, FP	1
Santos Musachio, EA	1
de Paula, MT	1
Prigol, M	2
Sales, AJ	1
Crestani, CC	1
Guimarães, FS	1
Joca, SRL	1
Contreras, CM	2
Gutiérrez-García, AG	2
Sánchez-Salcedo, JA	1
Farooq, RK	1
Tanti, A	1
Ainouche, S	1
Roger, S	1
Camus, V	1
Ryszewska-Pokraśniewicz, B	1
Mach, A	1
Skalski, M	1
Januszko, P	1
Wawrzyniak, ZM	1
Poleszak, E	1
Nowak, G	2
Pilc, A	1
Radziwoń-Zaleska, M	1
Micheli, L	1
Ceccarelli, M	1
D'Andrea, G	1
Tirone, F	1
Simard, S	1
Shail, P	1
MacGregor, J	1
El Sayed, M	1
Duman, RS	2
Vaccarino, FM	1
Salmaso, N	1
Mueller, PL	1
Pritchett, CE	1
Wiechman, TN	1
Zharikov, A	1
Hajnal, A	1
Lee-Kelland, R	1
Zehra, S	1
Mappa, P	1
Vera-Chang, MN	1
St-Jacques, AD	1
Gagné, R	1
Martyniuk, CJ	1
Yauk, CL	1
Moon, TW	1
Trudeau, VL	1
Gunlicks-Stoessel, M	1
Mufson, L	1
Bernstein, G	1
Westervelt, A	1
Reigstad, K	1
Klimes-Dougan, B	1
Cullen, K	1
Murray, A	1
Vock, D	1
Melvin, GA	1
Finnin, L	1
Taffe, J	1
Dudley, AL	1
Klimkeit, EI	1
Gordon, MS	1
Tonge, B	1
Wei, CL	1
Wang, S	2
Yen, JT	1
Cheng, YF	1
Liao, CL	1
Hsu, CC	1
Wu, CC	1
Tsai, YC	1
Taniguti, EH	1
Ferreira, YS	1
Stupp, IJV	1
Fraga-Junior, EB	1
Doneda, DL	1
Lopes, L	1
Rios-Santos, F	1
Lima, E	1
Buss, ZS	1
Viola, GG	1
Vandresen-Filho, S	1
Deng, X	1
Fu, J	1
Song, Y	1
Xu, B	1
Ji, Z	1
Guo, Q	1
Ma, S	1
Hu, MZ	1
Wang, AR	1
Zhao, ZY	1
Chen, XY	2
Li, YB	1
Liu, B	1
Fernandes, J	1
Gupta, GL	1
Poggini, S	1
Golia, MT	1
Alboni, S	1
Milior, G	1
Sciarria, LP	1
Viglione, A	1
Matte Bon, G	1
Brunello, N	1
Puglisi-Allegra, S	1
Limatola, C	1
Maggi, L	1
Branchi, I	1
Zhao, J	1
Jung, YH	1
Jin, Y	1
Kang, S	1
Jang, CG	1
Zubair, UB	1
Mansoor, S	1
Guo, S	1
Cheng, S	1
Xu, H	1
Szewczyk, B	1
Pochwat, B	1
Muszyńska, B	1
Opoka, W	1
Krakowska, A	1
Rafało-Ulińska, A	1
Friedland, K	1
Vitiello, B	5
Demyttenaere, K	2
Corruble, E	2
Hale, A	1
Quera-Salva, MA	1
Picarel-Blanchot, F	1
Kasper, S	6
Lin, CH	2
Chen, CC	2
Wang, FC	1
Lane, HY	1
Garlow, SJ	2
Kinkead, B	1
Thase, ME	17
Judd, LL	2
Rush, AJ	14
Yonkers, KA	3
Kupfer, DJ	7
Frank, E	7
Schettler, PJ	2
Rapaport, MH	3
Yang, CR	3
Zhang, ZG	1
Bai, YY	3
Zhou, HF	2
Zhou, L	2
Ruan, CS	3
Li, F	1
Li, CQ	1
Zheng, HY	2
Shen, LJ	2
Zhou, XF	3
Chang, T	1
Chen, YC	1
Zhang, RG	1
Wang, HN	1
Wu, WJ	1
Peng, ZW	1
Tan, QR	1
El Yacoubi, M	3
Rappeneau, V	1
Champion, E	1
Malleret, G	1
Vaugeois, JM	3
Schmelting, B	1
Corbach-Söhle, S	1
Kohlhause, S	1
Schlumbohm, C	1
Flügge, G	1
Fuchs, E	2
Stone, MB	1
Hammad, TA	1
Bastos, AG	2
Guimarães, LS	2
Trentini, CM	2
McIntyre, RS	1
Cha, DS	1
Kim, RD	1
Mansur, RB	1
Robison, AJ	2
Vialou, V	3
Sun, HS	1
Labonte, B	1
Golden, SA	1
Dias, C	1
Turecki, G	1
Tamminga, C	1
Russo, S	1
Mazei-Robison, M	2
Nestler, EJ	3
Mendez-David, I	1
David, DJ	4
Darcet, F	1
Wu, MV	1
Kerdine-Römer, S	1
Gardier, AM	4

Trial	Phase	Enrollment	Study Type	Start Date	Status
Efficacy of Individualized Homeopathic Treatment for Moderate to Severe Depression in Peri- and Postmenopausal Women: a Randomized Placebo-controlled, Double-blind, Double-dummy, Study Protocol[NCT01635218]	Phase 2	133 participants (Actual)	Interventional	2012-03-31	Completed
Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) a Multicentre Open-label Randomized Controlled Trial Protocol[NCT05814640]	Phase 1/Phase 2	520 participants (Anticipated)	Interventional	2023-02-20	Recruiting
A Personalized Approach to Achieving a Sustained Response to Treatment for Adolescent Depression[NCT02017535]	Phase 1/Phase 2	15 participants (Actual)	Interventional	2012-06-30	Completed
Depression Treatment to Improve Antiretroviral Adherence[NCT00338767]	Phase 2	150 participants (Actual)	Interventional	2001-01-31	Completed
Treatment of SSRI-Resistant Depression in Adolescents (TORDIA)[NCT00018902]	Phase 2/Phase 3	334 participants (Actual)	Interventional	2001-01-31	Completed
Efficacy and Safety of Auricular Acupuncture in Depression During the Covid 19 Pandemic: a Multicenter Triple-blinded Randomized Clinical Trial[NCT05855421]		280 participants (Anticipated)	Interventional	2023-03-01	Recruiting
The Study of Olanzapine Plus Fluoxetine in Combination for Treatment-Resistant Depression Without Psychotic Features[NCT00035321]	Phase 3	600 participants	Interventional	2002-04-30	Completed
A Preliminary Study of the Efficacy and Safety of Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency[NCT01379469]	Phase 2	20 participants (Actual)	Interventional	2012-01-31	Terminated
Evaluating a Multi-component Group Intervention for Improving Psychological Well-being of Trainee Civil Servants in Pakistan: a Randomised Controlled Study[NCT03762421]		240 participants (Actual)	Interventional	2018-12-01	Completed
Building and Sustaining Interventions for Children (BASIC): Task-sharing Mental Health Care in Low-resource Settings[NCT03243396]		2,880 participants (Anticipated)	Interventional	2018-02-01	Enrolling by invitation
The Effectiveness and Cost-effectiveness of a Collaborative Stepped Care Intervention for the Treatment of Common Mental Disorders in Primary Care Settings in Goa, India[NCT00446407]		2,796 participants (Actual)	Interventional	2007-04-30	Completed
Effectiveness of Non-medical Health Worker (NMHW) Led Counseling on Common Mental Disorders in Rural Mid-western Nepal[NCT03544450]		287 participants (Actual)	Interventional	2016-05-31	Completed
Sequenced Treatment Alternatives to Relieve Depression[NCT00021528]	Phase 4	4,000 participants	Interventional	2001-07-31	Completed
Minocycline as an Adjunct for the Treatment of Depressive Symptoms: Pilot Randomized Controlled Trial[NCT02263872]	Phase 4	41 participants (Actual)	Interventional	2014-10-31	Completed
Placebo-controlled, Dose-response Study of Ibuprofen Effects on Brain Function[NCT02507219]	Phase 2/Phase 3	24 participants (Actual)	Interventional	2015-07-31	Completed
Hypnotics in the Treatment of Psychiatric Disorders[NCT00247624]	Phase 4	60 participants (Actual)	Interventional	2005-10-31	Completed
Creatine Augmentation in Female & Male Veterans With Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder[NCT01175616]	Phase 4	0 participants (Actual)	Interventional	2012-09-30	Withdrawn (stopped due to Study withdrawn from ClinicalTrials.gov.)
Adjunctive Creatine Treatment for Adolescent Females With Major Depressive Disorder Who Are Non-Responders to Fluoxetine or Escitalopram: A Magnetic Resonance Spectroscopy Study[NCT00851006]	Phase 2	13 participants (Actual)	Interventional	2009-04-30	Completed
Placebo-Controlled Trial of Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder: a Magnetic Resonance Spectroscopy Study[NCT02134808]	Phase 4	71 participants (Actual)	Interventional	2014-11-21	Completed
Clinical, Neurocognitive and Neuroimaging Variables Associated With Response to Treatment in Patients With OCD[NCT03993535]	Phase 4	250 participants (Actual)	Interventional	2018-10-10	Active, not recruiting
Transcranial Direct Current Stimulation (tDCS) for Depression in Pregnancy: A Pilot Study[NCT02116127]		20 participants (Actual)	Interventional	2014-04-30	Completed
Efficacy and Safety of Antidepressant Augmentation With Lamotrigine in Patients With Treatment-Resistant Depression[NCT00652171]	Phase 3	34 participants (Actual)	Interventional	2004-01-31	Completed
The Influence of Pharmacotherapy and Psychotherapy for MDD After Remission on Psychology and Neuroimaging：A Comparative Longitudinal Study[NCT01831440]		200 participants (Anticipated)	Interventional	2011-01-31	Recruiting
Rumination Focused Cognitive Behavioral Therapy for Major Depression and Recurrent Depression and Relapse Prevention -a Pragmatic RCT Study in a Danish Psychiatric Outpatient Service[NCT02278224]		131 participants (Actual)	Interventional	2013-11-30	Completed
Medication Treatment Following Neuropsychologic, Dichotic and f-MRI Tests in Depressed Outpatients With Repeat f-MRI Following Treatment[NCT00296777]	Phase 4	28 participants (Actual)	Interventional	2004-12-31	Completed
Dichotic Listening as a Predictor of Placebo and Medication Response in Depression[NCT00296725]	Phase 1/Phase 2	25 participants (Actual)	Interventional	1994-04-30	Completed
A Pilot Study of Repetitive Transcranial Magnetic Stimulation for Improvement of Depression in Amyotrophic Lateral Sclerosis[NCT03892863]		0 participants (Actual)	Interventional	2019-11-15	Withdrawn (stopped due to Participants were not able to stay for two weeks near our center.)
Repetitive Transcranial Magnetic Stimulation (rTMS) for Motor and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial[NCT01080794]		61 participants (Actual)	Interventional	2010-05-31	Completed
A Double-Blind, Placebo-Controlled Study of Brexpiprazole in the Treatment of Borderline Personality Disorder.[NCT03418675]	Phase 2	80 participants (Actual)	Interventional	2018-11-26	Completed
[NCT00265291]	Phase 2	700 participants (Actual)	Interventional	1999-11-30	Completed
Treatment of Depression Occurring in the Setting of Cerebrovascular Risk -- A Pilot Study[NCT00781326]	Phase 4	9 participants (Actual)	Interventional	2008-08-31	Terminated (stopped due to Final cost of study medication was significantly greater than initial estimate,)
An Acute and Continuation Phase Study of the Comparative Efficacy Study of Venlafaxine ER (Effexor® XR) and Fluoxetine (Prozac®) in Achieving and Sustaining Remission (Wellness) in Patients With Recurrent Unipolar Major Depression; Followed by a Long Term[NCT00046020]	Phase 4	1,096 participants (Actual)	Interventional	2000-08-31	Completed
Folate Augmentation of Treatment - Evaluation for Depression: a Randomised Controlled Trial[NCT00514410]	Phase 4	730 participants (Anticipated)	Interventional	2007-07-31	Completed
Prospective 24-week Study, Comparing Clinical Outcomes Between Switching Antidepressants and Maintaining the Same Antidepressant in Patients With Major Depressive Disorder Who do Not Show a 20% Reduction in Symptoms at Week 2[NCT00519012]	Phase 4	200 participants (Anticipated)	Interventional	2007-08-31	Recruiting
Platelet Dysfunction in Patients Treated With SSRI Versus Non-SSRI Antidepressants[NCT00009568]		70 participants	Observational	2001-01-31	Completed
Model for Early Prediction of Clinical Response in Patients With Major Depression Receiving Fluoxetine[NCT01075529]	Phase 4	140 participants (Actual)	Interventional	2007-03-31	Completed
Silymarin Treatment of Body Dysmorphic Disorder: A Double-Blind, Placebo-Controlled, Cross-Over Study[NCT02843451]	Phase 2	0 participants (Actual)	Interventional	2016-10-31	Withdrawn (stopped due to Focus on other studies)
Quetiapine Augmentation Versus Clomipramine Augmentation of Selective Serotonin Reuptake Inhibitors for Obsessive-compulsive Disorder Patients That do Not Respond to a SSRI Trial: a Randomized Open-trial.[NCT00564564]	Phase 4	21 participants (Actual)	Interventional	2006-01-31	Completed
An Open Treatment Trial of Duloxetine in Elderly Patients With Dysthymic Disorder[NCT01852383]	Phase 4	30 participants (Actual)	Interventional	2006-01-31	Completed
A Randomized, Placebo-Controlled Pilot Study in Huntington's Disease (CIT-HD)[NCT00271596]	Phase 2	33 participants (Actual)	Interventional	2005-11-30	Completed
Double-Blind, Placebo-Controlled, Randomized Trial of Adjunctive Lisdexamfetamine Dimesylate in Residual Symptoms of Major Depressive Disorder Partially Responsive to Selective Serotonin or Norepinephrine Reuptake Inhibitor Monotherapy[NCT01148979]	Phase 4	35 participants (Actual)	Interventional	2010-09-30	Completed
Multicentre Prospective Interventional Cohort Study Assessing Risk and Protective Factors to Develop Psychopathology in Transitional Age Youth[NCT04333797]		300 participants (Anticipated)	Interventional	2020-06-02	Recruiting
A Controlled, Randomized, Double-Blind Trial of Sertraline in Patients With Frontal Lobe Dementia (FLD)[NCT00001777]	Phase 1	30 participants	Interventional	1997-12-31	Completed
Augment in Treatment-resistent Obsessive-compulsive Disorder: an Open-label Trial[NCT00590642]		30 participants (Anticipated)	Observational	2006-04-30	Completed
Clinical and Neurochemical Effects of Pharmacologic Treatment in Pediatric Depression[NCT00029640]		90 participants	Observational	2002-01-31	Completed
Double Blind, Placebo Controlled Pilot Study to Evaluate the Use of Selenium as an Augmentation Treatment for Sertraline Resistant Major Depression[NCT02890212]		60 participants (Anticipated)	Interventional	2005-08-31	Suspended (stopped due to due to COVID19 pandemic)
Cortical rTMS as a Treatment for Depression[NCT05487911]		50 participants (Anticipated)	Interventional	2023-06-14	Enrolling by invitation
Functional Connectivity Alterations in Suicidal Patients Among Opioid Users[NCT05489042]		80 participants (Anticipated)	Interventional	2022-01-04	Recruiting
Effect of Serotonin and Levodopa Functional Recovery in Patients With Cerebral Infarction[NCT02386475]	Phase 4	39 participants (Actual)	Interventional	2015-01-31	Completed
A Randomized, Placebo-controlled Trial of St.John's Wort(a Natural Health Product) in the Treatment on Raynaud's Phenomenon[NCT00351117]	Phase 3	20 participants (Actual)	Interventional	2007-03-31	Completed
Feasibility of Using Holographic Memory Resolution® (HMR) in Patients/Clients With Pain[NCT05001399]		60 participants (Actual)	Interventional	2021-10-25	Completed
Quetiapine in the Treatment of Psychotic Depression - a Pilot Study[NCT00751504]	Phase 3	16 participants (Actual)	Interventional	2008-09-30	Completed
CSP #430 - Reducing The Efficacy-Effectiveness Gap In Bipolar Disorder[NCT00007761]	Phase 3	382 participants (Anticipated)	Interventional	1997-07-31	Completed
Galantamine Versus Placebo in Childhood Autism[NCT00252603]	Phase 3	20 participants	Interventional	2004-04-30	Completed
Ketamine Frequency Treatment for Major Depressive Disorder[NCT00646087]	Phase 4	0 participants (Actual)	Interventional	2008-03-31	Withdrawn (stopped due to Pilot study determined that this study would not be feasible.)
Study of Antidepressants in Parkinson's Disease[NCT00086190]	Phase 3	115 participants (Actual)	Interventional	2005-06-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

17-item Hamilton Rating Scale for Depression (HRSD) is a well-known standardized scale used worldwide to assess severity of depression. Score ranges from 0 (no depression) up to 52 (maximum depression severity). A total score in HRSD was assessed at baseline and after six weeks of treatment. For this study the change was calculated as the later time point (total score in 17- HRSD at 6 weeks) minus the earlier time point (total score at baseline). A score < or = 7 is considered normal, 7 - 13 (mild depression), 14 - 24 (moderate to severe depression), > 24 (severe depression). (NCT01635218)
Timeframe: Baseline and 6 weeks

Change From Baseline in Beck Depression Inventory at 6 Weeks.

Intervention	Units in Hamilton Scale (Mean)
Individualized Homeopathic Treatment	9.9
Fluoxetine	11.7
Placebo	15

Beck Depression Inventory (BDI) is a 21-question multiple-choice self-report inventory that assess severity of depression. A total score range was assessed at baseline and after six weeks of treatment. A score 0 (without depression) up to 63 (most severe depression). For this study the change was calculated as the later time point (total score in BDI at 6 weeks) minus the earlier time point (total score in BDI at baseline). A score 0 - 8 is considered normal, 9 - 18 (mild to moderate depression), 19 - 28 (moderate to severe depression), > 29 (severe depression). (NCT01635218)
Timeframe: Baseline and 6 weeks

Change From Baseline in Greene´s Scale at 6 Weeks.

Intervention	Units in Beck Depression Inventory (Mean)
Individualized Homeopathic Treatment	12
Fluoxetine	14.2
Placebo	15.5

Greene Climacteric Scale (GS) is intended to be a standard measure of core climacteric symptoms. For this study a total range was assessed at baseline and after six weeks of treatment. A total score 0 (without climacteric symptoms) up to 63 (most severe climacteric symptoms). The change was calculated as the later time point (total score in GS at 6 weeks) minus the earlier time point (total score at baseline).The scale measures four separate sub-scales (anxiety, depression, somatic symptoms and sexual function). The score of the four sub-scales was summed. A total score of 0 -10 is considered without symptoms, 11 - 29 (mild symptoms), 30 - 49 (moderate symptoms) and > 50 (severe symptoms). (NCT01635218)
Timeframe: Baseline and 6 weeks

Remission Rates at 6 Weeks

Intervention	Units in Green Scale (Mean)
Individualized Homeopathic Treatment	18.1
Fluoxetine	23.1
Placebo	26.8

17-item Hamilton Rating Scale for Depression is a well-known standardized scale used worldwide to assess severity of depression. Score ranges from 0 (no depression) up to 52 (maximum depression severity). A total score in 17-item Hamilton Scale for Depression was assessed for this study. It ranges from 0 (no depression) up to 52 (most severe depression). A score < or = 7 is considered normal, 7 - 13 (mild depression), 14 - 24 (moderate to severe depression), > 24 (severe depression). Remission rate definition: 17-item Hamilton Rating Scale for Depression score < 7 points after 6 weeks of treatment. (NCT01635218)
Timeframe: 6 weeks

Responder Rates at 6 Weeks.

Intervention	participants with a score of < 7 in HS (Number)
Individualized Homeopathic Treatment	7
Fluoxetine	7
Placebo	2

17-item Hamilton Rating Scale for Depression is a well-known standardized scale used worldwide to assess severity of depression. Score ranges from 0 (no depression) up to 52 (maximum depression severity). A total score in 17-item Hamilton Scale for Depression was assessed for this study. It ranges from 0 (no depression) up to 52 (most severe depression). A score < or = 7 is considered normal, 7 - 13 (mild depression), 14 - 24 (moderate to severe depression), > 24 (severe depression). Responder rate definition: a decrease of 50% or more from baseline score using 17-item Hamilton Rating Scale for Depression after six weeks treatment. (NCT01635218)
Timeframe: 6 weeks

Beck Depression Inventory-II (BDI-II)

Intervention	participants with a decrease >50% in HS (Number)
Individualized Homeopathic Treatment	24
Fluoxetine	19
Placebo	5

BDI-II is a 21-item self-report multiple-choice inventory that assesses the severity of depressive symptoms reflective of DSM-IV diagnostic criteria over the prior week. Items are rated on a 4-point scale ranging from 0 to 3. Total scores are a sum of the 21 item scores ranging from 0 to 63. Higher scores indicate more severe depression symptoms. (NCT02017535)
Timeframe: 16 weeks, 32 weeks

Children's Depression Rating Scale-Revised (CDRS-R)

Intervention	score on a scale (Mean)
	16 weeks	32 weeks
10 IPT-A Sessions + Begin Fluoxetine	10	1.5
10 IPT-A Sessions + Increase Dose of Fluoxetine	NA	41
6 IPT-A Sessions	7.63	5.86
6 IPT-A Sessions + Continue Current Dose of Fluoxetine	11.33	9

The CDRS-R is a clinician-administered semi-structured interview designed to assess present episode and lifetime history of psychiatric diagnoses based on DSM-IV criteria. This survey contains 17 items; 3 items are rated on a scale from 0 to 5, 5 items are rated on a scale from 0 to 6, and the remaining 9 items are rated on a scale from 0 to 7. Total score is a raw sum of the 17 item scores and ranges from 0 to 108. Higher scores indicate greater depression severity. (NCT02017535)
Timeframe: 16 weeks, 32 weeks

Children's Global Assessment Scale (CGAS)

Intervention	score on a scale (Mean)
	16 Weeks	32 Weeks
10 IPT-A Sessions + Begin Fluoxetine	51	29
10 IPT-A Sessions + Increase Dose of Fluoxetine	45	51
6 IPT-A Sessions	32.38	29
6 IPT-A Sessions + Continue Current Dose of Fluoxetine	26.67	33.33

The CGAS is a numeric scale used by mental health clinicians to rate the general functioning of youths under the age of 18. Scores range from 1 to 100, with higher scores indicating better functioning. (NCT02017535)
Timeframe: 16 weeks, 32 weeks

Social Adjustment Scale - Self Report (SAS-SR)

Intervention	score on a scale (Mean)
	16 weeks	32 weeks
10 IPT-A Sessions + Begin Fluoxetine	53	72
10 IPT-A Sessions + Increase Dose of Fluoxetine	55	49
6 IPT-A Sessions	65	72
6 IPT-A Sessions + Continue Current Dose of Fluoxetine	77	71

The SAS-SR is a 42-item self report measure of role performance in the past 2 weeks. Items are rated on a 5-point scale. Total scores are calculated by summing the 42 item scores and dividing by the total number of items answered. Total scores range from 1 to 5, with higher scores indicating greater impairment of functioning. (NCT02017535)
Timeframe: 16 weeks, 32 weeks

Dose-dependent Differences in the BOLD Response to fMRI Tasks in the Amygdala

Intervention	score on a scale (Mean)
	16 weeks	32 weeks
10 IPT-A Sessions + Begin Fluoxetine	2.75	2.18
10 IPT-A Sessions + Increase Dose of Fluoxetine	NA	3.09
6 IPT-A Sessions	2.03	2.17
6 IPT-A Sessions + Continue Current Dose of Fluoxetine	2.07	1.62

Change in amygdala activation following administration of placebo, 200mg of ibuprofen or 600mg of ibuprofen (NCT02507219)
Timeframe: 3-6 weeks

Daily Living and Role Functioning (DLRF) Basis-32 Subscale Ratings

Intervention	percent signal change (Mean)
	Left amygdala	Right amygdala
Ibuprofen, 200mg	0.21	0.23
Ibuprofen, 600mg	0.23	0.17
Placebo	0.20	0.23

"The BASIS 32 psychometric includes several subscales, including daily living and role functioning (DLRF). These subscales are rated from 0-4, with higher scores indicating a greater deal of difficulty in this dimension and lower scores denoting better outcomes. Measured weekly for 9 weeks. Reported as mean of 9 weeks." (NCT00247624)
Timeframe: 9 weeks

Insomnia Severity Index (ISI)

Intervention	units on a scale (Mean)
Fluoxetine (FLX) Plus Eszopiclone (ESZ)	0.81
FLX Plus Placebo	1.2

The Insomnia Severity Index has seven questions. The seven answers are added up to get a total score, range 0-28. Lower scores represent better outcomes. Total score categories: 0-7 = No clinically significant insomnia, 8-14 = Subthreshold insomnia, 15-21 = Clinical insomnia (moderate severity), 22-28 = Clinical insomnia (severe). (NCT00247624)
Timeframe: 9 weeks

Quality of Life Ratings, as Measured by the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)

Intervention	units on a scale (Mean)
Fluoxetine (FLX) Plus Eszopiclone (ESZ)	21.1
FLX Plus Placebo	20.2

The Q-LES-Q is scored from 0-100, with higher scores better than lower. Measured weekly for 9 weeks. Reported as mean of 9 weeks. (NCT00247624)
Timeframe: 9 weeks

Relation to Self/Others (RSO) Basis-32 Subscale Ratings

Intervention	units on a scale (Mean)
Fluoxetine (FLX) Plus Eszopiclone (ESZ)	50.2
FLX Plus Placebo	46.9

"The BASIS 32 psychometric includes several subscales, including relation to self and others (RSO). These subscales are rated from 0-4, with higher scores indicating a greater deal of difficulty in this dimension. Measured weekly for 9 weeks. Reported as mean of 9 weeks." (NCT00247624)
Timeframe: 9 weeks

31-phosphorus Magnetic Resonance Spectroscopy Phosphocreatine Metabolite

Intervention	units on a scale (Mean)
Fluoxetine (FLX) Plus Eszopiclone (ESZ)	0.74
FLX Plus Placebo	1.04

Phosphocreatine Metabolite is a phosphorylated creatine molecule that plays a role in the production of the energy in the body. Phosphocreatine (PCr) metabolite was quantified by calculating the ratio of PCr over total phosphorus resonance from 31-Phosphorus Magnetic Resonance Spectroscopy. (NCT00851006)
Timeframe: 8 weeks

Mean Children's Depression Rating Scale (CDRS-R) [Reference: Poznanski EO et al. Preliminary Studies of the Reliability and Validity of the Children's Depression Rating Scale. J Am Acad Child Psychiatry. 1984 Mar;23(2):191-7.]

Intervention	ratio of PCr and total phosphorus (Mean)
	Baseline	After 8 weeks
Healthy Control Group	0.1556	0.1558
Open Label Creatine Treatment	0.1513	0.1610

The CDRS-R is a 17-item scale, with items ranging from 1 to 5 or 1 to 7 (possible total score from 17 to 113), rated by a clinician via interviews with the child or parent. Scores ≥40 are indicative of depression, whereas scores ≤28 is often used to define remission (NCT00851006)
Timeframe: 8 weeks

Hamilton Depression Scale (HAM-D)

Intervention	Units on a scale (Mean)
	Baseline	After 8 week Creatine treatment
Open Label Creatine Treatment	69	30.6

"The HAM-D is a commonly used measure of the severity of depression. While several versions exist consisting of different numbers of items, virtually all include the original 17. Each item is scored from on a 3 or 5 point scale (so, from 0-2 or 0-4), with 0 indicating the item is not present and the highest item score indicating it is present nearly all the time to the severest extent. Item scores are added to obtain a total HAM-D score. Minimum possible score is 0 (indicating none of the 17 items is present), maximal possible score is 52. By convention, scores of <=7 are accepted as indicating remission and scores that have decreased >= 50% from pre-treatment indicate positive response. Higher scores indicate worse depression, while lower scores indicate milder depression or lack of depressive symptoms." (NCT00296725)
Timeframe: 6 weeks

Number of Participants With Positive Response as Assessed by the Clinical Global Impression -Global Improvement Scale (CGI-I)

Intervention	score on a scale (Mean)
Fluoxetine	10
Imipramine	9

"The CGI consists of two ratings: 1) Global Severity (CGI-S) and 2) Global Improvement (CGI-I), both having seven possible ratings, each from 1-7. Ratings on the CGI-S are: 1=No psychopathology 2=Minimal psychopathology 3=Mild psychopathology 4=Moderate psychopathology 5=Moderately severe psychopathology 6=Severe psychopathology 7 Extreme psychopathology. CGI-I ratings are rated for how the past week's psychopathology compares to the week immediately prior to start of treatment and includes: 1=Very much improved 2=much improved 3=minimally improved 4=Unchanged 5=minimally worse 6=much worse 7=very much worse. Scores on both thus range from 1-7 with lower scores indicating less psychopathology/greater improvement, respectively, and higher scores indicating more psychopathology/less improvement, respectively. We define response as a CGI-I of 1 or 2; nonresponse is all other ratings (i.e., CGI-I = 3 or higher." (NCT00296725)
Timeframe: 6 weeks.

The Number All Types of Adverse Events.

Intervention	Participants (Count of Participants)
Fluoxetine	7
Imipramine	4

To establish the safety and tolerability of rTMS in Parkinson's Disease. (NCT01080794)
Timeframe: Baseline through Month 6

Apathy Evaluation Scale (AES)

Intervention	incidents of an adverse event (Number)
Double rTMS	18
M1 Active rTMS + DLPFC Sham rTMS	14
DLPFC Active rTMS + M1 Sham rTMS	1
Double Sham rTMS	1

To evaluate apathy in Parkinson's Disease. The AES mean scores were reported for each group at each time point. The AES Score Range is 0-42, where higher the score indicates greater severity of the apathy symptoms. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.

Beck Depression Inventory (BDI-II)

Intervention	units on a scale (Mean)
	Baseline (Pre-Treatment)	Week 1 Post Treatment	Month 1 Post Treatment	Month 3 Post Treatment	Month 6 Post Treatment
DLPFC Active rTMS + M1 Sham rTMS	18.7	18.1	19.0	19.3	15.8
Double rTMS	15.6	16.2	17	16.9	17.8
Double Sham rTMS	16.3	15.5	15.0	16.1	16.2
M1 Active rTMS + DLPFC Sham rTMS	15.9	16.9	14.6	15.1	12.4

To assess mood symptoms in Parkinson's Disease. The BDI-II mean scores were reported for each group at each time point. The BDI-II Score Range is 0 - 63, where higher the score indicates greater severity of the mood symptoms. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.

Clinical Anxiety Scale (CAS)

Intervention	units on a scale (Mean)
	Baseline (Pre-Treatment)	Week 1 Post Treatment	Month 1 Post Treatment	Month 3 Post Treatment	Month 6 Post Treatment
DLPFC Active rTMS + M1 Sham rTMS	21.7	18.2	20.2	19.0	15.7
Double rTMS	23.2	20.7	16.4	17.9	20.1
Double Sham rTMS	18.8	13.7	13.1	14.7	16.8
M1 Active rTMS + DLPFC Sham rTMS	18.5	16.5	16.7	19.1	16.3

To evaluate anxiety in Parkinson's Disease. The CAS mean scores were reported for each group at each time point. The CAS Score Range is 0 - 100, where higher the score indicates greater severity of the anxiety symptoms. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.

Global Impression Scales

Intervention	units on a scale (Mean)
	Baseline (Pre-Treatment)	Week 1 Post Treatment	Month 1 Post Treatment	Month 3 Post Treatment	Month 6 Post Treatment
DLPFC Active rTMS + M1 Sham rTMS	33.4	27.6	30.8	31.4	24.8
Double rTMS	36.3	34.2	31.7	33.1	33.4
Double Sham rTMS	37.5	32.4	28.2	28.5	35.0
M1 Active rTMS + DLPFC Sham rTMS	34.3	31.0	30.8	27.3	28.1

To assess symptom severity and treatment response in Parkinson's Disease. The CGI mean scores were reported for each group at each time point. The CGI Score Range is 1 - 8, where higher the score indicates greater severity of illness or worsening of illness. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.

Hamilton Depression Scale (HAM-D)

Intervention	units on a scale (Mean)
	Baseline (Pre-Treatment): Severity	Week 1 Post Treatment: Severity	Week 1 Post Treatment: Improvement	Month 1 Post Treatment: Severity	Month 1 Post Treatment: Improvement	Month 3 Post Treatment: Severity	Month 3 Post Treatment: Improvement	Month 6 Post Treatment: Severity	Month 6 Post Treatment: Improvement
DLPFC Active rTMS + M1 Sham rTMS	4.3	4.7	3.5	4.4	3.7	4.4	3.6	4.3	3.7
Double rTMS	4.9	4.8	3.6	4.4	3.5	4.6	3.7	4.2	3.5
Double Sham rTMS	3.6	3.9	3.0	4.1	3.5	4.4	3.6	4.6	3.4
M1 Active rTMS + DLPFC Sham rTMS	4.7	4.9	3.5	4.8	3.8	3.8	3.4	5.0	4.2

"To evaluate the depressive mood symptoms in PD.~The HAM-D mean scores were reported for each group at each time point. The HAM-D Score Range is 0 - 56, where higher the score indicates greater severity of depressive mood symptoms." (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.

Montreal Cognitive Assessment (MoCA)

Intervention	units on a scale (Mean)
	Baseline (Pre-Treatment)	Week 1 Post-Treatment	Month 1 Post-Treatment	Month 3 Post-Treatment	Month 6 Post-Treatment
DLPFC Active rTMS + M1 Sham rTMS	13.8	9.4	12.4	10.4	10.4
Double rTMS	15.2	11.3	10.6	10.7	10.4
Double Sham rTMS	14.1	9.3	8.0	11.1	10.4
M1 Active rTMS + DLPFC Sham rTMS	16.7	11.2	10.1	10.1	8.6

To screen and follow cognitive function in Parkinson's Disease. The MoCA mean scores were reported for each group at each time point. The MoCA Score Range is 0 - 30, where 26-30 indicates normal cognition. (NCT01080794)
Timeframe: pre-treatment; 0,1,3, and 6 months post-treatment

Motor Subscale of the Unified Parkinson's Disease Rating Scale (UPDRS Part III)

Intervention	units on a scale (Mean)
	Baseline (Pre-Treatment)	Week 1 Post Treatment	Month 1 Post Treatment	Month 3 Post Treatment	Month 6 Post Treatment
DLPFC Active rTMS + M1 Sham rTMS	27.3	26.3	26.8	26.7	26.6
Double rTMS	28.2	26.8	28.8	26.5	28.0
Double Sham rTMS	26.2	27.8	28.7	24.9	28.0
M1 Active rTMS + DLPFC Sham rTMS	26.6	27.1	27.2	25.3	27.9

"To evaluate the motor symptoms in Parkinson's Disease.~The UPDRS-III mean scores were reported for each group at each time point. The UPDRS-III Score Range is 0 - 56, where higher the score indicates greater severity of the motor symptoms." (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.

Parkinson's Disease Questionnaire 39 (PDQ-39)

Intervention	units on a scale (Mean)
	Baseline (Pre-Treatment)	Week 1 Post-Treatment	Month 1 Post-Treatment	Month 3 Post-Treatment	Month 6 Post-Treatment
DLPFC Active rTMS + M1 Sham rTMS	32.8	30.3	29.3	31.5	28.8
Double rTMS	32.3	31.2	30.1	29.6	30.5
Double Sham rTMS	28.9	28.2	28.6	28.6	29.0
M1 Active rTMS + DLPFC Sham rTMS	33.1	27.4	28.1	33.2	30.6

To assess the quality of life (QOL) in Parkinson's Disease. The PDQ-39 mean scores were reported for each group at each time point. The PDQ-39 Score Range is 0 - 156, where higher the score indicates greater impact on quality of life. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.

Unified Parkinson's Disease Rating Scale (UPDRS) Parts I, II, and IV

Intervention	units on a scale (Mean)
	Baseline (Pre-Treatment)	Week 1 Post Treatment	Month 1 Post Treatment	Month 3 Post Treatment	Month 6 Post Treatment
DLPFC Active rTMS + M1 Sham rTMS	51.9	46.8	49.4	49.4	49
Double rTMS	57.6	51.2	49.9	51.7	50.5
Double Sham rTMS	55.5	43.1	40.9	43.1	47.5
M1 Active rTMS + DLPFC Sham rTMS	61.5	60.7	56.8	53.1	48.3

"To assess apathy, cognition, depression, activities of daily living (ADL), quality of life (QOL), and motor symptoms in Parkinson's Disease.~The UPDRS I, II, IV total mean scores were reported for each group at each time point. The UPDRS I, II, IV scores were added together for each patient, with a total score range of 0 - 91, where higher the score indicates greater severity of the symptoms." (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.

Hamilton Anxiety Rating Scale (HAM-A)

Intervention	units on a scale (Mean)
	Baseline (Pre-Treatment)	Week 1 Post Treatment	Month 1 Post Treatment	Month 3 Post Treatment	Month 6 Post Treatment
DLPFC Active rTMS + M1 Sham rTMS	21.5	19.3	19.9	18.9	20.2
Double rTMS	25.4	23.3	21.8	21.1	23.8
Double Sham rTMS	19.6	15.5	16.5	16.9	18.8
M1 Active rTMS + DLPFC Sham rTMS	26.1	23.2	23.0	23.2	22.7

A clinician-administered assessment of anxiety that will be assessed at all study visits (Visit 1-Visit 8). Changes in scores from baseline to final visit will be assessed. Higher scores (up to 56) indicate higher levels of anxiety, with 0 being no symptoms of anxiety. (NCT03418675)
Timeframe: assessed at Visits 1 to 8, change in scores from Visit 1 to Visit 8 (baseline to Week 12) is reported

Hamilton Depression Rating Scale (HAM-D)

Intervention	change in score on a scale (Mean)
Placebo	-2.41
Rexulti	-4.88

A clinician-administered assessment of depression that will be assessed at all study visits (Visits 1-8). Higher total scores indicate higher levels of depression (up to 52), while a score of 0 would indicate no depressive symptoms. (NCT03418675)
Timeframe: Assessed at Visits 1 to 8, change in scores from Visit 1 to Visit 8 (baseline to week 12) is reported

Barratt Impulsiveness Scale (BIS)

Intervention	change in score on a scale (Mean)
Placebo	-2.09
Rexulti	-3.81

A self-report assessment of impulsivity that will be assessed at baseline and visit 8. The BIS is composed of 30 items describing common impulsive or non-impulsive (for reverse scored items) behaviors and preferences. Items are scored on a 4-point scale: (Rarely/Never = 1, Occasionally = 2, Often = 3, Almost Always/Always = 4). These scores are summed to produce an overall impulsivity score ranging from 30 (not impulsive) to 120 (extremely impulsive). (NCT03418675)
Timeframe: Baseline (Visit 1), Week 12 (Visit 8)

Borderline Evaluation of Severity Over Time (BEST)

Intervention	score on a scale (Mean)
	Visit 1	Visit 8
Placebo	76.53	68.13
Rexulti	72.27	70.5

A self rated scale used to measure severity and change. The first 12 items of the scale are on a scale from 1-5, with 5 meaning that the item caused extreme distress, severe difficulties in relationships, and/or kept them from getting things done. The lowest rating (1) means it caused little or no problems. Items 13-15 (positive behaviors) are rated according to frequency. Completed at every visit. (NCT03418675)
Timeframe: Assessed at Visits 1 to 8, change in scores from Visit 1 to Visit 8 (baseline to week 12) is reported

Columbia Suicide Severity Rating Scale (CSSRS)

Intervention	score on a scale (Mean)
	Visit 1	Visit 8
Placebo	40.90	29.15
Rexulti	40.54	23.15

"A self-report scale measuring suicidality. Subjects will complete the scale at all visits. Subjects are asked about suicidal thoughts. If answers are no, rater can proceed to suicidal behavior section where subject is asked about any non-suicidal self injurious behavior. If yes, subject is asked about intensity of ideations. In the event of serious threat to themselves, the subject will be escorted to the emergency room. Total score indicates severity of suicidal ideation and behavior, with lower scores representing lower levels of suicidality and higher scores representing higher levels of suicidality. A score of 0 would reflect no suicidality present, whereas a maximum score of 5 would reflect active suicidal ideation with intent to act." (NCT03418675)
Timeframe: Baseline (Visit 1), Week 12 (Visit 8)

MINI International Neuropsychiatric Interview

Intervention	score on a scale (Mean)
	Visit 1	Visit 8
Placebo	1.15	0.23
Rexulti	0.73	0.08

A short-structured interview that assesses comorbid psychiatric disorders according to the DSM 5 criteria. This assessment will be done during the baseline visit. (NCT03418675)
Timeframe: Baseline (Week 1)

Quality of Life Inventory (QOLI)

Intervention	Participants (Count of Participants)
	Major Depressive Episode (Current)	Major Depressive Episode (Past)	Manic Episode (Current)	Manic Episode (Past)	Hypomanic Episode (Current)	Bipolar I Disorder (Current)	Bipolar I Disorder (Past)	Bipolar II Disorder (Current)	Bipolar II Disorder (Past)	Panic Disorder (Current)	Panic Disorder (Lifetime)	Agoraphobia (Current)	Social Anxiety Disorder (Current)	Obsessive Compulsive Disorder (Current)	Post Traumatic Stress Disorder (Current)	Alcohol Use Disorder (Past 12 months)	Substance Use Disorder (Past 12 months)	Any Psychotic Disorder (Current)	Any Psychotic Disorder (Lifetime)	Major Depressive Disorder with Psychotic Features (Current)	Major Depressive Disorder with Psychotic Features (Past)	Anorexia Nervosa (current)	Bulimia Nervosa (Current)	Binge Eating Disorder (Current)	Generalized Anxiety Disorder (Current)	Antisocial Personality Disorder (Lifetime)	ADHD Combined Type (Current)	ADHD Inattentive Type (Current)	ADHD Hyperactive Type (Current)	Tourette's Syndrome (Lifetime)	Persistent Motor Tic Disorder (Lifetime)	Provisional Vocal Tic Disorder (Lifetime)	Provisional Tic Disorder (Lifetime)	Specific Phobia	Body Dysmorphic Disorder (Current)
Placebo	16	12	2	1	1	0	0	0	0	6	11	7	6	3	9	13	11	0	0	0	0	0	4	2	10	8	2	0	1	0	1	0	0	4	3
Rexulti	18	18	2	3	0	0	0	0	1	6	10	9	9	3	12	8	8	0	1	0	0	1	4	4	15	4	4	1	1	1	1	0	0	1	2

A self-report assessment of patient perceived quality of life that will be assessed at baseline and visit 8. Higher scores indicate a higher quality of life, whereas lower scores indicate a lower quality of life. Participants are asked to rate the importance of each domain on a 3-point scale ranging from 1=not important to 3=very important, and to rate how satisfied they are with that domain on a 6-point scale, ranging from -3=very dissatisfied to +3=very satisfied. In scoring, importance ratings are multiplied by satisfaction ratings to produce weighted satisfaction scores for each of the 16 domains. Weighted satisfaction scores are summed and divided by the number of domains that were rated as important or very important to produce a raw score, which is then converted to a t-score, which provides a proxy measurement for perceived quality of life. T-scores range from very low perceived quality of life (0-36) to high perceived quality of life (58-77). (NCT03418675)
Timeframe: Baseline (Week 1), Week 12 (Visit 8)

Self Report Version of Zanarini Scale

Intervention	score on a scale (Mean)
	Visit 1	Visit 8
Placebo	28.89	30.75
Rexulti	28.70	35.71

A self-report scale assessing Borderline Personality severity that will be assessed at all visits.This scale is assessing severity and change in BPD symptoms. This is a 9-item scale measuring severity of different aspects of Borderline Personality Disorder, with each item rated on a 0-4 scale, 0=no symptoms, 4=severe symptoms. Total scores range from 0-36. (NCT03418675)
Timeframe: Baseline (Visit 1), Week 1 (Visit 2), Week 2 (Visit 3), Week 4 (Visit 4), Week 6 (Visit 5), Week 8 (Visit 6), Week 10 (Visit 7), Week 12 (Visit 8)

Sheehan Disability Scale (SDS)

Intervention	score on a scale (Mean)
	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7	Visit 8
Placebo	18.2	12.8	10.7	10.7	9.7	9.6	8.7	9.3
Rexulti	17.6	10.9	7.9	8.0	7.0	6.6	6.0	5.8

Subjects will complete the SDS at all visits. The change in scores from baseline to study completion will be assessed. The scale itself assesses the level of disability from borderline personality disorder (or target disorder) with higher scores indicating a more debilitating disorder. Scores range from 0-30. (NCT03418675)
Timeframe: Baseline (Visit 1), Week 1 (Visit 2), Week 2 (Visit 3), Week 4 (Visit 4), Week 6 (Visit 5), Week 8 (Visit 6), Week 10 (Visit 7), Week 12 (Visit 8)

Symptom Checklist-90 Revised

Intervention	score on a scale (Mean)
	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7	Visit 8
Placebo	17.3	13.3	11.5	12.4	11.7	11.2	12.0	12.7
Rexulti	15.8	10.7	7.8	7.8	7.0	7.9	6.9	7.7

An instrument that helps evaluate a broad range of psychological problems and symptoms of Borderline Personality Disorder psychopathology. This will be assessed at baseline and visit 8.The 115 items are rated by using a 5-step Likert scale (0=not at all, 4=very strong) and provide a global picture of borderline psychopathology. Global scores of borderline psychopathology are calculated by summing 12 items and range from 0-48. Higher scores indicate more severe symptoms of Borderline Personality Disorder. (NCT03418675)
Timeframe: Baseline, Visit 8 (Week 12)

Zanarini Rating Scale for Borderline Personality Disorder

Intervention	score on a scale (Mean)
	Visit 1	Visit 8
Placebo	26.17	20.25
Rexulti	25.42	14.21

A clinician-administered scale assessing Borderline Personality Scale severity at all study visits. Scores range from 0-36. Higher scores represent worse Borderline Personality Disorder severity, and lower scores represent milder Borderline Personality Disorder severity. (NCT03418675)
Timeframe: Baseline (Visit 1), Week 1 (Visit 2), Week 2 (Visit 3), Week 4 (Visit 4), Week 6 (Visit 5), Week 8 (Visit 6), Week 10 (Visit 7), Week 12 (Visit 8)

Hamilton Depression Rating Scale (24 Item) [Phase I Primary Outcome]

Intervention	score on a scale (Mean)
	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7	Visit 8
Placebo	14.9	7.6	4.7	6	4.2	5.7	5	8.4
Rexulti	14.9	6.7	5.3	4.4	4.5	4.9	4	3.1

Hamilton Depression Rating Scale (24 item) measures symptoms of major depression. We report total score which is the sum of all items. Total score range is 0 to 76 with higher scores indicating more severe depression. We reports scores at end of Phase I for subjects completing the phase. (NCT00781326)
Timeframe: End of Phase I (at 24 weeks)

Change in Cornell Dysthymia Rating Scale Scores From Week 0 to Week 12

Intervention	units on a scale (Mean)
Open Label Antidepressant	9.5

Cornell Dysthymia Rating Scale scores from range 0-64. Lower or decreasing scores represent decreased severity and a better outcome, while higher or increasing scores represent more severe depression and a worse outcome. The change score was calculated by subtracting the Week 12 score from the Week 0 score. (NCT01852383)
Timeframe: Week 0 and 12

Change in Hamilton Rating Scale for Depression (HAM-D, 24-item) From 0 Weeks to 12 Weeks.

Intervention	units on a scale (Mean)
Duloxetine	28.8

The research rater completed the 24-item Hamilton Rating Scale for Depression (HAM-D) and documented the scores on each visit. Hamilton Rating Scale for Depression scores range from 0-50 with low scores or decreasing scores representing decreased severity and better outcome, and higher scores or increasing scores representing more severe depressive symptoms and a worse outcome. The change score was calculated by subtracting the Week 12 score from the Week 0 score. (NCT01852383)
Timeframe: Screen (0) and 12 weeks

Change in the Treatment Emergent Symptom Scale (TESS) Total Score From Week 0 to Week 12.

Intervention	units on a scale (Mean)
Duloxetine	8

The Treatment Emergent Symptom Scale (TESS) documents the presence of common side effects. There are 26 items and the total score range is 0-26. Low scores or decrease in scores represent less side effects and high scores or increase in scores represent more side effects. The change in side effect severity scores was calculated by subtracting the Week 12 score from the Week 0 score. (NCT01852383)
Timeframe: 0 and 12 weeks

Maximum Duloxetine Oral Dose

Intervention	units on a scale (Mean)
Duloxetine	5.2

Maximum duloxetine oral dose (NCT01852383)
Timeframe: Week 0, 1, 2, 4, 6, 8, 10, 12

Executive Function Composite Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort.

Intervention	mg (Mean)
Duloxetine	101

Full Scale Name: The Executive Composite Score (ECS). Definition: Subscales were averaged to compute this composite total score. The ECS is the weighted average of performance on 6 subtests of executive function, including (1) the Controlled Oral Word Association Test, (2) Symbol Digit Modalities test; (3) Stroop Color Word Test (Interference Trial), (4) Trail Making test (Part B), (5) Letter-Number Sequencing, and (6) Animal Naming. Construct Measured: Thinking tasks involving planning, working memory, attention, problem solving, verbal reasoning, inhibition, mental flexibility, and task switching. ECS Scale Range: The ECS score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance on executive functioning tasks. Change Calculation Details: Compares change in executive functioning performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) & 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment

Hamilton Rating Scale for Depression Comparing Screening (Intake Visit) to Visit 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

Intervention	units on a scale (Least Squares Mean)
Citalopram	0.005
Placebo	0.172

Full Scale Name: Hamilton Rating Scale for Depression (HAM-D). Definition: The Hamilton Rating Scale for Depression is a clinician-administered multiple item questionnaire used to provide an indication of depression. Construct Measured: Depression. HAM-D Score Range: Raw scores may range from 0 to 54, where higher scores indicate worsening mood. Change Calculation Details: Compares change in mood from screening (intake visit) to visit 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment

Letter Number Sequencing Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

Intervention	units on a scale (Least Squares Mean)
Citalopram	-0.67
Placebo	1.23

Full Scale Name: Letter Number Sequencing (LNS) subtest from the Wechsler Adult Intelligence Scale (WAIS) third edition. Definition: LNS is a task that requires the reordering of an initially unordered set of letters and numbers. Construct Measured: Working memory. LNS Score Range: Raw scores may range from 0 to 21, where lower scores indicate poorer performance in working memory. Change Calculation Details: Compares change in working memory performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) & 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment

Semantic Fluency Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

Semantic Fluency Score. Definition: The Semantic Fluency Score is the number of words a person can produce given a category, including naming (1) Animal names, (2) Fruit names, (3) Boy names, (4) Girl names, and (5) Vegetable names. Construct Measured: Working memory and verbal initiation. Scale Range: The Semantic Fluency Score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance on working memory tasks. Change Calculation Details: Compares change in working memory performance from visit 2 (week 0) where patients named fruit names to the weighted average of visits 5 (week 12) & 6 (week 15) where patients named girl names and vegetable names respectively for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment

Stroop Interference Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

"Full Scale Name: Stroop Interference subtest from The Stroop Color and Word Test. Definition: Participants are asked to name the ink color in which a word is printed when the word itself (which is irrelevant to the task) is the name of a different color rather than the same color. For example, participants may be asked to say red to the word blue printed in red ink. Constructs Measured: Selective attention, response inhibition, cognitive flexibility, and processing speed. Scale Range: The Stroop Interference score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in attention and processing speed performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) and 6 (week 15) for the citalopram versus placebo cohort." (NCT00271596)
Timeframe: after 15 weeks of treatment

Subgroup Analysis of the Hamilton Depression Rating Scale Comparing Screening (Intake Visit) to Visit 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

Full Scale Name: Hamilton Rating Scale for Depression (HAM-D). Definition: The Hamilton Rating Scale for Depression is a clinician-administered multiple item questionnaire used to provide an indication of depression. Construct Measured: Depression. HAM-D Score Range: Raw scores may range from 0 to 54, where higher scores indicate worsening mood. Change Calculation Details: This analysis was restricted to a subgroup and, accordingly, does not reflect the total number of participants as reported in the Participant Flow. This analysis compares change in mood from screening (intake visit) to visit 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment

Symbol-Digit Modalities Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

Full Scale Name: The Symbol Digit Modalities Test (SDMT). Definition: The SDMT screens for organic cerebral dysfunction by having the examinee use a reference key to pair specific numbers with given geometric figures in 90 seconds. Construct Measured: Attention, processing speed, and working memory. SDMT Scale Range: Raw scores may range from 0 to 110, where lower scores indicate poorer performance. Change Calculation Details: Compares change in performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) & 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment

Total Functional Capacity Score Comparing Baseline (Week -4) to Visits 4 (Week 6) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

Full Scale Name: The Total Functional Capacity (TFC) subscale from the Unified Huntington's Disease Rating Scale (UHDRS). Definition: The TFC is a score that classifies five stages of Huntington's Disease and five levels of function in the domains of workplace, finances, domestic chores, activities of daily living and requirements for unskilled or skilled care. Construct Measured: Activities of Daily Living. Scale Range: The TFC score ranges from 0 to 13, where lower scores indicate poorer performance in activities of daily living. Change Calculation Details: Compares change in TFC performance from Baseline (week -4) to the weighted average of visits 4 (week 6) and 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment

Trails B Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

"Full Scale Name: Trail Making Test Part B (TMT-B). Definition: The TMT-B test requires participants to connect-the-dots of 25 consecutive targets on a sheet of paper where the subject alternates between numbers and letters, going in both numerical and alphabetical order. Constructs Measured: Attention, set shifting, and processing speed. Scale range: The TMT-B score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in attention and processing speed performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) and 6 (week 15) for the citalopram versus placebo cohort." (NCT00271596)
Timeframe: after 15 weeks of treatment

Verbal Fluency Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

Full Scale Name: The Verbal Fluency Score (VFC). Definition: The VFC is the number of words a person can produce given a letter, including (1) Naming words that start with F, A, and S; (2) naming words that start with K, W, and R; (3) naming words that start with V, I, and P; (4) naming words that start with O, G, and B; (5) naming words that start with E, N, and T; and (6) naming words that start with J, C, and S. Construct Measured: Verbal initiation and flexibility. Scale Range: The Verbal Fluency Composite Score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in verbal initiation and flexibility from visit 2 (week 0) where patients named words starting with O, G, and B to the weighted average of visits 5 (week 12) and 6 (week 15) where patients named words starting with E, N, and T, and J, C, and S respectively for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment

Change From Baseline in the Dysphoric Apathy/Retardation Sub-factor (MDAR) of Montgomery-Asberg Depression Rating Scale (MADRS) at 4 Weeks.

The Montgomery-Asberg Depression Rating Scale Dysphoric Apathy Retardation subfactor (MDAR) is a 5-item subscale of the clinician-administered 10-item Montgomery-Asberg Depression Rating Scale (MADRS). MDAR score can range from 0-30 with a higher score representing a greater severity of depressive symptoms. (NCT01148979)
Timeframe: Baseline to 4 weeks of treatment

Change in Beck Depression Inventory II (BDI-II)

Beck Depression Inventory II ranges from 0-63. Higher score indicates more severe depression. 0-13 minimal depression, 14-19 mild depression, 20-28 moderate depression, 29-63 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

Change in Brief Psychiatric Rating Scale (BPRS)

Brief Psychiatric Rating Scale. Maximum score 126. Higher score indicates greater psychiatric difficulties. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

Change in Geriatric Depression Rating Scale (GDS)

Geriatric Depression Scale ranges from 0-30. Higher score indicates more severe depression. 0-9 normal, 10-19 mild depression, 20-30 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

Change in Hamilton Depression Rating Scale (HAM-D) Scores

Change in Hamilton Rating Scale for Depression over 12 weeks. Hamilton Depression Rating Scale ranges from 0-50. Higher scores represent more significant depression. Mild depression ranges from 8-13, moderate depression from 14-18, severe 19-22 and very severe any score over 23. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

Change in Montgomery-Asberg Depression Rating Scale (MADRS)

Montgomery-Asberg Depression Rating Scale ranges from 0-60. Higher score indicates more severe depression. 0-6 normal, 7-19 mild depression, 20-34 moderate depression, greater than 34 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

Change in Parkinson's Disease Questionnaire (PDQ) - 39 - Emotional Well-Being

Parkinson's Disease Questionnaire (PDQ-39) - Emotional Well-Being maximum score 24, minimum score of 0.Lower score indicates a better perceived health status. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

Change in Parkinson's Disease Questionnaire (PDQ) - 39 - Overall

Parkinson's Disease Questionnaire (PDQ-39) Total. Range 0-100. Lower score indicates a better perceived health status. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

Change in Pittsburgh Sleep Quality Index (PSQI)

Pittsburgh Sleep Quality Index scores range from 0-21, with higher scores indicating severe sleep difficulties. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

Change in Short Form 36 Health Survey - Mental Component Summary

Short Form 36 Health Survey. Range 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

Change in Short Form 36 Health Survey - Mental Health

Short Form 36 Health Survey - Mental Health subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

Change in Short Form 36 Health Survey - Role-Emotional

Short Form 36 Health Survey - Emotional subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

Change in Short Form 36 Health Survey - Vitality

Short Form 36 Health Survey - Vitality subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

Change in Snaith Clinical Anxiety Scale (CAS)

Snaith Clinical Anxiety Scale. Range 0-21. Higher scores indicate increased anxiety. Score greater than 8 indicates clinical anxiety. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

Change in Unified Parkinson's Disease Rating Scale (UPDRS)

Unified Parkinson's Disease Rating Scale. Higher score indicates more severe Parkinson's disease symptoms. Total maximum = 176. Mental maximum = 52, Activities of Daily Living maximum = 52, Motor maximum = 72. Minimum = 0. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

Change in Unified Parkinson's Disease Rating Scale (UPDRS) - Bulbar

Unified Parkinson's Disease Rating Scale - Bulbar maximum score 24, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

Change in Unified Parkinson's Disease Rating Scale (UPDRS) - Motor

Unified Parkinson's Disease Rating Scale - Motor has a maximum score of 72, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

Change in Unified Parkinson's Disease Rating Scale (UPDRS) - Tremor

Unified Parkinson's Disease Rating Scale - Tremor subscale ranges from 0-23. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

Intervention	scores on a scale (Mean)
	Baseline Mean MDAR score	Week 4 Mean MDAR score	Change from BL in mean MDAR score
Lisdexamfetamine Dimesylate (Vyvanse)	13.46	6.36	-7.08
Placebo Adjunct	12.57	9.08	-3.49

Intervention	Change in PDQ-39 Emotional score (Mean)
Paroxetine	-21.4
Venlafaxine Extended Release	-20.7
Placebo	-10.9

Authors	Studies
Bymaster, FP	3
Beedle, EE	1
Findlay, J	1
Gallagher, PT	1
Krushinski, JH	1
Mitchell, S	2
Robertson, DW	1
Thompson, DC	1
Wallace, L	1
Wong, DT	2
Li, TZ	1
Zhang, WD	1
Yang, GJ	1
Liu, WY	1
Chen, HS	1
Shen, YH	1
Vinnikova, MA	1
Severtsev, VV	1
Komarov, SD	1
Vdovin, AS	1
Xiang, Y	1
Cuijpers, P	1
Teng, T	1
Li, X	1
Fan, L	2
Liu, X	1
Jiang, Y	1
Du, K	1
Lin, J	2
Zhou, X	2
Xie, P	1
Masi, G	2
Malikowska-Racia, N	2
Golebiowska, J	2
Nikiforuk, A	2
Khoo, SY	2
Popik, P	2
Sun, L	1
Zhang, H	1
Cao, Y	1